{"atlas_id":"pmmr-mucinous-colon","policy_id":"surface-reconciliation-and-prioritization/v0.2","records":[{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":{"cagesp_tier":"Tier I","cancer_type":"Colon adenocarcinoma","ensembl_gene_id":"ENSG00000086548","hgnc_symbol":"CEACAM6","primary_site":"Colon","source_row":{"row":53,"sheet":"Table S9"}},"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":186,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":1,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":80,"sheet":"Table S6"},"values":{"adipocyte":1.5774180157741802,"b_cell":2.6704736311723214,"dc":2.6143790849673203,"endothelial":4.402789886660854,"fibroblast":5.2377358490566035,"granulocyte":2.910958904109589,"macrophage_group_a":3.388918773534158,"macrophage_group_b":4.870129870129871,"nk_cell":2.6128266033254155,"t_cd4":2.87176570941143,"t_cd8":3.604852686308492,"t_reg":3.78585086042065,"tumor":38.84841909485431}},"transcript_fusion_event_count":{"source_row":{"row":343,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["tumor"],"highest_observed_percent_expressing":38.84841909485431,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":1.5774180157741802,"b_cell":2.6704736311723214,"dc":2.6143790849673203,"endothelial":4.402789886660854,"fibroblast":5.2377358490566035,"granulocyte":2.910958904109589,"macrophage_group_a":3.388918773534158,"macrophage_group_b":4.870129870129871,"nk_cell":2.6128266033254155,"t_cd4":2.87176570941143,"t_cd8":3.604852686308492,"t_reg":3.78585086042065,"tumor":38.84841909485431},"owner_category":"malignant-epithelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000086548","source_id":"cancer-surfaceome-atlas","source_row":{"row":80,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000086548","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":1,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":3.22,"raw_score":0.004784005896751974,"state":"derived"},{"cagesp_tier":"Tier I","component":"tcsa-cancer-specific-gesp","maximum":20,"points":20.0,"state":"observed"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":5.2377358490566035,"points":10.56,"state":"derived","tumor_percent":38.84841909485431}],"maximum":100,"measured_component_count":4,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":73.78},"gene_symbol":"CEACAM6","identifiers":{"approved_symbol":"CEACAM6","ensembl_gene_id":"ENSG00000086548","uniprot_accessions":["P40199"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":80},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":80},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":72},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":185,"datasource_scores":[{"id":"europepmc","score":0.039346632178752144}],"score":0.004784005896751974,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CEACAM6","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":6.74,"observed_signals":[{"highest_other_cell_type":"fibroblast","highest_other_percent":5.2377358490566035,"points":6.74,"signal":"tumor-microenvironment-sharing","tumor_percent":38.84841909485431}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":11.07},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":2.58}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":13.65},"structure_resource_rank":20,"structure_tier":"structure-b","structure_tier_assignment":{"priority_score":13.65,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-b cap.","resource_rank":20,"tier_id":"structure-b"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt records an integral or GPI-anchored membrane form."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":true,"explicit_extracellular_matrix":false,"extracellular_topology":false,"gpi_anchored":true,"integral_membrane":false,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P40199"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000086548"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":{"cagesp_tier":"Tier I","cancer_type":"Colon adenocarcinoma","ensembl_gene_id":"ENSG00000119888","hgnc_symbol":"EPCAM","primary_site":"Colon","source_row":{"row":58,"sheet":"Table S9"}},"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":451,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":28,"sheet":"Table S6"},"values":{"adipocyte":6.434205064342051,"b_cell":10.631508229761504,"dc":11.11111111111111,"endothelial":16.434176111595466,"fibroblast":13.20754716981132,"granulocyte":10.102739726027398,"macrophage_group_a":10.54330285099516,"macrophage_group_b":17.4512987012987,"nk_cell":10.688836104513063,"t_cd4":9.75263008245664,"t_cd8":13.136915077989602,"t_reg":14.302103250478012,"tumor":61.616553006819586}},"transcript_fusion_event_count":{"source_row":{"row":918,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["tumor"],"highest_observed_percent_expressing":61.616553006819586,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":6.434205064342051,"b_cell":10.631508229761504,"dc":11.11111111111111,"endothelial":16.434176111595466,"fibroblast":13.20754716981132,"granulocyte":10.102739726027398,"macrophage_group_a":10.54330285099516,"macrophage_group_b":17.4512987012987,"nk_cell":10.688836104513063,"t_cd4":9.75263008245664,"t_cd8":13.136915077989602,"t_reg":14.302103250478012,"tumor":61.616553006819586},"owner_category":"malignant-epithelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-EPCAM","source_id":"cancer-surfaceome-atlas","source_row":{"row":28,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-EPCAM","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":2,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":"Tier I","component":"tcsa-cancer-specific-gesp","maximum":20,"points":20.0,"state":"observed"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":17.4512987012987,"points":11.43,"state":"derived","tumor_percent":61.616553006819586}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":71.43},"gene_symbol":"EPCAM","identifiers":{"approved_symbol":"EPCAM","ensembl_gene_id":"ENSG00000119888","uniprot_accessions":["P16422"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":3,"curated_candidate_alias_count":0,"directness_counts":{"registry-explicit":3},"intervention_ids":["I-CTG-car-t-cell-immunotherapy-1ef738f219","I-CTG-car-t-cells-targeting-epcam-552a0c6e28","I-CTG-epcam-car-t-6e829ef49b"],"modality_counts":{"car-t-cell-therapy":3},"registry_explicit_count":3},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"verified antibody or nanobody complex","points":15},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":95},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17},{"basis":"verified experimental target anchor","points":10},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":90},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"verified experimental target anchor","points":10},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":82},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10},{"basis":"verified antibody complex","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12},{"basis":"explicit assigned cell-therapy intervention","points":20},{"basis":"verified experimental target anchor","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":92},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"verified experimental target anchor","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"verified experimental target anchor","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":23}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"EPCAM","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":14.16,"observed_signals":[{"highest_other_cell_type":"macrophage_group_b","highest_other_percent":17.4512987012987,"points":14.16,"signal":"tumor-microenvironment-sharing","tumor_percent":61.616553006819586}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"verified-structure-anchor","source_id":"rcsb:6I07","url":"https://www.rcsb.org/structure/6I07"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":true,"interaction_classes":["research-antibody-complex"],"pdb_ids":["6I07"],"verified_anchor_count":1},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":60.0},{"component":"bound-complex-anchor","maximum":10,"points":10.0},{"component":"assigned-interventions","maximum":10,"points":3.0},{"component":"evidence-readiness","maximum":15,"points":10.71},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":5.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":88.71},"structure_resource_rank":4,"structure_tier":"structure-a","structure_tier_assignment":{"priority_score":88.71,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-a cap.","resource_rank":4,"tier_id":"structure-a"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P16422"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000119888"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":{"cagesp_tier":"Tier II","cancer_type":"Colon adenocarcinoma","ensembl_gene_id":"ENSG00000165215","hgnc_symbol":"CLDN3","primary_site":"Colon","source_row":{"row":64,"sheet":"Table S9"}},"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":957,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":1,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":233,"sheet":"Table S6"},"values":{"adipocyte":3.4869240348692405,"b_cell":7.255626469600268,"dc":10.457516339869281,"endothelial":8.108108108108109,"fibroblast":7.909433962264151,"granulocyte":5.650684931506849,"macrophage_group_a":5.809575040344271,"macrophage_group_b":8.806818181818182,"nk_cell":5.7007125890736345,"t_cd4":5.08956497014501,"t_cd8":4.298093587521664,"t_reg":5.6978967495219885,"tumor":49.077805331680096}},"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["tumor"],"highest_observed_percent_expressing":49.077805331680096,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":3.4869240348692405,"b_cell":7.255626469600268,"dc":10.457516339869281,"endothelial":8.108108108108109,"fibroblast":7.909433962264151,"granulocyte":5.650684931506849,"macrophage_group_a":5.809575040344271,"macrophage_group_b":8.806818181818182,"nk_cell":5.7007125890736345,"t_cd4":5.08956497014501,"t_cd8":4.298093587521664,"t_reg":5.6978967495219885,"tumor":49.077805331680096},"owner_category":"malignant-epithelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000165215","source_id":"cancer-surfaceome-atlas","source_row":{"row":233,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000165215","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":3,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":3.1,"raw_score":0.0044349582562164215,"state":"derived"},{"cagesp_tier":"Tier II","component":"tcsa-cancer-specific-gesp","maximum":20,"points":16.0,"state":"observed"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":10.457516339869281,"points":10.94,"state":"derived","tumor_percent":49.077805331680096}],"maximum":100,"measured_component_count":4,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":70.04},"gene_symbol":"CLDN3","identifiers":{"approved_symbol":"CLDN3","ensembl_gene_id":"ENSG00000165215","uniprot_accessions":["O15551"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":80},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":80},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":72},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":200,"datasource_scores":[{"id":"europepmc","score":0.03647584785669726}],"score":0.0044349582562164215,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CLDN3","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":10.65,"observed_signals":[{"highest_other_cell_type":"dc","highest_other_percent":10.457516339869281,"points":10.65,"signal":"tumor-microenvironment-sharing","tumor_percent":49.077805331680096}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":10.51},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":10.51},"structure_resource_rank":28,"structure_tier":"structure-b","structure_tier_assignment":{"priority_score":10.51,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-b cap.","resource_rank":28,"tier_id":"structure-b"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["O15551"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000165215"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":{"cagesp_tier":"Tier II","cancer_type":"Colon adenocarcinoma","ensembl_gene_id":"ENSG00000181885","hgnc_symbol":"CLDN7","primary_site":"Colon","source_row":{"row":68,"sheet":"Table S9"}},"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":1171,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":1,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":247,"sheet":"Table S6"},"values":{"adipocyte":3.4039020340390205,"b_cell":3.644608666442727,"dc":7.18954248366013,"endothelial":6.408020924149957,"fibroblast":7.607547169811321,"granulocyte":3.595890410958904,"macrophage_group_a":5.701990317374932,"macrophage_group_b":14.3262987012987,"nk_cell":7.1258907363420425,"t_cd4":3.6678987773670744,"t_cd8":3.5008665511265162,"t_reg":4.894837476099426,"tumor":48.217606943583384}},"transcript_fusion_event_count":{"source_row":{"row":163,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["tumor"],"highest_observed_percent_expressing":48.217606943583384,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":3.4039020340390205,"b_cell":3.644608666442727,"dc":7.18954248366013,"endothelial":6.408020924149957,"fibroblast":7.607547169811321,"granulocyte":3.595890410958904,"macrophage_group_a":5.701990317374932,"macrophage_group_b":14.3262987012987,"nk_cell":7.1258907363420425,"t_cd4":3.6678987773670744,"t_cd8":3.5008665511265162,"t_reg":4.894837476099426,"tumor":48.217606943583384},"owner_category":"malignant-epithelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000181885","source_id":"cancer-surfaceome-atlas","source_row":{"row":247,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000181885","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":4,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.19,"raw_score":0.0022174791281082107,"state":"derived"},{"cagesp_tier":"Tier II","component":"tcsa-cancer-specific-gesp","maximum":20,"points":16.0,"state":"observed"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":14.3262987012987,"points":10.46,"state":"derived","tumor_percent":48.217606943583384}],"maximum":100,"measured_component_count":4,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":68.65},"gene_symbol":"CLDN7","identifiers":{"approved_symbol":"CLDN7","ensembl_gene_id":"ENSG00000181885","uniprot_accessions":["O95471"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":80},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":80},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":72},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":466,"datasource_scores":[{"id":"europepmc","score":0.01823792392834863}],"score":0.0022174791281082107,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CLDN7","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":14.86,"observed_signals":[{"highest_other_cell_type":"macrophage_group_b","highest_other_percent":14.3262987012987,"points":14.86,"signal":"tumor-microenvironment-sharing","tumor_percent":48.217606943583384}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":10.3},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":10.3},"structure_resource_rank":29,"structure_tier":"structure-b","structure_tier_assignment":{"priority_score":10.3,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-b cap.","resource_rank":29,"tier_id":"structure-b"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["O95471"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000181885"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":{"cagesp_tier":"Tier I","cancer_type":"Colon adenocarcinoma","ensembl_gene_id":"ENSG00000105388","hgnc_symbol":"CEACAM5","primary_site":"Colon","source_row":{"row":55,"sheet":"Table S9"}},"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":286,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":1,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":1298,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000105388","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000105388","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":5,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":8.17,"raw_score":0.030824262319350516,"state":"derived"},{"cagesp_tier":"Tier I","component":"tcsa-cancer-specific-gesp","maximum":20,"points":20.0,"state":"observed"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":68.17},"gene_symbol":"CEACAM5","identifiers":{"approved_symbol":"CEACAM5","ensembl_gene_id":"ENSG00000105388","uniprot_accessions":["P06731"]},"intervention_summary":{"action_counts":{"molecular-imaging":1},"assigned_intervention_count":13,"curated_candidate_alias_count":2,"directness_counts":{"curated-candidate-alias":2,"registry-explicit":11},"intervention_ids":["I-CTG-111in-in-dota-anti-cea-antibody-injection-db4657027f","I-CTG-anti-cea-car-t-7a15bcb339","I-CTG-anti-cea-car-t-cells-a8afa7bb5a","I-CTG-cea-targeted-car-t-cells-716275dc4a","I-CTG-copper-cu-64-anti-cea-monoclonal-antibody--1c38eaff9c","I-CTG-cu-64-anti-cea-monoclonal-antibody-m5a-iv-ffd848d4d4","I-CTG-eb-duo-car-nk-cea-gcc-9ddb5588c2","I-CTG-eb-duo-car-nk-cea-gcc-iv-ea153d70da","I-CTG-intraperitoneal-infusion-of-fast-cea-targe-5d1a5c7453","I-CTG-iodine-i-123-anti-cea-recombinant-diabody--bd95c1eb88","I-CTG-radionuclide-imaging-4ddc489e17","I-CTG-sgm-101-3d31779152","I-CTG-yttrium-y-90-dota-anti-cea-monoclonal-anti-961f658b9c"],"modality_counts":{"antibody":2,"car-nk-cell-therapy":2,"car-t-cell-therapy":4,"molecular-imaging-agent":4,"radioligand-therapy":1},"registry_explicit_count":11},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"verified antibody or nanobody complex","points":15},{"basis":"explicit assigned antibody-format intervention","points":10},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":100.0},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17},{"basis":"verified experimental target anchor","points":10},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":90},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"verified experimental target anchor","points":10},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":82},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10},{"basis":"verified antibody complex","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12},{"basis":"explicit assigned cell-therapy intervention","points":20},{"basis":"verified experimental target anchor","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":92},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"explicit assigned radioligand or radioimmunotherapy intervention","points":20},{"basis":"verified experimental target anchor","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":85},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"verified experimental target anchor","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":23}],"open_targets_association":{"associated_target_rank":11,"datasource_scores":[{"id":"europepmc","score":0.2535178546674215}],"score":0.030824262319350516,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CEACAM5","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"verified-structure-anchor","source_id":"rcsb:8BW0","url":"https://www.rcsb.org/structure/8BW0"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":true,"interaction_classes":["therapeutic-antibody-complex"],"pdb_ids":["8BW0"],"verified_anchor_count":1},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":60.0},{"component":"bound-complex-anchor","maximum":10,"points":10.0},{"component":"assigned-interventions","maximum":10,"points":10.0},{"component":"evidence-readiness","maximum":15,"points":10.23},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":5.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":95.23},"structure_resource_rank":1,"structure_tier":"structure-a","structure_tier_assignment":{"priority_score":95.23,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-a cap.","resource_rank":1,"tier_id":"structure-a"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt records an integral or GPI-anchored membrane form."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":true,"explicit_extracellular_matrix":false,"extracellular_topology":false,"gpi_anchored":true,"integral_membrane":false,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P06731"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000105388"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":{"cagesp_tier":"Tier II","cancer_type":"Colon adenocarcinoma","ensembl_gene_id":"ENSG00000127324","hgnc_symbol":"TSPAN8","primary_site":"Colon","source_row":{"row":59,"sheet":"Table S9"}},"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":491,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":1,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":378,"sheet":"Table S6"},"values":{"adipocyte":7.76255707762557,"b_cell":8.851192475646624,"dc":12.418300653594772,"endothelial":12.728857890148213,"fibroblast":15.637735849056602,"granulocyte":7.705479452054795,"macrophage_group_a":11.403980634749864,"macrophage_group_b":16.314935064935064,"nk_cell":9.263657957244655,"t_cd4":9.127096957634349,"t_cd8":10.814558058925476,"t_reg":12.31357552581262,"tumor":63.72442653440794}},"transcript_fusion_event_count":{"source_row":{"row":20,"sheet":"Table S22"},"values":{"count":2}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["tumor"],"highest_observed_percent_expressing":63.72442653440794,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":7.76255707762557,"b_cell":8.851192475646624,"dc":12.418300653594772,"endothelial":12.728857890148213,"fibroblast":15.637735849056602,"granulocyte":7.705479452054795,"macrophage_group_a":11.403980634749864,"macrophage_group_b":16.314935064935064,"nk_cell":9.263657957244655,"t_cd4":9.127096957634349,"t_cd8":10.814558058925476,"t_reg":12.31357552581262,"tumor":63.72442653440794},"owner_category":"malignant-epithelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-TSPAN8","source_id":"cancer-surfaceome-atlas","source_row":{"row":378,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-TSPAN8","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":6,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":"Tier II","component":"tcsa-cancer-specific-gesp","maximum":20,"points":16.0,"state":"observed"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":16.314935064935064,"points":11.7,"state":"derived","tumor_percent":63.72442653440794}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":67.7},"gene_symbol":"TSPAN8","identifiers":{"approved_symbol":"TSPAN8","ensembl_gene_id":"ENSG00000127324","uniprot_accessions":["P19075"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":80},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":80},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":72},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"TSPAN8","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":12.8,"observed_signals":[{"highest_other_cell_type":"macrophage_group_b","highest_other_percent":16.314935064935064,"points":12.8,"signal":"tumor-microenvironment-sharing","tumor_percent":63.72442653440794}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":10.15},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":10.15},"structure_resource_rank":31,"structure_tier":"structure-c","structure_tier_assignment":{"priority_score":10.15,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-c cap.","resource_rank":31,"tier_id":"structure-c"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["P19075"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000127324"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":{"cagesp_tier":"Tier II","cancer_type":"Colon adenocarcinoma","ensembl_gene_id":"ENSG00000189143","hgnc_symbol":"CLDN4","primary_site":"Colon","source_row":{"row":69,"sheet":"Table S9"}},"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":1276,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":1,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":226,"sheet":"Table S6"},"values":{"adipocyte":4.69074304690743,"b_cell":6.684581793752099,"dc":9.15032679738562,"endothelial":9.415867480383609,"fibroblast":11.169811320754718,"granulocyte":4.794520547945205,"macrophage_group_a":7.154384077461,"macrophage_group_b":11.241883116883116,"nk_cell":6.413301662707839,"t_cd4":6.681831106056298,"t_cd8":5.892547660311958,"t_reg":6.768642447418738,"tumor":46.303471791692495}},"transcript_fusion_event_count":{"source_row":{"row":426,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["tumor"],"highest_observed_percent_expressing":46.303471791692495,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":4.69074304690743,"b_cell":6.684581793752099,"dc":9.15032679738562,"endothelial":9.415867480383609,"fibroblast":11.169811320754718,"granulocyte":4.794520547945205,"macrophage_group_a":7.154384077461,"macrophage_group_b":11.241883116883116,"nk_cell":6.413301662707839,"t_cd4":6.681831106056298,"t_cd8":5.892547660311958,"t_reg":6.768642447418738,"tumor":46.303471791692495},"owner_category":"malignant-epithelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-CLDN4","source_id":"cancer-surfaceome-atlas","source_row":{"row":226,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-CLDN4","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":7,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":"Tier II","component":"tcsa-cancer-specific-gesp","maximum":20,"points":16.0,"state":"observed"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":11.241883116883116,"points":10.59,"state":"derived","tumor_percent":46.303471791692495}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":66.59},"gene_symbol":"CLDN4","identifiers":{"approved_symbol":"CLDN4","ensembl_gene_id":"ENSG00000189143","uniprot_accessions":["O14493"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":80},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":80},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":72},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CLDN4","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":12.14,"observed_signals":[{"highest_other_cell_type":"macrophage_group_b","highest_other_percent":11.241883116883116,"points":12.14,"signal":"tumor-microenvironment-sharing","tumor_percent":46.303471791692495}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":9.99},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":1.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":10.99},"structure_resource_rank":25,"structure_tier":"structure-b","structure_tier_assignment":{"priority_score":10.99,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-b cap.","resource_rank":25,"tier_id":"structure-b"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["O14493"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000189143"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":{"cagesp_tier":"Tier III","cancer_type":"Colon adenocarcinoma","ensembl_gene_id":"ENSG00000039068","hgnc_symbol":"CDH1","primary_site":"Colon","source_row":{"row":49,"sheet":"Table S9"}},"mutation_categories":{"source_row":{"row":24,"sheet":"Table S17"},"values":{"in_frame":null,"missense":null,"silent":null,"truncating":null}},"mutation_clonality":{"source_row":{"row":24,"sheet":"Table S20"},"values":{"clonal":null,"subclonal":null,"unknown":null}},"mutation_frequency_percent":{"source_row":{"row":22,"sheet":"Table S15"},"values":{"percent":null}},"mutation_timing":{"source_row":{"row":24,"sheet":"Table S19"},"values":{"early":null,"late":null,"unknown":null}},"mutation_zygosity":{"source_row":{"row":24,"sheet":"Table S18"},"values":{"heter":null,"homo":null,"unknown":null}},"potential_target_summary":{"source_row":{"row":57,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":1,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":{"source_row":{"row":22,"sheet":"Table S14"},"values":{"flag":0}},"scna_g_score":{"source_row":{"row":398,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":12,"sheet":"Table S6"},"values":{"adipocyte":1.36986301369863,"b_cell":1.394020826335237,"dc":3.9215686274509802,"endothelial":2.0052310374891023,"fibroblast":2.7471698113207546,"granulocyte":0.8561643835616438,"macrophage_group_a":1.6675632060247445,"macrophage_group_b":2.5974025974025974,"nk_cell":1.66270783847981,"t_cd4":1.8481660506113167,"t_cd8":1.1785095320623917,"t_reg":1.9502868068833654,"tumor":34.22194668319901}},"transcript_fusion_event_count":{"source_row":{"row":114,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["tumor"],"highest_observed_percent_expressing":34.22194668319901,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":1.36986301369863,"b_cell":1.394020826335237,"dc":3.9215686274509802,"endothelial":2.0052310374891023,"fibroblast":2.7471698113207546,"granulocyte":0.8561643835616438,"macrophage_group_a":1.6675632060247445,"macrophage_group_b":2.5974025974025974,"nk_cell":1.66270783847981,"t_cd4":1.8481660506113167,"t_cd8":1.1785095320623917,"t_reg":1.9502868068833654,"tumor":34.22194668319901},"owner_category":"malignant-epithelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000039068","source_id":"cancer-surfaceome-atlas","source_row":{"row":12,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000039068","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":8,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":3.69,"raw_score":0.006295381282772935,"state":"derived"},{"cagesp_tier":"Tier III","component":"tcsa-cancer-specific-gesp","maximum":20,"points":12.0,"state":"observed"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":3.9215686274509802,"points":10.28,"state":"derived","tumor_percent":34.22194668319901}],"maximum":100,"measured_component_count":4,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":65.97},"gene_symbol":"CDH1","identifiers":{"approved_symbol":"CDH1","ensembl_gene_id":"ENSG00000039068","uniprot_accessions":["P12830"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":80},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":80},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":72},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":152,"datasource_scores":[{"id":"europepmc","score":0.05177712091166966}],"score":0.006295381282772935,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CDH1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":25.73,"observed_signals":[{"highest_other_cell_type":"dc","highest_other_percent":3.9215686274509802,"points":5.73,"signal":"tumor-microenvironment-sharing","tumor_percent":34.22194668319901},{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":9.9},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":9.9},"structure_resource_rank":34,"structure_tier":"structure-c","structure_tier_assignment":{"priority_score":9.9,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-c cap.","resource_rank":34,"tier_id":"structure-c"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P12830"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000039068"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":{"cagesp_tier":"Tier I","cancer_type":"Colon adenocarcinoma","ensembl_gene_id":"ENSG00000173702","hgnc_symbol":"MUC13","primary_site":"Colon","source_row":{"row":65,"sheet":"Table S9"}},"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":1094,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":1,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":1107,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000173702","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000173702","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":9,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.19,"raw_score":0.0022174791281082107,"state":"derived"},{"cagesp_tier":"Tier I","component":"tcsa-cancer-specific-gesp","maximum":20,"points":20.0,"state":"observed"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":62.19},"gene_symbol":"MUC13","identifiers":{"approved_symbol":"MUC13","ensembl_gene_id":"ENSG00000173702","uniprot_accessions":["Q9H3R2"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":80},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":80},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":72},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":434,"datasource_scores":[{"id":"europepmc","score":0.01823792392834863}],"score":0.0022174791281082107,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"MUC13","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":20.0,"observed_signals":[{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":9.33},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":2.58}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":11.91},"structure_resource_rank":22,"structure_tier":"structure-b","structure_tier_assignment":{"priority_score":11.91,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-b cap.","resource_rank":22,"tier_id":"structure-b"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q9H3R2"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000173702"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":{"cagesp_tier":"Tier II","cancer_type":"Colon adenocarcinoma","ensembl_gene_id":"ENSG00000133216","hgnc_symbol":"EPHB2","primary_site":"Colon","source_row":{"row":60,"sheet":"Table S9"}},"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":548,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":1,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":702,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":30,"sheet":"Table S6"},"values":{"adipocyte":1.5774180157741802,"b_cell":0.6718172657037286,"dc":0,"endothelial":1.6564952048823016,"fibroblast":5.026415094339623,"granulocyte":0.8561643835616438,"macrophage_group_a":1.2910166756320602,"macrophage_group_b":9.212662337662337,"nk_cell":0,"t_cd4":0.5117998294000569,"t_cd8":0.41594454072790293,"t_reg":0.7265774378585086,"tumor":15.909795412275262}},"transcript_fusion_event_count":{"source_row":{"row":290,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["tumor"],"highest_observed_percent_expressing":15.909795412275262,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":1.5774180157741802,"b_cell":0.6718172657037286,"dc":0.0,"endothelial":1.6564952048823016,"fibroblast":5.026415094339623,"granulocyte":0.8561643835616438,"macrophage_group_a":1.2910166756320602,"macrophage_group_b":9.212662337662337,"nk_cell":0.0,"t_cd4":0.5117998294000569,"t_cd8":0.41594454072790293,"t_reg":0.7265774378585086,"tumor":15.909795412275262},"owner_category":"malignant-epithelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-EPHB2","source_id":"cancer-surfaceome-atlas","source_row":{"row":30,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-EPHB2","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":10,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":"Tier II","component":"tcsa-cancer-specific-gesp","maximum":20,"points":16.0,"state":"observed"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":9.212662337662337,"points":6.09,"state":"derived","tumor_percent":15.909795412275262}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":62.09},"gene_symbol":"EPHB2","identifiers":{"approved_symbol":"EPHB2","ensembl_gene_id":"ENSG00000133216","uniprot_accessions":["P29323"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":80},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":80},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":72},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"EPHB2","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":48.95,"observed_signals":[{"highest_other_cell_type":"macrophage_group_b","highest_other_percent":9.212662337662337,"points":28.95,"signal":"tumor-microenvironment-sharing","tumor_percent":15.909795412275262},{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":9.31},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":1.58}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":10.89},"structure_resource_rank":26,"structure_tier":"structure-b","structure_tier_assignment":{"priority_score":10.89,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-b cap.","resource_rank":26,"tier_id":"structure-b"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P29323"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000133216"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":{"cagesp_tier":"Tier III","cancer_type":"Colon adenocarcinoma","ensembl_gene_id":"ENSG00000149418","hgnc_symbol":"ST14","primary_site":"Colon","source_row":{"row":63,"sheet":"Table S9"}},"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":757,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":1,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":550,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":118,"sheet":"Table S6"},"values":{"adipocyte":1.0792860107928601,"b_cell":3.8461538461538463,"dc":7.18954248366013,"endothelial":1.9616390584132521,"fibroblast":2.9283018867924526,"granulocyte":3.767123287671233,"macrophage_group_a":8.875739644970414,"macrophage_group_b":24.675324675324674,"nk_cell":0.23752969121140144,"t_cd4":1.8197327267557577,"t_cd8":1.074523396880416,"t_reg":1.3001912045889101,"tumor":32.54804711717297}},"transcript_fusion_event_count":{"source_row":{"row":385,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["tumor"],"highest_observed_percent_expressing":32.54804711717297,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":1.0792860107928601,"b_cell":3.8461538461538463,"dc":7.18954248366013,"endothelial":1.9616390584132521,"fibroblast":2.9283018867924526,"granulocyte":3.767123287671233,"macrophage_group_a":8.875739644970414,"macrophage_group_b":24.675324675324674,"nk_cell":0.23752969121140144,"t_cd4":1.8197327267557577,"t_cd8":1.074523396880416,"t_reg":1.3001912045889101,"tumor":32.54804711717297},"owner_category":"malignant-epithelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000149418","source_id":"cancer-surfaceome-atlas","source_row":{"row":118,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000149418","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":11,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.19,"raw_score":0.0022174791281082107,"state":"derived"},{"cagesp_tier":"Tier III","component":"tcsa-cancer-specific-gesp","maximum":20,"points":12.0,"state":"observed"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":24.675324675324674,"points":6.91,"state":"derived","tumor_percent":32.54804711717297}],"maximum":100,"measured_component_count":4,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":61.1},"gene_symbol":"ST14","identifiers":{"approved_symbol":"ST14","ensembl_gene_id":"ENSG00000149418","uniprot_accessions":["Q9Y5Y6"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":80},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":80},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":72},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":459,"datasource_scores":[{"id":"europepmc","score":0.01823792392834863}],"score":0.0022174791281082107,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"ST14","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":37.91,"observed_signals":[{"highest_other_cell_type":"macrophage_group_b","highest_other_percent":24.675324675324674,"points":37.91,"signal":"tumor-microenvironment-sharing","tumor_percent":32.54804711717297}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":9.16},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":9.16},"structure_resource_rank":41,"structure_tier":"structure-c","structure_tier_assignment":{"priority_score":9.16,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-c cap.","resource_rank":41,"tier_id":"structure-c"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":false,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["Q9Y5Y6"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000149418"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":{"cagesp_tier":"Tier II","cancer_type":"Colon adenocarcinoma","ensembl_gene_id":"ENSG00000108375","hgnc_symbol":"RNF43","primary_site":"Colon","source_row":{"row":57,"sheet":"Table S9"}},"mutation_categories":{"source_row":{"row":17,"sheet":"Table S17"},"values":{"in_frame":null,"missense":null,"silent":null,"truncating":null}},"mutation_clonality":{"source_row":{"row":17,"sheet":"Table S20"},"values":{"clonal":null,"subclonal":null,"unknown":null}},"mutation_frequency_percent":{"source_row":{"row":15,"sheet":"Table S15"},"values":{"percent":null}},"mutation_timing":{"source_row":{"row":17,"sheet":"Table S19"},"values":{"early":null,"late":null,"unknown":null}},"mutation_zygosity":{"source_row":{"row":17,"sheet":"Table S18"},"values":{"heter":null,"homo":null,"unknown":null}},"potential_target_summary":{"source_row":{"row":318,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":1,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":{"source_row":{"row":15,"sheet":"Table S14"},"values":{"flag":0}},"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":354,"sheet":"Table S22"},"values":{"count":1}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000108375","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000108375","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":12,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":4.55,"raw_score":0.009588544007653096,"state":"derived"},{"cagesp_tier":"Tier II","component":"tcsa-cancer-specific-gesp","maximum":20,"points":16.0,"state":"observed"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":60.55},"gene_symbol":"RNF43","identifiers":{"approved_symbol":"RNF43","ensembl_gene_id":"ENSG00000108375","uniprot_accessions":["Q68DV7"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":80},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":80},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":72},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":76,"datasource_scores":[{"id":"europepmc","score":0.0788621340235075}],"score":0.009588544007653096,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"RNF43","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":20.0,"observed_signals":[{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":9.08},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":9.08},"structure_resource_rank":43,"structure_tier":"structure-c","structure_tier_assignment":{"priority_score":9.08,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-c cap.","resource_rank":43,"tier_id":"structure-c"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q68DV7"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000108375"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":1225,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":25,"sheet":"Table S6"},"values":{"adipocyte":2.69821502698215,"b_cell":1.7131340275445077,"dc":5.88235294117647,"endothelial":3.9232781168265043,"fibroblast":7.471698113207548,"granulocyte":1.7123287671232876,"macrophage_group_a":3.2275416890801503,"macrophage_group_b":5.560064935064935,"nk_cell":1.187648456057007,"t_cd4":2.0471993176002274,"t_cd8":0.6932409012131715,"t_reg":2.0650095602294454,"tumor":30.73465592064476}},"transcript_fusion_event_count":{"source_row":{"row":573,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["tumor"],"highest_observed_percent_expressing":30.73465592064476,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":2.69821502698215,"b_cell":1.7131340275445077,"dc":5.88235294117647,"endothelial":3.9232781168265043,"fibroblast":7.471698113207548,"granulocyte":1.7123287671232876,"macrophage_group_a":3.2275416890801503,"macrophage_group_b":5.560064935064935,"nk_cell":1.187648456057007,"t_cd4":2.0471993176002274,"t_cd8":0.6932409012131715,"t_reg":2.0650095602294454,"tumor":30.73465592064476},"owner_category":"malignant-epithelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000185499","source_id":"cancer-surfaceome-atlas","source_row":{"row":25,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000185499","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":13,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":7.08,"raw_score":0.02316383958511195,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":7.471698113207548,"points":9.33,"state":"derived","tumor_percent":30.73465592064476}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":56.41},"gene_symbol":"MUC1","identifiers":{"approved_symbol":"MUC1","ensembl_gene_id":"ENSG00000185499","uniprot_accessions":["P15941"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":2,"curated_candidate_alias_count":0,"directness_counts":{"registry-explicit":2},"intervention_ids":["I-CTG-anti-muc1-car-pnk-cells-ec10721779","I-CTG-anti-muc1-car-t-cells-7dae37eda8"],"modality_counts":{"car-nk-cell-therapy":1,"car-t-cell-therapy":1},"registry_explicit_count":2},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":80},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":80},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":72},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12},{"basis":"explicit assigned cell-therapy intervention","points":20}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":87},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":15,"datasource_scores":[{"id":"europepmc","score":0.19051378607660419}],"score":0.02316383958511195,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"MUC1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":32.16,"observed_signals":[{"highest_other_cell_type":"fibroblast","highest_other_percent":7.471698113207548,"points":12.16,"signal":"tumor-microenvironment-sharing","tumor_percent":30.73465592064476},{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":2.0},{"component":"evidence-readiness","maximum":15,"points":8.46},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":4.64}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":15.1},"structure_resource_rank":17,"structure_tier":"structure-b","structure_tier_assignment":{"priority_score":15.1,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-b cap.","resource_rank":17,"tier_id":"structure-b"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P15941"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000185499"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":{"cagesp_tier":"Tier II","cancer_type":"Colon adenocarcinoma","ensembl_gene_id":"ENSG00000079112","hgnc_symbol":"CDH17","primary_site":"Colon","source_row":{"row":52,"sheet":"Table S9"}},"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":155,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":1,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":845,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-CDH17","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-CDH17","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":14,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":"Tier II","component":"tcsa-cancer-specific-gesp","maximum":20,"points":16.0,"state":"observed"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":56.0},"gene_symbol":"CDH17","identifiers":{"approved_symbol":"CDH17","ensembl_gene_id":"ENSG00000079112","uniprot_accessions":["Q12864"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":3,"curated_candidate_alias_count":0,"directness_counts":{"registry-explicit":3},"intervention_ids":["I-CTG-cdh17-car-t-5fafb7c24d","I-CTG-chm-2101-car-t-cells-1f528dedbe","I-CTG-fast-laco-stim-cdh17-car-t-41ef783a2e"],"modality_counts":{"car-t-cell-therapy":3},"registry_explicit_count":3},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":80},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17},{"basis":"verified experimental target anchor","points":10},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":90},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"verified experimental target anchor","points":10},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":82},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12},{"basis":"explicit assigned cell-therapy intervention","points":20},{"basis":"verified experimental target anchor","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":92},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"verified experimental target anchor","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"verified experimental target anchor","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":23}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CDH17","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"verified-structure-anchor","source_id":"rcsb:6ULM","url":"https://www.rcsb.org/structure/6ULM"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":true,"interaction_classes":["target-apo-structure"],"pdb_ids":["6ULM"],"verified_anchor_count":1},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":60.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":3.0},{"component":"evidence-readiness","maximum":15,"points":8.4},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":2.81}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":74.21},"structure_resource_rank":14,"structure_tier":"structure-b","structure_tier_assignment":{"priority_score":74.21,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-b cap.","resource_rank":14,"tier_id":"structure-b"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q12864"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000079112"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":{"cagesp_tier":"Tier II","cancer_type":"Colon adenocarcinoma","ensembl_gene_id":"ENSG00000143167","hgnc_symbol":"GPA33","primary_site":"Colon","source_row":{"row":62,"sheet":"Table S9"}},"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":683,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":1,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-GPA33","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-GPA33","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":15,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":"Tier II","component":"tcsa-cancer-specific-gesp","maximum":20,"points":16.0,"state":"observed"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":56.0},"gene_symbol":"GPA33","identifiers":{"approved_symbol":"GPA33","ensembl_gene_id":"ENSG00000143167","uniprot_accessions":["Q99795"]},"intervention_summary":{"action_counts":{"molecular-imaging":2},"assigned_intervention_count":3,"curated_candidate_alias_count":0,"directness_counts":{"registry-explicit":3},"intervention_ids":["I-CTG-18f-f-resca-wwh347-2c82aa5ec4","I-CTG-68ga-ga-nota-wwh347-6c428e5c54","I-CTG-iodine-124-labeled-humanized-a33-antibody-e8caa6e23e"],"modality_counts":{"molecular-imaging-agent":3},"registry_explicit_count":3},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":80},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":80},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"public-cohort evidence score at least 55","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":72},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"GPA33","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":3.0},{"component":"evidence-readiness","maximum":15,"points":8.4},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":4.32}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":15.72},"structure_resource_rank":16,"structure_tier":"structure-b","structure_tier_assignment":{"priority_score":15.72,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-b cap.","resource_rank":16,"tier_id":"structure-b"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":false,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q99795"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000143167"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":{"source_row":{"row":9,"sheet":"Table S17"},"values":{"in_frame":null,"missense":null,"silent":null,"truncating":null}},"mutation_clonality":{"source_row":{"row":9,"sheet":"Table S20"},"values":{"clonal":null,"subclonal":null,"unknown":null}},"mutation_frequency_percent":{"source_row":{"row":7,"sheet":"Table S15"},"values":{"percent":null}},"mutation_timing":{"source_row":{"row":9,"sheet":"Table S19"},"values":{"early":null,"late":null,"unknown":null}},"mutation_zygosity":{"source_row":{"row":9,"sheet":"Table S18"},"values":{"heter":null,"homo":null,"unknown":null}},"potential_target_summary":null,"recurrent_mutation_flag":{"source_row":{"row":7,"sheet":"Table S14"},"values":{"flag":0}},"scna_g_score":{"source_row":{"row":11,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":5,"sheet":"Table S6"},"values":{"adipocyte":6.309672063096721,"b_cell":0.47027208599261006,"dc":1.3071895424836601,"endothelial":0.8282476024411508,"fibroblast":15.969811320754717,"granulocyte":0.5136986301369862,"macrophage_group_a":0.43033889187735336,"macrophage_group_b":0.8116883116883116,"nk_cell":0,"t_cd4":0.34119988626670456,"t_cd8":0.2772963604852686,"t_reg":0.49713193116634796,"tumor":11.01983880967142}},"transcript_fusion_event_count":{"source_row":{"row":48,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["fibroblast"],"highest_observed_percent_expressing":15.969811320754717,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":6.309672063096721,"b_cell":0.47027208599261006,"dc":1.3071895424836601,"endothelial":0.8282476024411508,"fibroblast":15.969811320754717,"granulocyte":0.5136986301369862,"macrophage_group_a":0.43033889187735336,"macrophage_group_b":0.8116883116883116,"nk_cell":0.0,"t_cd4":0.34119988626670456,"t_cd8":0.2772963604852686,"t_reg":0.49713193116634796,"tumor":11.01983880967142},"owner_category":"stromal","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000146648","source_id":"cancer-surfaceome-atlas","source_row":{"row":5,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000146648","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":16,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":9.73,"raw_score":0.04379826333949396,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":15.969811320754717,"points":3.32,"state":"derived","tumor_percent":11.01983880967142}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":53.05},"gene_symbol":"EGFR","identifiers":{"approved_symbol":"EGFR","ensembl_gene_id":"ENSG00000146648","uniprot_accessions":["P00533"]},"intervention_summary":{"action_counts":{"antagonist":2,"binder":3,"blocker":2,"cytotoxic-payload-delivery":2,"inhibitor":2},"assigned_intervention_count":15,"curated_candidate_alias_count":4,"directness_counts":{"curated-candidate-alias":4,"registry-explicit":11},"intervention_ids":["I-CTG-111in-fpi-2107-37ea0ec994","I-CTG-225ac-fpi-2068-86d75ffcc8","I-CTG-anti-egfr-containing-regimen-079e0c7097","I-CTG-anti-egfr-monoclonal-antibody-11294839cd","I-CTG-cetuximab-22d728a3c3","I-CTG-ibi3028-ff981e0ea3","I-CTG-investigator-choice-re-challenge-with-anti-9694a696df","I-CTG-js212-0f8ea7a70b","I-CTG-nimotuzumab-9d33f20df6","I-CTG-panitumumab-b41fb4011c","I-CTG-recombinant-anti-egfr-antibody-95e6a19c1f","I-CTG-recombinant-full-human-anti-egfr-monoclona-465bb5f843","I-CTG-standard-of-care-treatment-with-panitumuma-dd47c9ecad","I-CTG-tqb2922-injection-tas-102-tablets-39aec93b5f","I-CTG-tqb2922-injection-tas-102-tablets-bevacizu-862724615d"],"modality_counts":{"antibody":8,"antibody-drug-conjugate":1,"bispecific-antibody":2,"bispecific-antibody-drug-conjugate":1,"conventional-cytotoxic-regimen":1,"molecular-imaging-agent":1,"radioligand-therapy":1},"registry_explicit_count":11},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"verified antibody or nanobody complex","points":15},{"basis":"explicit assigned antibody-format intervention","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":100.0},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17},{"basis":"verified experimental target anchor","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":85},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"verified experimental target anchor","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":77},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10},{"basis":"explicit assigned ADC intervention","points":20},{"basis":"verified antibody complex","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":95},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12},{"basis":"verified experimental target anchor","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":72},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"explicit assigned radioligand or radioimmunotherapy intervention","points":20},{"basis":"verified experimental target anchor","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":85},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30},{"basis":"verified experimental target anchor","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":53}],"open_targets_association":{"associated_target_rank":8,"datasource_scores":[{"id":"europepmc","score":0.36022408727740296}],"score":0.04379826333949396,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"EGFR","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":70.0,"observed_signals":[{"highest_other_cell_type":"fibroblast","highest_other_percent":15.969811320754717,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":11.01983880967142},{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"verified-structure-anchor","source_id":"rcsb:1YY9","url":"https://www.rcsb.org/structure/1YY9"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":true,"interaction_classes":["therapeutic-antibody-complex"],"pdb_ids":["1YY9"],"verified_anchor_count":1},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":60.0},{"component":"bound-complex-anchor","maximum":10,"points":10.0},{"component":"assigned-interventions","maximum":10,"points":10.0},{"component":"evidence-readiness","maximum":15,"points":7.96},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":5.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":92.96},"structure_resource_rank":2,"structure_tier":"structure-a","structure_tier_assignment":{"priority_score":92.96,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-a cap.","resource_rank":2,"tier_id":"structure-a"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P00533"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000146648"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":{"source_row":{"row":7,"sheet":"Table S17"},"values":{"in_frame":null,"missense":null,"silent":null,"truncating":null}},"mutation_clonality":{"source_row":{"row":7,"sheet":"Table S20"},"values":{"clonal":null,"subclonal":null,"unknown":null}},"mutation_frequency_percent":{"source_row":{"row":5,"sheet":"Table S15"},"values":{"percent":null}},"mutation_timing":{"source_row":{"row":7,"sheet":"Table S19"},"values":{"early":null,"late":null,"unknown":null}},"mutation_zygosity":{"source_row":{"row":7,"sheet":"Table S18"},"values":{"heter":null,"homo":null,"unknown":null}},"potential_target_summary":null,"recurrent_mutation_flag":{"source_row":{"row":5,"sheet":"Table S14"},"values":{"flag":0}},"scna_g_score":{"source_row":{"row":6,"sheet":"Table S12"},"values":{"amp":0.246517,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":8,"sheet":"Table S6"},"values":{"adipocyte":6.641760066417602,"b_cell":0.7893852872018812,"dc":3.2679738562091507,"endothelial":3.7489102005231034,"fibroblast":12.573584905660375,"granulocyte":1.36986301369863,"macrophage_group_a":0.8068854222700376,"macrophage_group_b":1.8262987012987013,"nk_cell":2.8503562945368173,"t_cd4":0.8245663918112027,"t_cd8":1.0051993067590987,"t_reg":0.7265774378585086,"tumor":21.737445753254807}},"transcript_fusion_event_count":{"source_row":{"row":27,"sheet":"Table S22"},"values":{"count":1}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["tumor"],"highest_observed_percent_expressing":21.737445753254807,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":6.641760066417602,"b_cell":0.7893852872018812,"dc":3.2679738562091507,"endothelial":3.7489102005231034,"fibroblast":12.573584905660375,"granulocyte":1.36986301369863,"macrophage_group_a":0.8068854222700376,"macrophage_group_b":1.8262987012987013,"nk_cell":2.8503562945368173,"t_cd4":0.8245663918112027,"t_cd8":1.0051993067590987,"t_reg":0.7265774378585086,"tumor":21.737445753254807},"owner_category":"malignant-epithelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000141736","source_id":"cancer-surfaceome-atlas","source_row":{"row":8,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000141736","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":17,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":6.06,"raw_score":0.01696748548457422,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":12.573584905660375,"points":6.77,"state":"derived","tumor_percent":21.737445753254807}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":52.83},"gene_symbol":"ERBB2","identifiers":{"approved_symbol":"ERBB2","ensembl_gene_id":"ENSG00000141736","uniprot_accessions":["P04626"]},"intervention_summary":{"action_counts":{"binder":2,"cytotoxic-payload-delivery":2,"inhibitor":1,"molecular-imaging":2},"assigned_intervention_count":12,"curated_candidate_alias_count":3,"directness_counts":{"curated-candidate-alias":3,"registry-explicit":9},"intervention_ids":["I-CTG-18f-f-resca-rb14-b3e631ee50","I-CTG-68ga-ga-dota-h2d3-c90970f5a7","I-CTG-a166-64561330f1","I-CTG-anti-her2-car-t-c75d83eaec","I-CTG-ct-0508-e0402d4074","I-CTG-pertuzumab-fc1d976b9c","I-CTG-tqb2102-injection-fe523b8bde","I-CTG-tqb2930-injection-oxaliplatin-injection-ca-64a50abf1a","I-CTG-tqb2930-injection-oxaliplatin-injection-ca-f14a3dfa1c","I-CTG-trastuzumab-672bb991dc","I-CTG-tucatinib-096d38d2ad","I-CTG-zanidatamab-ab22a9e067"],"modality_counts":{"antibody":2,"antibody-drug-conjugate":2,"bispecific-antibody":1,"car-t-cell-therapy":1,"conventional-cytotoxic-regimen":2,"molecular-imaging-agent":2,"other-or-unclear":1,"small-molecule":1},"registry_explicit_count":9},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"verified antibody or nanobody complex","points":15},{"basis":"explicit assigned antibody-format intervention","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":100.0},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17},{"basis":"verified experimental target anchor","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":85},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"verified experimental target anchor","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":77},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10},{"basis":"explicit assigned ADC intervention","points":20},{"basis":"verified antibody complex","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":95},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12},{"basis":"explicit assigned cell-therapy intervention","points":20},{"basis":"verified experimental target anchor","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":92},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"verified experimental target anchor","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30},{"basis":"explicit assigned small-molecule intervention","points":15},{"basis":"verified experimental target anchor","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":68}],"open_targets_association":{"associated_target_rank":25,"datasource_scores":[{"id":"europepmc","score":0.13955112614161358}],"score":0.01696748548457422,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"ERBB2","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":28.92,"observed_signals":[{"highest_other_cell_type":"fibroblast","highest_other_percent":12.573584905660375,"points":28.92,"signal":"tumor-microenvironment-sharing","tumor_percent":21.737445753254807}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"verified-structure-anchor","source_id":"rcsb:1N8Z","url":"https://www.rcsb.org/structure/1N8Z"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":true,"interaction_classes":["therapeutic-antibody-complex"],"pdb_ids":["1N8Z"],"verified_anchor_count":1},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":60.0},{"component":"bound-complex-anchor","maximum":10,"points":10.0},{"component":"assigned-interventions","maximum":10,"points":10.0},{"component":"evidence-readiness","maximum":15,"points":7.92},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":4.75}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":92.67},"structure_resource_rank":3,"structure_tier":"structure-a","structure_tier_assignment":{"priority_score":92.67,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-a cap.","resource_rank":3,"tier_id":"structure-a"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P04626"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000141736"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":{"source_row":{"row":12,"sheet":"Table S17"},"values":{"in_frame":null,"missense":null,"silent":null,"truncating":null}},"mutation_clonality":{"source_row":{"row":12,"sheet":"Table S20"},"values":{"clonal":null,"subclonal":null,"unknown":null}},"mutation_frequency_percent":{"source_row":{"row":10,"sheet":"Table S15"},"values":{"percent":null}},"mutation_timing":{"source_row":{"row":12,"sheet":"Table S19"},"values":{"early":null,"late":null,"unknown":null}},"mutation_zygosity":{"source_row":{"row":12,"sheet":"Table S18"},"values":{"heter":null,"homo":null,"unknown":null}},"potential_target_summary":null,"recurrent_mutation_flag":{"source_row":{"row":10,"sheet":"Table S14"},"values":{"flag":0}},"scna_g_score":{"source_row":{"row":317,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":15,"sheet":"Table S6"},"values":{"adipocyte":9.630552096305522,"b_cell":1.1084984884111522,"dc":1.9607843137254901,"endothelial":2.048823016564952,"fibroblast":3.9698113207547165,"granulocyte":1.1986301369863013,"macrophage_group_a":0.9682625067240451,"macrophage_group_b":1.6639610389610389,"nk_cell":1.187648456057007,"t_cd4":1.2510662496445835,"t_cd8":1.317157712305026,"t_reg":1.835564053537285,"tumor":32.69528828270304}},"transcript_fusion_event_count":{"source_row":{"row":19,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["tumor"],"highest_observed_percent_expressing":32.69528828270304,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":9.630552096305522,"b_cell":1.1084984884111522,"dc":1.9607843137254901,"endothelial":2.048823016564952,"fibroblast":3.9698113207547165,"granulocyte":1.1986301369863013,"macrophage_group_a":0.9682625067240451,"macrophage_group_b":1.6639610389610389,"nk_cell":1.187648456057007,"t_cd4":1.2510662496445835,"t_cd8":1.317157712305026,"t_reg":1.835564053537285,"tumor":32.69528828270304},"owner_category":"malignant-epithelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000065361","source_id":"cancer-surfaceome-atlas","source_row":{"row":15,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000065361","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":18,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":3.15,"raw_score":0.004599215969409622,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":9.630552096305522,"points":9.25,"state":"derived","tumor_percent":32.69528828270304}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":52.4},"gene_symbol":"ERBB3","identifiers":{"approved_symbol":"ERBB3","ensembl_gene_id":"ENSG00000065361","uniprot_accessions":["P21860"]},"intervention_summary":{"action_counts":{"cytotoxic-payload-delivery":1},"assigned_intervention_count":1,"curated_candidate_alias_count":0,"directness_counts":{"registry-explicit":1},"intervention_ids":["I-CTG-js212-0f8ea7a70b"],"modality_counts":{"bispecific-antibody-drug-conjugate":1},"registry_explicit_count":1},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"explicit assigned antibody-format intervention","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":85},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10},{"basis":"explicit assigned ADC intervention","points":20}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":85},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":192,"datasource_scores":[{"id":"europepmc","score":0.03782680518472309}],"score":0.004599215969409622,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"ERBB3","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":34.73,"observed_signals":[{"highest_other_cell_type":"adipocyte","highest_other_percent":9.630552096305522,"points":14.73,"signal":"tumor-microenvironment-sharing","tumor_percent":32.69528828270304},{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":1.0},{"component":"evidence-readiness","maximum":15,"points":7.86},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":2.58}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":11.44},"structure_resource_rank":23,"structure_tier":"structure-b","structure_tier_assignment":{"priority_score":11.44,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-b cap.","resource_rank":23,"tier_id":"structure-b"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P21860"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000065361"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":252,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":78,"sheet":"Table S6"},"values":{"adipocyte":2.3246160232461603,"b_cell":0.3527040644944575,"dc":2.6143790849673203,"endothelial":1.3077593722755012,"fibroblast":4.528301886792453,"granulocyte":0.5136986301369862,"macrophage_group_a":1.3986013986013985,"macrophage_group_b":2.840909090909091,"nk_cell":0.9501187648456058,"t_cd4":0.5402331532556156,"t_cd8":0.5199306759098787,"t_reg":1.0325047801147227,"tumor":21.411965282083077}},"transcript_fusion_event_count":{"source_row":{"row":869,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["tumor"],"highest_observed_percent_expressing":21.411965282083077,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":2.3246160232461603,"b_cell":0.3527040644944575,"dc":2.6143790849673203,"endothelial":1.3077593722755012,"fibroblast":4.528301886792453,"granulocyte":0.5136986301369862,"macrophage_group_a":1.3986013986013985,"macrophage_group_b":2.840909090909091,"nk_cell":0.9501187648456058,"t_cd4":0.5402331532556156,"t_cd8":0.5199306759098787,"t_reg":1.0325047801147227,"tumor":21.411965282083077},"owner_category":"malignant-epithelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000102854","source_id":"cancer-surfaceome-atlas","source_row":{"row":78,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000102854","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":19,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":4.528301886792453,"points":8.57,"state":"derived","tumor_percent":21.411965282083077}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":51.4},"gene_symbol":"MSLN","identifiers":{"approved_symbol":"MSLN","ensembl_gene_id":"ENSG00000102854","uniprot_accessions":["Q13421"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":3,"curated_candidate_alias_count":0,"directness_counts":{"registry-explicit":3},"intervention_ids":["I-CTG-car-t-cells-c5bd1845e7","I-CTG-kt032-anti-msln-chimeric-antigen-receptor--6cffa98224","I-CTG-pd1-msln-car-t-cells-2d2d907322"],"modality_counts":{"car-t-cell-therapy":3},"registry_explicit_count":3},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12},{"basis":"explicit assigned cell-therapy intervention","points":20}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":87},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":280,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"MSLN","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":30.57,"observed_signals":[{"highest_other_cell_type":"fibroblast","highest_other_percent":4.528301886792453,"points":10.57,"signal":"tumor-microenvironment-sharing","tumor_percent":21.411965282083077},{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":3.0},{"component":"evidence-readiness","maximum":15,"points":7.71},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":3.58}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":14.29},"structure_resource_rank":19,"structure_tier":"structure-b","structure_tier_assignment":{"priority_score":14.29,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-b cap.","resource_rank":19,"tier_id":"structure-b"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt records an integral or GPI-anchored membrane form."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":false,"gpi_anchored":true,"integral_membrane":false,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q13421"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000102854"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":913,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":390,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":133,"sheet":"Table S6"},"values":{"adipocyte":2.03403902034039,"b_cell":0.3694994961370507,"dc":0,"endothelial":0.6538796861377506,"fibroblast":3.154716981132075,"granulocyte":0.3424657534246575,"macrophage_group_a":0.6993006993006993,"macrophage_group_b":3.8149350649350646,"nk_cell":0,"t_cd4":0.4549331816889394,"t_cd8":0.41594454072790293,"t_reg":0.6118546845124283,"tumor":14.747365158090513}},"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["tumor"],"highest_observed_percent_expressing":14.747365158090513,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":2.03403902034039,"b_cell":0.3694994961370507,"dc":0.0,"endothelial":0.6538796861377506,"fibroblast":3.154716981132075,"granulocyte":0.3424657534246575,"macrophage_group_a":0.6993006993006993,"macrophage_group_b":3.8149350649350646,"nk_cell":0.0,"t_cd4":0.4549331816889394,"t_cd8":0.41594454072790293,"t_reg":0.6118546845124283,"tumor":14.747365158090513},"owner_category":"malignant-epithelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000163347","source_id":"cancer-surfaceome-atlas","source_row":{"row":133,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000163347","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":20,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":3.79,"raw_score":0.006652437384324632,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":3.8149350649350646,"points":7.55,"state":"derived","tumor_percent":14.747365158090513}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":51.34},"gene_symbol":"CLDN1","identifiers":{"approved_symbol":"CLDN1","ensembl_gene_id":"ENSG00000163347","uniprot_accessions":["O95832"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":147,"datasource_scores":[{"id":"europepmc","score":0.0547137717850459}],"score":0.006652437384324632,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CLDN1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":12.93,"observed_signals":[{"highest_other_cell_type":"macrophage_group_b","highest_other_percent":3.8149350649350646,"points":12.93,"signal":"tumor-microenvironment-sharing","tumor_percent":14.747365158090513}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":7.7},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":1.58}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":9.28},"structure_resource_rank":37,"structure_tier":"structure-c","structure_tier_assignment":{"priority_score":9.28,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-c cap.","resource_rank":37,"tier_id":"structure-c"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["O95832"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000163347"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":409,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":37,"sheet":"Table S6"},"values":{"adipocyte":1.1623080116230802,"b_cell":3.359086328518643,"dc":15.032679738562091,"endothelial":4.0104620749782045,"fibroblast":7.849056603773585,"granulocyte":1.1986301369863013,"macrophage_group_a":3.1199569661108124,"macrophage_group_b":6.737012987012987,"nk_cell":5.463182897862233,"t_cd4":2.814899061700313,"t_cd8":3.3968804159445405,"t_reg":2.5239005736137665,"tumor":24.43428394296342}},"transcript_fusion_event_count":{"source_row":{"row":913,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["tumor"],"highest_observed_percent_expressing":24.43428394296342,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":1.1623080116230802,"b_cell":3.359086328518643,"dc":15.032679738562091,"endothelial":4.0104620749782045,"fibroblast":7.849056603773585,"granulocyte":1.1986301369863013,"macrophage_group_a":3.1199569661108124,"macrophage_group_b":6.737012987012987,"nk_cell":5.463182897862233,"t_cd4":2.814899061700313,"t_cd8":3.3968804159445405,"t_reg":2.5239005736137665,"tumor":24.43428394296342},"owner_category":"malignant-epithelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000117394","source_id":"cancer-surfaceome-atlas","source_row":{"row":37,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000117394","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":21,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":4.27,"raw_score":0.008444350989877074,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":15.032679738562091,"points":6.87,"state":"derived","tumor_percent":24.43428394296342}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":51.14},"gene_symbol":"SLC2A1","identifiers":{"approved_symbol":"SLC2A1","ensembl_gene_id":"ENSG00000117394","uniprot_accessions":["P11166"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":94,"datasource_scores":[{"id":"europepmc","score":0.06945158086292398}],"score":0.008444350989877074,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"SLC2A1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":30.76,"observed_signals":[{"highest_other_cell_type":"dc","highest_other_percent":15.032679738562091,"points":30.76,"signal":"tumor-microenvironment-sharing","tumor_percent":24.43428394296342}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":7.67},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":7.67},"structure_resource_rank":61,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":7.67,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":61,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":true,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["P11166"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000117394"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":177,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":939,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":650,"sheet":"Table S6"},"values":{"adipocyte":8.094645080946451,"b_cell":15.938864628820962,"dc":16.99346405228758,"endothelial":19.18047079337402,"fibroblast":26.17358490566038,"granulocyte":14.383561643835616,"macrophage_group_a":10.48951048951049,"macrophage_group_b":12.946428571428573,"nk_cell":17.339667458432302,"t_cd4":15.24026158657947,"t_cd8":18.856152512998268,"t_reg":17.62906309751434,"tumor":15.45257284562926}},"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["fibroblast"],"highest_observed_percent_expressing":26.17358490566038,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":8.094645080946451,"b_cell":15.938864628820962,"dc":16.99346405228758,"endothelial":19.18047079337402,"fibroblast":26.17358490566038,"granulocyte":14.383561643835616,"macrophage_group_a":10.48951048951049,"macrophage_group_b":12.946428571428573,"nk_cell":17.339667458432302,"t_cd4":15.24026158657947,"t_cd8":18.856152512998268,"t_reg":17.62906309751434,"tumor":15.45257284562926},"owner_category":"stromal","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000083457","source_id":"cancer-surfaceome-atlas","source_row":{"row":650,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000083457","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":22,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":6.63,"raw_score":0.020326892007658602,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":26.17358490566038,"points":3.93,"state":"derived","tumor_percent":15.45257284562926}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":50.56},"gene_symbol":"ITGAE","identifiers":{"approved_symbol":"ITGAE","ensembl_gene_id":"ENSG00000083457","uniprot_accessions":["P38570"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":18,"datasource_scores":[{"id":"europepmc","score":0.16718096934319582}],"score":0.020326892007658602,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"ITGAE","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"fibroblast","highest_other_percent":26.17358490566038,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":15.45257284562926}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":7.58},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":7.58},"structure_resource_rank":64,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":7.58,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":64,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":false,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P38570"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000083457"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":{"source_row":{"row":50,"sheet":"Table S17"},"values":{"in_frame":null,"missense":null,"silent":null,"truncating":null}},"mutation_clonality":{"source_row":{"row":50,"sheet":"Table S20"},"values":{"clonal":null,"subclonal":null,"unknown":null}},"mutation_frequency_percent":{"source_row":{"row":48,"sheet":"Table S15"},"values":{"percent":null}},"mutation_timing":{"source_row":{"row":50,"sheet":"Table S19"},"values":{"early":null,"late":null,"unknown":null}},"mutation_zygosity":{"source_row":{"row":50,"sheet":"Table S18"},"values":{"heter":null,"homo":null,"unknown":null}},"potential_target_summary":null,"recurrent_mutation_flag":{"source_row":{"row":48,"sheet":"Table S14"},"values":{"flag":0}},"scna_g_score":{"source_row":{"row":165,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":7,"sheet":"Table S6"},"values":{"adipocyte":1.2038190120381902,"b_cell":0.41988579106483037,"dc":1.3071895424836601,"endothelial":10.767218831734962,"fibroblast":0.9207547169811321,"granulocyte":0.17123287671232876,"macrophage_group_a":0.48413125336202256,"macrophage_group_b":1.2175324675324677,"nk_cell":0,"t_cd4":0.4549331816889394,"t_cd8":0.34662045060658575,"t_reg":0.30592734225621415,"tumor":14.8093614383137}},"transcript_fusion_event_count":{"source_row":{"row":30,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["tumor"],"highest_observed_percent_expressing":14.8093614383137,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":1.2038190120381902,"b_cell":0.41988579106483037,"dc":1.3071895424836601,"endothelial":10.767218831734962,"fibroblast":0.9207547169811321,"granulocyte":0.17123287671232876,"macrophage_group_a":0.48413125336202256,"macrophage_group_b":1.2175324675324677,"nk_cell":0.0,"t_cd4":0.4549331816889394,"t_cd8":0.34662045060658575,"t_reg":0.30592734225621415,"tumor":14.8093614383137},"owner_category":"malignant-epithelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000105976","source_id":"cancer-surfaceome-atlas","source_row":{"row":7,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000105976","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":23,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":5.15,"raw_score":0.01225773184704261,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":10.767218831734962,"points":5.21,"state":"derived","tumor_percent":14.8093614383137}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":50.36},"gene_symbol":"MET","identifiers":{"approved_symbol":"MET","ensembl_gene_id":"ENSG00000105976","uniprot_accessions":["P08581"]},"intervention_summary":{"action_counts":{"binder":2,"blocker":2,"cytotoxic-payload-delivery":1},"assigned_intervention_count":6,"curated_candidate_alias_count":2,"directness_counts":{"curated-candidate-alias":2,"registry-explicit":4},"intervention_ids":["I-CTG-111in-fpi-2107-37ea0ec994","I-CTG-225ac-fpi-2068-86d75ffcc8","I-CTG-68ga-ga-fl-261-pet-imaging-111in-in-fl-261-1cd979f4ad","I-CTG-ibi3028-ff981e0ea3","I-CTG-tqb2922-injection-tas-102-tablets-39aec93b5f","I-CTG-tqb2922-injection-tas-102-tablets-bevacizu-862724615d"],"modality_counts":{"antibody-drug-conjugate":1,"bispecific-antibody":2,"molecular-imaging-agent":2,"radioligand-therapy":1},"registry_explicit_count":4},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"verified antibody or nanobody complex","points":15},{"basis":"explicit assigned antibody-format intervention","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":100.0},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17},{"basis":"verified experimental target anchor","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":85},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"verified experimental target anchor","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":77},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10},{"basis":"explicit assigned ADC intervention","points":20},{"basis":"verified antibody complex","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":95},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12},{"basis":"verified experimental target anchor","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":72},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"explicit assigned radioligand or radioimmunotherapy intervention","points":20},{"basis":"verified experimental target anchor","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":85},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30},{"basis":"verified experimental target anchor","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":53}],"open_targets_association":{"associated_target_rank":45,"datasource_scores":[{"id":"europepmc","score":0.10081519060392716}],"score":0.01225773184704261,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"MET","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":56.35,"observed_signals":[{"highest_other_cell_type":"endothelial","highest_other_percent":10.767218831734962,"points":36.35,"signal":"tumor-microenvironment-sharing","tumor_percent":14.8093614383137},{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"verified-structure-anchor","source_id":"rcsb:4K3J","url":"https://www.rcsb.org/structure/4K3J"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":true,"interaction_classes":["natural-partner-and-therapeutic-antibody-complex"],"pdb_ids":["4K3J"],"verified_anchor_count":1},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":60.0},{"component":"bound-complex-anchor","maximum":10,"points":10.0},{"component":"assigned-interventions","maximum":10,"points":5.0},{"component":"evidence-readiness","maximum":15,"points":7.55},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":4.58}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":87.13},"structure_resource_rank":5,"structure_tier":"structure-a","structure_tier_assignment":{"priority_score":87.13,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-a cap.","resource_rank":5,"tier_id":"structure-a"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":false,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P08581"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000105976"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":682,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":298,"sheet":"Table S6"},"values":{"adipocyte":10.668327106683272,"b_cell":5.307356399059455,"dc":13.071895424836603,"endothelial":6.9747166521360064,"fibroblast":21.4188679245283,"granulocyte":11.472602739726028,"macrophage_group_a":10.758472296933835,"macrophage_group_b":20.454545454545457,"nk_cell":3.32541567695962,"t_cd4":4.918965027011658,"t_cd8":4.055459272097054,"t_reg":13.346080305927345,"tumor":38.98791072535648}},"transcript_fusion_event_count":{"source_row":{"row":377,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["tumor"],"highest_observed_percent_expressing":38.98791072535648,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":10.668327106683272,"b_cell":5.307356399059455,"dc":13.071895424836603,"endothelial":6.9747166521360064,"fibroblast":21.4188679245283,"granulocyte":11.472602739726028,"macrophage_group_a":10.758472296933835,"macrophage_group_b":20.454545454545457,"nk_cell":3.32541567695962,"t_cd4":4.918965027011658,"t_cd8":4.055459272097054,"t_reg":13.346080305927345,"tumor":38.98791072535648},"owner_category":"malignant-epithelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000143153","source_id":"cancer-surfaceome-atlas","source_row":{"row":298,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000143153","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":24,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":1.79,"raw_score":0.0014783194187388072,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":21.4188679245283,"points":8.5,"state":"derived","tumor_percent":38.98791072535648}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":50.29},"gene_symbol":"ATP1B1","identifiers":{"approved_symbol":"ATP1B1","ensembl_gene_id":"ENSG00000143153","uniprot_accessions":["P05026"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":536,"datasource_scores":[{"id":"europepmc","score":0.012158615952232422}],"score":0.0014783194187388072,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":13503,"filename":"MONDO_0005007-associated-targets-page-2.json","sha256":"26a9df77e260244ca3b7d5d09ea58127fca45365ce5ac3dd036ffb2a38df2b0d"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"ATP1B1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":27.47,"observed_signals":[{"highest_other_cell_type":"fibroblast","highest_other_percent":21.4188679245283,"points":27.47,"signal":"tumor-microenvironment-sharing","tumor_percent":38.98791072535648}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":7.54},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":7.54},"structure_resource_rank":65,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":7.54,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":65,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["P05026"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000143153"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":{"source_row":{"row":10,"sheet":"Table S17"},"values":{"in_frame":null,"missense":null,"silent":null,"truncating":null}},"mutation_clonality":{"source_row":{"row":10,"sheet":"Table S20"},"values":{"clonal":null,"subclonal":null,"unknown":null}},"mutation_frequency_percent":{"source_row":{"row":8,"sheet":"Table S15"},"values":{"percent":null}},"mutation_timing":{"source_row":{"row":10,"sheet":"Table S19"},"values":{"early":null,"late":null,"unknown":null}},"mutation_zygosity":{"source_row":{"row":10,"sheet":"Table S18"},"values":{"heter":null,"homo":null,"unknown":null}},"potential_target_summary":{"source_row":{"row":1388,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":{"source_row":{"row":8,"sheet":"Table S14"},"values":{"flag":0}},"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":56,"sheet":"Table S6"},"values":{"adipocyte":62.97218762972187,"b_cell":87.8736983540477,"dc":92.15686274509804,"endothelial":93.11246730601569,"fibroblast":82.77735849056603,"granulocyte":68.32191780821918,"macrophage_group_a":83.48574502420657,"macrophage_group_b":87.2159090909091,"nk_cell":89.54869358669833,"t_cd4":93.23286892237702,"t_cd8":93.69150779896015,"t_reg":95.06692160611856,"tumor":65.17358958462492}},"transcript_fusion_event_count":{"source_row":{"row":113,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["t_reg"],"highest_observed_percent_expressing":95.06692160611856,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":62.97218762972187,"b_cell":87.8736983540477,"dc":92.15686274509804,"endothelial":93.11246730601569,"fibroblast":82.77735849056603,"granulocyte":68.32191780821918,"macrophage_group_a":83.48574502420657,"macrophage_group_b":87.2159090909091,"nk_cell":89.54869358669833,"t_cd4":93.23286892237702,"t_cd8":93.69150779896015,"t_reg":95.06692160611856,"tumor":65.17358958462492},"owner_category":"immune","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000234745","source_id":"cancer-surfaceome-atlas","source_row":{"row":56,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000234745","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":25,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.19,"raw_score":0.0022174791281082107,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":95.06692160611856,"points":8.07,"state":"derived","tumor_percent":65.17358958462492}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":50.26},"gene_symbol":"HLA-B","identifiers":{"approved_symbol":"HLA-B","ensembl_gene_id":"ENSG00000234745","uniprot_accessions":["P01889"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":495,"datasource_scores":[{"id":"europepmc","score":0.01823792392834863}],"score":0.0022174791281082107,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"HLA-B","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"t_reg","highest_other_percent":95.06692160611856,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":65.17358958462492}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":7.54},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":7.54},"structure_resource_rank":66,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":7.54,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":66,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P01889"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000234745"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":103,"sheet":"Table S6"},"values":{"adipocyte":18.34786218347862,"b_cell":26.805508901578772,"dc":34.64052287581699,"endothelial":37.61987794245859,"fibroblast":42.158490566037734,"granulocyte":23.8013698630137,"macrophage_group_a":40.07530930607854,"macrophage_group_b":22.930194805194805,"nk_cell":13.77672209026128,"t_cd4":17.543360818879727,"t_cd8":11.161178509532062,"t_reg":7.380497131931166,"tumor":27.03812771233726}},"transcript_fusion_event_count":{"source_row":{"row":250,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["fibroblast"],"highest_observed_percent_expressing":42.158490566037734,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":18.34786218347862,"b_cell":26.805508901578772,"dc":34.64052287581699,"endothelial":37.61987794245859,"fibroblast":42.158490566037734,"granulocyte":23.8013698630137,"macrophage_group_a":40.07530930607854,"macrophage_group_b":22.930194805194805,"nk_cell":13.77672209026128,"t_cd4":17.543360818879727,"t_cd8":11.161178509532062,"t_reg":7.380497131931166,"tumor":27.03812771233726},"owner_category":"stromal","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000196352","source_id":"cancer-surfaceome-atlas","source_row":{"row":103,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000196352","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":26,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":4.9,"raw_score":0.011087395640541052,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":42.158490566037734,"points":5.2,"state":"derived","tumor_percent":27.03812771233726}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":50.1},"gene_symbol":"CD55","identifiers":{"approved_symbol":"CD55","ensembl_gene_id":"ENSG00000196352","uniprot_accessions":["P08174"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":55,"datasource_scores":[{"id":"europepmc","score":0.09118961964174316}],"score":0.011087395640541052,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CD55","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":70.0,"observed_signals":[{"highest_other_cell_type":"fibroblast","highest_other_percent":42.158490566037734,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":27.03812771233726},{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":7.51},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":7.51},"structure_resource_rank":67,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":7.51,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":67,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt records an integral or GPI-anchored membrane form."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":false,"gpi_anchored":true,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P08174"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000196352"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":1076,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":647,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":168,"sheet":"Table S6"},"values":{"adipocyte":37.02781237027813,"b_cell":36.24454148471616,"dc":45.09803921568628,"endothelial":59.54664341761116,"fibroblast":72.15094339622642,"granulocyte":27.22602739726027,"macrophage_group_a":31.791285637439483,"macrophage_group_b":47.48376623376623,"nk_cell":26.60332541567696,"t_cd4":33.57975547341484,"t_cd8":26.51646447140381,"t_reg":37.2848948374761,"tumor":48.496590204587726}},"transcript_fusion_event_count":{"source_row":{"row":239,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["fibroblast"],"highest_observed_percent_expressing":72.15094339622642,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":37.02781237027813,"b_cell":36.24454148471616,"dc":45.09803921568628,"endothelial":59.54664341761116,"fibroblast":72.15094339622642,"granulocyte":27.22602739726027,"macrophage_group_a":31.791285637439483,"macrophage_group_b":47.48376623376623,"nk_cell":26.60332541567696,"t_cd4":33.57975547341484,"t_cd8":26.51646447140381,"t_reg":37.2848948374761,"tumor":48.496590204587726},"owner_category":"stromal","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000172270","source_id":"cancer-surfaceome-atlas","source_row":{"row":168,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000172270","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":27,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":72.15094339622642,"points":6.96,"state":"derived","tumor_percent":48.496590204587726}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":49.79},"gene_symbol":"BSG","identifiers":{"approved_symbol":"BSG","ensembl_gene_id":"ENSG00000172270","uniprot_accessions":["P35613"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":306,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"BSG","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"fibroblast","highest_other_percent":72.15094339622642,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":48.496590204587726}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":7.47},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":7.47},"structure_resource_rank":68,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":7.47,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":68,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P35613"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000172270"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":37,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":242,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":165,"sheet":"Table S6"},"values":{"adipocyte":28.435035284350352,"b_cell":88.20960698689956,"dc":90.84967320261438,"endothelial":68.52659110723627,"fibroblast":37.93207547169811,"granulocyte":25.85616438356164,"macrophage_group_a":79.98924152770307,"macrophage_group_b":94.19642857142857,"nk_cell":46.080760095011875,"t_cd4":58.37361387546204,"t_cd8":63.11958405545928,"t_reg":72.69598470363289,"tumor":36.50030998140112}},"transcript_fusion_event_count":{"source_row":{"row":34,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["macrophage_group_b"],"highest_observed_percent_expressing":94.19642857142857,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":28.435035284350352,"b_cell":88.20960698689956,"dc":90.84967320261438,"endothelial":68.52659110723627,"fibroblast":37.93207547169811,"granulocyte":25.85616438356164,"macrophage_group_a":79.98924152770307,"macrophage_group_b":94.19642857142857,"nk_cell":46.080760095011875,"t_cd4":58.37361387546204,"t_cd8":63.11958405545928,"t_reg":72.69598470363289,"tumor":36.50030998140112},"owner_category":"immune","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000019582","source_id":"cancer-surfaceome-atlas","source_row":{"row":165,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000019582","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":28,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":3.43,"raw_score":0.005433439830289591,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":94.19642857142857,"points":6.04,"state":"derived","tumor_percent":36.50030998140112}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":49.47},"gene_symbol":"CD74","identifiers":{"approved_symbol":"CD74","ensembl_gene_id":"ENSG00000019582","uniprot_accessions":["P04233"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":165,"datasource_scores":[{"id":"europepmc","score":0.044687979714434244}],"score":0.005433439830289591,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CD74","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":70.0,"observed_signals":[{"highest_other_cell_type":"macrophage_group_b","highest_other_percent":94.19642857142857,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":36.50030998140112},{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":7.42},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":7.42},"structure_resource_rank":69,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":7.42,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":69,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["P04233"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000019582"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":269,"sheet":"Table S6"},"values":{"adipocyte":1.9925280199252802,"b_cell":1.1924756466241182,"dc":0.6535947712418301,"endothelial":1.7436791630340016,"fibroblast":4.513207547169811,"granulocyte":0.684931506849315,"macrophage_group_a":1.3448090371167294,"macrophage_group_b":2.313311688311688,"nk_cell":0.9501187648456058,"t_cd4":0.7392664202445266,"t_cd8":0.6932409012131715,"t_reg":0.6118546845124283,"tumor":24.876007439553625}},"transcript_fusion_event_count":{"source_row":{"row":1165,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["tumor"],"highest_observed_percent_expressing":24.876007439553625,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":1.9925280199252802,"b_cell":1.1924756466241182,"dc":0.6535947712418301,"endothelial":1.7436791630340016,"fibroblast":4.513207547169811,"granulocyte":0.684931506849315,"macrophage_group_a":1.3448090371167294,"macrophage_group_b":2.313311688311688,"nk_cell":0.9501187648456058,"t_cd4":0.7392664202445266,"t_cd8":0.6932409012131715,"t_reg":0.6118546845124283,"tumor":24.876007439553625},"owner_category":"malignant-epithelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-DDR1","source_id":"cancer-surfaceome-atlas","source_row":{"row":269,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-DDR1","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":29,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":4.513207547169811,"points":9.08,"state":"derived","tumor_percent":24.876007439553625}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":49.08},"gene_symbol":"DDR1","identifiers":{"approved_symbol":"DDR1","ensembl_gene_id":"ENSG00000204580","uniprot_accessions":["Q08345"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"DDR1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":29.07,"observed_signals":[{"highest_other_cell_type":"fibroblast","highest_other_percent":4.513207547169811,"points":9.07,"signal":"tumor-microenvironment-sharing","tumor_percent":24.876007439553625},{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":7.36},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":2.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":9.36},"structure_resource_rank":35,"structure_tier":"structure-c","structure_tier_assignment":{"priority_score":9.36,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-c cap.","resource_rank":35,"tier_id":"structure-c"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q08345"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000204580"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":997,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":191,"sheet":"Table S6"},"values":{"adipocyte":10.585305105853053,"b_cell":21.968424588511926,"dc":25.49019607843137,"endothelial":29.46817785527463,"fibroblast":27.064150943396225,"granulocyte":13.527397260273974,"macrophage_group_a":18.28940290478752,"macrophage_group_b":33.19805194805195,"nk_cell":13.30166270783848,"t_cd4":20.699459766846743,"t_cd8":16.256499133448873,"t_reg":21.529636711281068,"tumor":22.303161810291382}},"transcript_fusion_event_count":{"source_row":{"row":315,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["macrophage_group_b"],"highest_observed_percent_expressing":33.19805194805195,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":10.585305105853053,"b_cell":21.968424588511926,"dc":25.49019607843137,"endothelial":29.46817785527463,"fibroblast":27.064150943396225,"granulocyte":13.527397260273974,"macrophage_group_a":18.28940290478752,"macrophage_group_b":33.19805194805195,"nk_cell":13.30166270783848,"t_cd4":20.699459766846743,"t_cd8":16.256499133448873,"t_reg":21.529636711281068,"tumor":22.303161810291382},"owner_category":"immune","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000168003","source_id":"cancer-surfaceome-atlas","source_row":{"row":191,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000168003","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":30,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":4.15,"raw_score":0.00794596687572109,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":33.19805194805195,"points":4.72,"state":"derived","tumor_percent":22.303161810291382}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":48.87},"gene_symbol":"SLC3A2","identifiers":{"approved_symbol":"SLC3A2","ensembl_gene_id":"ENSG00000168003","uniprot_accessions":["P08195"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":105,"datasource_scores":[{"id":"europepmc","score":0.06535256074324927}],"score":0.00794596687572109,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"SLC3A2","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"macrophage_group_b","highest_other_percent":33.19805194805195,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":22.303161810291382}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":7.33},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":7.33},"structure_resource_rank":72,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":7.33,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":72,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["P08195"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000168003"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":574,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":993,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":177,"sheet":"Table S6"},"values":{"adipocyte":6.890826068908261,"b_cell":3.997312730937185,"dc":1.3071895424836601,"endothelial":19.049694856146466,"fibroblast":24.13584905660377,"granulocyte":1.0273972602739725,"macrophage_group_a":1.7213555675094134,"macrophage_group_b":4.301948051948052,"nk_cell":0.7125890736342043,"t_cd4":0.9382996872334376,"t_cd8":0.8318890814558059,"t_reg":0.5353728489483747,"tumor":12.616243025418475}},"transcript_fusion_event_count":{"source_row":{"row":958,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["fibroblast"],"highest_observed_percent_expressing":24.13584905660377,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":6.890826068908261,"b_cell":3.997312730937185,"dc":1.3071895424836601,"endothelial":19.049694856146466,"fibroblast":24.13584905660377,"granulocyte":1.0273972602739725,"macrophage_group_a":1.7213555675094134,"macrophage_group_b":4.301948051948052,"nk_cell":0.7125890736342043,"t_cd4":0.9382996872334376,"t_cd8":0.8318890814558059,"t_reg":0.5353728489483747,"tumor":12.616243025418475},"owner_category":"stromal","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000135318","source_id":"cancer-surfaceome-atlas","source_row":{"row":177,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000135318","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":31,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":4.73,"raw_score":0.010348235931171651,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":24.13584905660377,"points":3.55,"state":"derived","tumor_percent":12.616243025418475}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":48.28},"gene_symbol":"NT5E","identifiers":{"approved_symbol":"NT5E","ensembl_gene_id":"ENSG00000135318","uniprot_accessions":["P21589"]},"intervention_summary":{"action_counts":{"inhibitor":1},"assigned_intervention_count":3,"curated_candidate_alias_count":2,"directness_counts":{"curated-candidate-alias":2,"registry-explicit":1},"intervention_ids":["I-CTG-ab680-d446c5ca53","I-CTG-cpi-006-7295548d5e","I-CTG-oleclumab-ad0acf4f20"],"modality_counts":{"antibody":2,"small-molecule":1},"registry_explicit_count":1},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"verified antibody or nanobody complex","points":15},{"basis":"explicit assigned antibody-format intervention","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":100.0},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17},{"basis":"verified experimental target anchor","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":85},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"verified experimental target anchor","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":77},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10},{"basis":"verified antibody complex","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12},{"basis":"verified experimental target anchor","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":72},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"verified experimental target anchor","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30},{"basis":"verified small-molecule complex","points":30},{"basis":"explicit assigned small-molecule intervention","points":15},{"basis":"verified experimental target anchor","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":98}],"open_targets_association":{"associated_target_rank":63,"datasource_scores":[{"id":"europepmc","score":0.08511031166562696}],"score":0.010348235931171651,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"NT5E","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"fibroblast","highest_other_percent":24.13584905660377,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":12.616243025418475}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"verified-structure-anchor","source_id":"rcsb:7BBJ","url":"https://www.rcsb.org/structure/7BBJ"},{"evidence_role":"verified-structure-anchor","source_id":"rcsb:9R0G","url":"https://www.rcsb.org/structure/9R0G"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":true,"interaction_classes":["antagonist-antibody-complex","small-molecule-complex"],"pdb_ids":["7BBJ","9R0G"],"verified_anchor_count":2},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":60.0},{"component":"bound-complex-anchor","maximum":10,"points":10.0},{"component":"assigned-interventions","maximum":10,"points":2.0},{"component":"evidence-readiness","maximum":15,"points":7.24},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":3.17}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":82.41},"structure_resource_rank":7,"structure_tier":"structure-a","structure_tier_assignment":{"priority_score":82.41,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-a cap.","resource_rank":7,"tier_id":"structure-a"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt records an integral or GPI-anchored membrane form."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":false,"gpi_anchored":true,"integral_membrane":false,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P21589"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000135318"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":44,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":83,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":44,"sheet":"Table S6"},"values":{"adipocyte":26.525529265255294,"b_cell":43.500167954316424,"dc":42.48366013071895,"endothelial":6.713164777680906,"fibroblast":45.132075471698116,"granulocyte":66.43835616438356,"macrophage_group_a":60.0322754168908,"macrophage_group_b":60.9172077922078,"nk_cell":34.204275534441805,"t_cd4":57.52061415979528,"t_cd8":54.280762564991335,"t_reg":61.95028680688337,"tumor":28.409795412275262}},"transcript_fusion_event_count":{"source_row":{"row":598,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["granulocyte"],"highest_observed_percent_expressing":66.43835616438356,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":26.525529265255294,"b_cell":43.500167954316424,"dc":42.48366013071895,"endothelial":6.713164777680906,"fibroblast":45.132075471698116,"granulocyte":66.43835616438356,"macrophage_group_a":60.0322754168908,"macrophage_group_b":60.9172077922078,"nk_cell":34.204275534441805,"t_cd4":57.52061415979528,"t_cd8":54.280762564991335,"t_reg":61.95028680688337,"tumor":28.409795412275262},"owner_category":"immune","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000026508","source_id":"cancer-surfaceome-atlas","source_row":{"row":44,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000026508","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":32,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":66.43835616438356,"points":5.33,"state":"derived","tumor_percent":28.409795412275262}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":48.16},"gene_symbol":"CD44","identifiers":{"approved_symbol":"CD44","ensembl_gene_id":"ENSG00000026508","uniprot_accessions":["P16070"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":293,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CD44","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":70.0,"observed_signals":[{"highest_other_cell_type":"granulocyte","highest_other_percent":66.43835616438356,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":28.409795412275262},{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":7.22},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":7.22},"structure_resource_rank":74,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":7.22,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":74,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P16070"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000026508"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":253,"sheet":"Table S6"},"values":{"adipocyte":0.62266500622665,"b_cell":0.11756802149815251,"dc":4.57516339869281,"endothelial":7.367044463818657,"fibroblast":2.973584905660377,"granulocyte":0.5136986301369862,"macrophage_group_a":2.151694459386767,"macrophage_group_b":3.043831168831169,"nk_cell":0.4750593824228029,"t_cd4":0.5402331532556156,"t_cd8":0.4506065857885615,"t_reg":1.2619502868068833,"tumor":19.350588964662123}},"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["tumor"],"highest_observed_percent_expressing":19.350588964662123,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":0.62266500622665,"b_cell":0.11756802149815251,"dc":4.57516339869281,"endothelial":7.367044463818657,"fibroblast":2.973584905660377,"granulocyte":0.5136986301369862,"macrophage_group_a":2.151694459386767,"macrophage_group_b":3.043831168831169,"nk_cell":0.4750593824228029,"t_cd4":0.5402331532556156,"t_cd8":0.4506065857885615,"t_reg":1.2619502868068833,"tumor":19.350588964662123},"owner_category":"malignant-epithelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-TACSTD2","source_id":"cancer-surfaceome-atlas","source_row":{"row":253,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-TACSTD2","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":33,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":7.367044463818657,"points":7.5,"state":"derived","tumor_percent":19.350588964662123}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":47.5},"gene_symbol":"TACSTD2","identifiers":{"approved_symbol":"TACSTD2","ensembl_gene_id":"ENSG00000184292","uniprot_accessions":["P09758"]},"intervention_summary":{"action_counts":{"molecular-imaging":2},"assigned_intervention_count":3,"curated_candidate_alias_count":1,"directness_counts":{"curated-candidate-alias":1,"registry-explicit":2},"intervention_ids":["I-CTG-18f-f-resca-t4-35b147630c","I-CTG-68ga-ga-nota-t4-9e339e2328","I-CTG-datopotamab-deruxtecan-dato-dxd-90cdcc43e0"],"modality_counts":{"antibody-drug-conjugate":1,"molecular-imaging-agent":2},"registry_explicit_count":2},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"verified antibody or nanobody complex","points":15},{"basis":"explicit assigned antibody-format intervention","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":100.0},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17},{"basis":"verified experimental target anchor","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":85},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"verified experimental target anchor","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":77},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10},{"basis":"explicit assigned ADC intervention","points":20},{"basis":"verified antibody complex","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":95},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12},{"basis":"verified experimental target anchor","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":72},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"verified experimental target anchor","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"verified experimental target anchor","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":23}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"TACSTD2","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":19.04,"observed_signals":[{"highest_other_cell_type":"endothelial","highest_other_percent":7.367044463818657,"points":19.04,"signal":"tumor-microenvironment-sharing","tumor_percent":19.350588964662123}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"verified-structure-anchor","source_id":"rcsb:9PI9","url":"https://www.rcsb.org/structure/9PI9"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":true,"interaction_classes":["therapeutic-antibody-complex"],"pdb_ids":["9PI9"],"verified_anchor_count":1},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":60.0},{"component":"bound-complex-anchor","maximum":10,"points":10.0},{"component":"assigned-interventions","maximum":10,"points":2.5},{"component":"evidence-readiness","maximum":15,"points":7.12},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":4.17}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":83.79},"structure_resource_rank":6,"structure_tier":"structure-a","structure_tier_assignment":{"priority_score":83.79,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-a cap.","resource_rank":6,"tier_id":"structure-a"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":false,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P09758"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000184292"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":182,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":352,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":421,"sheet":"Table S6"},"values":{"adipocyte":5.3964300539643,"b_cell":14.326503191132012,"dc":9.803921568627452,"endothelial":7.802964254577158,"fibroblast":17.750943396226415,"granulocyte":35.1027397260274,"macrophage_group_a":8.337816030123722,"macrophage_group_b":16.599025974025974,"nk_cell":3.32541567695962,"t_cd4":16.60506113164629,"t_cd8":15.493934142114385,"t_reg":28.107074569789674,"tumor":21.543707377557347}},"transcript_fusion_event_count":{"source_row":{"row":617,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["granulocyte"],"highest_observed_percent_expressing":35.1027397260274,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":5.3964300539643,"b_cell":14.326503191132012,"dc":9.803921568627452,"endothelial":7.802964254577158,"fibroblast":17.750943396226415,"granulocyte":35.1027397260274,"macrophage_group_a":8.337816030123722,"macrophage_group_b":16.599025974025974,"nk_cell":3.32541567695962,"t_cd4":16.60506113164629,"t_cd8":15.493934142114385,"t_reg":28.107074569789674,"tumor":21.543707377557347},"owner_category":"immune","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000085117","source_id":"cancer-surfaceome-atlas","source_row":{"row":421,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000085117","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":34,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":35.1027397260274,"points":4.64,"state":"derived","tumor_percent":21.543707377557347}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":47.47},"gene_symbol":"CD82","identifiers":{"approved_symbol":"CD82","ensembl_gene_id":"ENSG00000085117","uniprot_accessions":["P27701"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":250,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CD82","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"granulocyte","highest_other_percent":35.1027397260274,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":21.543707377557347}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":7.12},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":7.12},"structure_resource_rank":77,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":7.12,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":77,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["P27701"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000085117"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":{"source_row":{"row":72,"sheet":"Table S17"},"values":{"in_frame":null,"missense":null,"silent":null,"truncating":null}},"mutation_clonality":{"source_row":{"row":72,"sheet":"Table S20"},"values":{"clonal":null,"subclonal":null,"unknown":null}},"mutation_frequency_percent":{"source_row":{"row":70,"sheet":"Table S15"},"values":{"percent":null}},"mutation_timing":{"source_row":{"row":72,"sheet":"Table S19"},"values":{"early":null,"late":null,"unknown":null}},"mutation_zygosity":{"source_row":{"row":72,"sheet":"Table S18"},"values":{"heter":null,"homo":null,"unknown":null}},"potential_target_summary":{"source_row":{"row":393,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":{"source_row":{"row":70,"sheet":"Table S14"},"values":{"flag":0}},"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":483,"sheet":"Table S6"},"values":{"adipocyte":0.33208800332088,"b_cell":0.08397715821296607,"dc":0,"endothelial":0.5231037489102005,"fibroblast":0.9509433962264151,"granulocyte":0,"macrophage_group_a":0.26896180742334586,"macrophage_group_b":0.4058441558441558,"nk_cell":0.4750593824228029,"t_cd4":0.17059994313335228,"t_cd8":0.17331022530329288,"t_reg":0.15296367112810708,"tumor":8.477991320520768}},"transcript_fusion_event_count":{"source_row":{"row":99,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["tumor"],"highest_observed_percent_expressing":8.477991320520768,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":0.33208800332088,"b_cell":0.08397715821296607,"dc":0.0,"endothelial":0.5231037489102005,"fibroblast":0.9509433962264151,"granulocyte":0.0,"macrophage_group_a":0.26896180742334586,"macrophage_group_b":0.4058441558441558,"nk_cell":0.4750593824228029,"t_cd4":0.17059994313335228,"t_cd8":0.17331022530329288,"t_reg":0.15296367112810708,"tumor":8.477991320520768},"owner_category":"malignant-epithelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-ITGB6","source_id":"cancer-surfaceome-atlas","source_row":{"row":483,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-ITGB6","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":35,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":0.9509433962264151,"points":7.35,"state":"derived","tumor_percent":8.477991320520768}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":47.35},"gene_symbol":"ITGB6","identifiers":{"approved_symbol":"ITGB6","ensembl_gene_id":"ENSG00000115221","uniprot_accessions":["P18564"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17},{"basis":"verified experimental target anchor","points":10},{"basis":"verified miniprotein complex","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":95},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"verified experimental target anchor","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":77},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12},{"basis":"verified experimental target anchor","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":72},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"verified experimental target anchor","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"verified experimental target anchor","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":23}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"ITGB6","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":5.61,"observed_signals":[{"highest_other_cell_type":"fibroblast","highest_other_percent":0.9509433962264151,"points":5.61,"signal":"tumor-microenvironment-sharing","tumor_percent":8.477991320520768}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"verified-structure-anchor","source_id":"rcsb:8TCG","url":"https://www.rcsb.org/structure/8TCG"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":true,"interaction_classes":["miniprotein-complex"],"pdb_ids":["8TCG"],"verified_anchor_count":1},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":60.0},{"component":"bound-complex-anchor","maximum":10,"points":10.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":7.1},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":1.58}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":78.68},"structure_resource_rank":11,"structure_tier":"structure-b","structure_tier_assignment":{"priority_score":78.68,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-b cap.","resource_rank":11,"tier_id":"structure-b"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P18564"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000115221"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":33,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000171094","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000171094","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":36,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":7.3,"raw_score":0.024668165142386934,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":47.3},"gene_symbol":"ALK","identifiers":{"approved_symbol":"ALK","ensembl_gene_id":"ENSG00000171094","uniprot_accessions":["Q9UM73"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":14,"datasource_scores":[{"id":"europepmc","score":0.20288629264466287}],"score":0.024668165142386934,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"ALK","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":7.09},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":7.09},"structure_resource_rank":78,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":7.09,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":78,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q9UM73"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000171094"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":{"source_row":{"row":32,"sheet":"Table S17"},"values":{"in_frame":null,"missense":null,"silent":null,"truncating":null}},"mutation_clonality":{"source_row":{"row":32,"sheet":"Table S20"},"values":{"clonal":null,"subclonal":null,"unknown":null}},"mutation_frequency_percent":{"source_row":{"row":30,"sheet":"Table S15"},"values":{"percent":null}},"mutation_timing":{"source_row":{"row":32,"sheet":"Table S19"},"values":{"early":null,"late":null,"unknown":null}},"mutation_zygosity":{"source_row":{"row":32,"sheet":"Table S18"},"values":{"heter":null,"homo":null,"unknown":null}},"potential_target_summary":{"source_row":{"row":744,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":{"source_row":{"row":30,"sheet":"Table S14"},"values":{"flag":0}},"scna_g_score":{"source_row":{"row":772,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":85,"sheet":"Table S6"},"values":{"adipocyte":4.275633042756331,"b_cell":1.8474974806852538,"dc":3.2679738562091507,"endothelial":28.90148212728858,"fibroblast":6.867924528301887,"granulocyte":1.36986301369863,"macrophage_group_a":3.7116729424421733,"macrophage_group_b":5.762987012987013,"nk_cell":3.5629453681710213,"t_cd4":2.4452658515780494,"t_cd8":3.2582322357019065,"t_reg":4.053537284894838,"tumor":9.353688778673279}},"transcript_fusion_event_count":{"source_row":{"row":195,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["endothelial"],"highest_observed_percent_expressing":28.90148212728858,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":4.275633042756331,"b_cell":1.8474974806852538,"dc":3.2679738562091507,"endothelial":28.90148212728858,"fibroblast":6.867924528301887,"granulocyte":1.36986301369863,"macrophage_group_a":3.7116729424421733,"macrophage_group_b":5.762987012987013,"nk_cell":3.5629453681710213,"t_cd4":2.4452658515780494,"t_cd8":3.2582322357019065,"t_reg":4.053537284894838,"tumor":9.353688778673279},"owner_category":"endothelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000148400","source_id":"cancer-surfaceome-atlas","source_row":{"row":85,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000148400","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":37,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":4.21,"raw_score":0.00819235344551089,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":28.90148212728858,"points":3.06,"state":"derived","tumor_percent":9.353688778673279}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":47.27},"gene_symbol":"NOTCH1","identifiers":{"approved_symbol":"NOTCH1","ensembl_gene_id":"ENSG00000148400","uniprot_accessions":["P46531"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":100,"datasource_scores":[{"id":"europepmc","score":0.06737899673528801}],"score":0.00819235344551089,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"NOTCH1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"endothelial","highest_other_percent":28.90148212728858,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":9.353688778673279}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":7.09},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":7.09},"structure_resource_rank":79,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":7.09,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":79,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P46531"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000148400"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":652,"sheet":"Table S6"},"values":{"adipocyte":7.22291407222914,"b_cell":16.090023513604297,"dc":14.37908496732026,"endothelial":46.03312990409765,"fibroblast":14.369811320754716,"granulocyte":1.36986301369863,"macrophage_group_a":20.494889725658958,"macrophage_group_b":24.350649350649352,"nk_cell":18.052256532066508,"t_cd4":11.145862951379018,"t_cd8":21.49046793760832,"t_reg":36.59655831739962,"tumor":1.6429014259144452}},"transcript_fusion_event_count":{"source_row":{"row":1443,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["endothelial"],"highest_observed_percent_expressing":46.03312990409765,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":7.22291407222914,"b_cell":16.090023513604297,"dc":14.37908496732026,"endothelial":46.03312990409765,"fibroblast":14.369811320754716,"granulocyte":1.36986301369863,"macrophage_group_a":20.494889725658958,"macrophage_group_b":24.350649350649352,"nk_cell":18.052256532066508,"t_cd4":11.145862951379018,"t_cd8":21.49046793760832,"t_reg":36.59655831739962,"tumor":1.6429014259144452},"owner_category":"endothelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000138185","source_id":"cancer-surfaceome-atlas","source_row":{"row":652,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000138185","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":38,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":5.83,"raw_score":0.01570714382409983,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":46.03312990409765,"points":1.28,"state":"derived","tumor_percent":1.6429014259144452}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":47.11},"gene_symbol":"ENTPD1","identifiers":{"approved_symbol":"ENTPD1","ensembl_gene_id":"ENSG00000138185","uniprot_accessions":["P49961"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":29,"datasource_scores":[{"id":"europepmc","score":0.1291852944924695}],"score":0.01570714382409983,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"ENTPD1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"endothelial","highest_other_percent":46.03312990409765,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":1.6429014259144452}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":7.07},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":2.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":9.07},"structure_resource_rank":44,"structure_tier":"structure-c","structure_tier_assignment":{"priority_score":9.07,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-c cap.","resource_rank":44,"tier_id":"structure-c"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":false,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["P49961"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000138185"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":257,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":969,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":33,"sheet":"Table S6"},"values":{"adipocyte":0.9547530095475302,"b_cell":4.13167618407793,"dc":16.99346405228758,"endothelial":1.5257192676547515,"fibroblast":1.6905660377358491,"granulocyte":4.965753424657534,"macrophage_group_a":4.142011834319527,"macrophage_group_b":4.464285714285714,"nk_cell":3.32541567695962,"t_cd4":4.606198464600512,"t_cd8":6.724436741767764,"t_reg":6.768642447418738,"tumor":7.0908245505269685}},"transcript_fusion_event_count":{"source_row":{"row":1286,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["dc"],"highest_observed_percent_expressing":16.99346405228758,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":0.9547530095475302,"b_cell":4.13167618407793,"dc":16.99346405228758,"endothelial":1.5257192676547515,"fibroblast":1.6905660377358491,"granulocyte":4.965753424657534,"macrophage_group_a":4.142011834319527,"macrophage_group_b":4.464285714285714,"nk_cell":3.32541567695962,"t_cd4":4.606198464600512,"t_cd8":6.724436741767764,"t_reg":6.768642447418738,"tumor":7.0908245505269685},"owner_category":"immune","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000103257","source_id":"cancer-surfaceome-atlas","source_row":{"row":33,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000103257","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":39,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":4.38,"raw_score":0.008869916512432843,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":16.99346405228758,"points":2.66,"state":"derived","tumor_percent":7.0908245505269685}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":47.04},"gene_symbol":"SLC7A5","identifiers":{"approved_symbol":"SLC7A5","ensembl_gene_id":"ENSG00000103257","uniprot_accessions":["Q01650"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":82,"datasource_scores":[{"id":"europepmc","score":0.07295169571339452}],"score":0.008869916512432843,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"SLC7A5","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"dc","highest_other_percent":16.99346405228758,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":7.0908245505269685}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":7.06},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":7.06},"structure_resource_rank":80,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":7.06,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":80,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["Q01650"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000103257"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":573,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":237,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":232,"sheet":"Table S6"},"values":{"adipocyte":0.5396430053964301,"b_cell":0.6550218340611353,"dc":11.11111111111111,"endothelial":0.7846556233653008,"fibroblast":0.39245283018867927,"granulocyte":13.527397260273974,"macrophage_group_a":20.763851533082303,"macrophage_group_b":34.45616883116883,"nk_cell":27.078384798099762,"t_cd4":3.6963321012226333,"t_cd8":14.454072790294628,"t_reg":13.001912045889103,"tumor":0.3487290762554247}},"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["macrophage_group_b"],"highest_observed_percent_expressing":34.45616883116883,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":0.5396430053964301,"b_cell":0.6550218340611353,"dc":11.11111111111111,"endothelial":0.7846556233653008,"fibroblast":0.39245283018867927,"granulocyte":13.527397260273974,"macrophage_group_a":20.763851533082303,"macrophage_group_b":34.45616883116883,"nk_cell":27.078384798099762,"t_cd4":3.6963321012226333,"t_cd8":14.454072790294628,"t_reg":13.001912045889103,"tumor":0.3487290762554247},"owner_category":"immune","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000135077","source_id":"cancer-surfaceome-atlas","source_row":{"row":232,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000135077","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":40,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":6.32,"raw_score":0.01847899273423509,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":34.45616883116883,"points":0.59,"state":"derived","tumor_percent":0.3487290762554247}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":46.91},"gene_symbol":"HAVCR2","identifiers":{"approved_symbol":"HAVCR2","ensembl_gene_id":"ENSG00000135077","uniprot_accessions":["Q8TDQ0"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":1,"curated_candidate_alias_count":0,"directness_counts":{"registry-explicit":1},"intervention_ids":["I-CTG-tqb2618-injection-1e9a8d0d95"],"modality_counts":{"antibody":1},"registry_explicit_count":1},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"explicit assigned antibody-format intervention","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":85},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":22,"datasource_scores":[{"id":"europepmc","score":0.15198269940290526}],"score":0.01847899273423509,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"HAVCR2","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"macrophage_group_b","highest_other_percent":34.45616883116883,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":0.3487290762554247}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":1.0},{"component":"evidence-readiness","maximum":15,"points":7.04},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":8.04},"structure_resource_rank":54,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":8.04,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":54,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q8TDQ0"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000135077"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000173585","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000173585","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":41,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":6.9,"raw_score":0.021990001353739755,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":46.9},"gene_symbol":"CCR9","identifiers":{"approved_symbol":"CCR9","ensembl_gene_id":"ENSG00000173585","uniprot_accessions":["P51686"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":16,"datasource_scores":[{"id":"europepmc","score":0.18085941228945726}],"score":0.021990001353739755,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CCR9","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":7.03},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":7.03},"structure_resource_rank":81,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":7.03,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":81,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["P51686"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000173585"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":591,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":780,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":416,"sheet":"Table S6"},"values":{"adipocyte":11.249481112494811,"b_cell":11.219348337252267,"dc":1.3071895424836601,"endothelial":18.00348735832607,"fibroblast":34.06792452830189,"granulocyte":3.595890410958904,"macrophage_group_a":5.9171597633136095,"macrophage_group_b":5.925324675324675,"nk_cell":0.23752969121140144,"t_cd4":4.094398635200455,"t_cd8":0.4506065857885615,"t_reg":1.147227533460803,"tumor":16.24302541847489}},"transcript_fusion_event_count":{"source_row":{"row":1428,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["fibroblast"],"highest_observed_percent_expressing":34.06792452830189,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":11.249481112494811,"b_cell":11.219348337252267,"dc":1.3071895424836601,"endothelial":18.00348735832607,"fibroblast":34.06792452830189,"granulocyte":3.595890410958904,"macrophage_group_a":5.9171597633136095,"macrophage_group_b":5.925324675324675,"nk_cell":0.23752969121140144,"t_cd4":4.094398635200455,"t_cd8":0.4506065857885615,"t_reg":1.147227533460803,"tumor":16.24302541847489},"owner_category":"stromal","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000136026","source_id":"cancer-surfaceome-atlas","source_row":{"row":416,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000136026","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":42,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":34.06792452830189,"points":4.03,"state":"derived","tumor_percent":16.24302541847489}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":46.86},"gene_symbol":"CKAP4","identifiers":{"approved_symbol":"CKAP4","ensembl_gene_id":"ENSG00000136026","uniprot_accessions":["Q07065"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":236,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CKAP4","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"fibroblast","highest_other_percent":34.06792452830189,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":16.24302541847489}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":7.03},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":7.03},"structure_resource_rank":82,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":7.03,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":82,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["Q07065"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000136026"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":603,"sheet":"Table S6"},"values":{"adipocyte":4.483188044831881,"b_cell":4.198857910648304,"dc":1.3071895424836601,"endothelial":35.74542284219703,"fibroblast":9.947169811320755,"granulocyte":1.0273972602739725,"macrophage_group_a":7.261968800430339,"macrophage_group_b":12.5,"nk_cell":17.577197149643705,"t_cd4":11.231162922945693,"t_cd8":13.206239168110919,"t_reg":14.952198852772467,"tumor":15.685058896466211}},"transcript_fusion_event_count":{"source_row":{"row":1419,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["endothelial"],"highest_observed_percent_expressing":35.74542284219703,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":4.483188044831881,"b_cell":4.198857910648304,"dc":1.3071895424836601,"endothelial":35.74542284219703,"fibroblast":9.947169811320755,"granulocyte":1.0273972602739725,"macrophage_group_a":7.261968800430339,"macrophage_group_b":12.5,"nk_cell":17.577197149643705,"t_cd4":11.231162922945693,"t_cd8":13.206239168110919,"t_reg":14.952198852772467,"tumor":15.685058896466211},"owner_category":"endothelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000135048","source_id":"cancer-surfaceome-atlas","source_row":{"row":603,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000135048","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":43,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":35.74542284219703,"points":3.96,"state":"derived","tumor_percent":15.685058896466211}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":46.79},"gene_symbol":"CEMIP2","identifiers":{"approved_symbol":"CEMIP2","ensembl_gene_id":"ENSG00000135048","uniprot_accessions":["Q9UHN6"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":267,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CEMIP2","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"endothelial","highest_other_percent":35.74542284219703,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":15.685058896466211}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":7.02},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":7.02},"structure_resource_rank":83,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":7.02,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":83,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["Q9UHN6"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000135048"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":501,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":851,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":55,"sheet":"Table S6"},"values":{"adipocyte":5.06434205064342,"b_cell":4.014108162579778,"dc":26.797385620915033,"endothelial":5.492589363557106,"fibroblast":18.777358490566037,"granulocyte":15.41095890410959,"macrophage_group_a":48.628294782140934,"macrophage_group_b":77.80032467532467,"nk_cell":1.66270783847981,"t_cd4":1.6775661074779642,"t_cd8":1.490467937608319,"t_reg":3.2504780114722758,"tumor":13.158710477371358}},"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["macrophage_group_b"],"highest_observed_percent_expressing":77.80032467532467,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":5.06434205064342,"b_cell":4.014108162579778,"dc":26.797385620915033,"endothelial":5.492589363557106,"fibroblast":18.777358490566037,"granulocyte":15.41095890410959,"macrophage_group_a":48.628294782140934,"macrophage_group_b":77.80032467532467,"nk_cell":1.66270783847981,"t_cd4":1.6775661074779642,"t_cd8":1.490467937608319,"t_reg":3.2504780114722758,"tumor":13.158710477371358},"owner_category":"immune","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000129226","source_id":"cancer-surfaceome-atlas","source_row":{"row":55,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000129226","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":44,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":3.1,"raw_score":0.004434958256216422,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":77.80032467532467,"points":3.63,"state":"derived","tumor_percent":13.158710477371358}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":46.73},"gene_symbol":"CD68","identifiers":{"approved_symbol":"CD68","ensembl_gene_id":"ENSG00000129226","uniprot_accessions":["P34810"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":196,"datasource_scores":[{"id":"europepmc","score":0.03647584785669727}],"score":0.004434958256216422,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CD68","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"macrophage_group_b","highest_other_percent":77.80032467532467,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":13.158710477371358}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":7.01},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":7.01},"structure_resource_rank":84,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":7.01,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":84,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P34810"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000129226"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":{"source_row":{"row":25,"sheet":"Table S17"},"values":{"in_frame":null,"missense":null,"silent":null,"truncating":null}},"mutation_clonality":{"source_row":{"row":25,"sheet":"Table S20"},"values":{"clonal":null,"subclonal":null,"unknown":null}},"mutation_frequency_percent":{"source_row":{"row":23,"sheet":"Table S15"},"values":{"percent":null}},"mutation_timing":{"source_row":{"row":25,"sheet":"Table S19"},"values":{"early":null,"late":null,"unknown":null}},"mutation_zygosity":{"source_row":{"row":25,"sheet":"Table S18"},"values":{"heter":null,"homo":null,"unknown":null}},"potential_target_summary":{"source_row":{"row":917,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":{"source_row":{"row":23,"sheet":"Table S14"},"values":{"flag":0}},"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":140,"sheet":"Table S6"},"values":{"adipocyte":23.868825238688252,"b_cell":8.246556936513269,"dc":19.607843137254903,"endothelial":66.21621621621621,"fibroblast":35.033962264150944,"granulocyte":12.32876712328767,"macrophage_group_a":18.074233458848845,"macrophage_group_b":29.017857142857146,"nk_cell":9.73871733966746,"t_cd4":11.032129655956782,"t_cd8":12.062391681109187,"t_reg":7.8776290630975145,"tumor":12.72473651580905}},"transcript_fusion_event_count":{"source_row":{"row":1062,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["endothelial"],"highest_observed_percent_expressing":66.21621621621621,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":23.868825238688252,"b_cell":8.246556936513269,"dc":19.607843137254903,"endothelial":66.21621621621621,"fibroblast":35.033962264150944,"granulocyte":12.32876712328767,"macrophage_group_a":18.074233458848845,"macrophage_group_b":29.017857142857146,"nk_cell":9.73871733966746,"t_cd4":11.032129655956782,"t_cd8":12.062391681109187,"t_reg":7.8776290630975145,"tumor":12.72473651580905},"owner_category":"endothelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000163513","source_id":"cancer-surfaceome-atlas","source_row":{"row":140,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000163513","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":45,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":3.16,"raw_score":0.004619748183558772,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":66.21621621621621,"points":3.57,"state":"derived","tumor_percent":12.72473651580905}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":46.73},"gene_symbol":"TGFBR2","identifiers":{"approved_symbol":"TGFBR2","ensembl_gene_id":"ENSG00000163513","uniprot_accessions":["P37173"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":188,"datasource_scores":[{"id":"europepmc","score":0.037995674850726316}],"score":0.004619748183558772,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"TGFBR2","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":70.0,"observed_signals":[{"highest_other_cell_type":"endothelial","highest_other_percent":66.21621621621621,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":12.72473651580905},{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":7.01},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":7.01},"structure_resource_rank":85,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":7.01,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":85,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P37173"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000163513"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":175,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":257,"sheet":"Table S6"},"values":{"adipocyte":10.460772104607722,"b_cell":0.40309035942223714,"dc":0,"endothelial":8.195292066259809,"fibroblast":29.539622641509432,"granulocyte":0.5136986301369862,"macrophage_group_a":3.012372243141474,"macrophage_group_b":14.935064935064934,"nk_cell":0,"t_cd4":0.31276656241114587,"t_cd8":0.34662045060658575,"t_reg":0.42065009560229444,"tumor":14.11965282083075}},"transcript_fusion_event_count":{"source_row":{"row":342,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["fibroblast"],"highest_observed_percent_expressing":29.539622641509432,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":10.460772104607722,"b_cell":0.40309035942223714,"dc":0.0,"endothelial":8.195292066259809,"fibroblast":29.539622641509432,"granulocyte":0.5136986301369862,"macrophage_group_a":3.012372243141474,"macrophage_group_b":14.935064935064934,"nk_cell":0.0,"t_cd4":0.31276656241114587,"t_cd8":0.34662045060658575,"t_reg":0.42065009560229444,"tumor":14.11965282083075},"owner_category":"stromal","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000082781","source_id":"cancer-surfaceome-atlas","source_row":{"row":257,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000082781","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":46,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":29.539622641509432,"points":3.76,"state":"derived","tumor_percent":14.11965282083075}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":46.59},"gene_symbol":"ITGB5","identifiers":{"approved_symbol":"ITGB5","ensembl_gene_id":"ENSG00000082781","uniprot_accessions":["P18084"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":278,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"ITGB5","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"fibroblast","highest_other_percent":29.539622641509432,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":14.11965282083075}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.99},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.99},"structure_resource_rank":88,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.99,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":88,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P18084"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000082781"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":658,"sheet":"Table S6"},"values":{"adipocyte":45.952677459526775,"b_cell":78.08196170641585,"dc":75.16339869281046,"endothelial":87.35832606800349,"fibroblast":65.61509433962264,"granulocyte":53.93835616438356,"macrophage_group_a":66.11081226465842,"macrophage_group_b":72.97077922077922,"nk_cell":72.68408551068883,"t_cd4":81.0634063121979,"t_cd8":80.10398613518197,"t_reg":83.17399617590823,"tumor":42.103223806571606}},"transcript_fusion_event_count":{"source_row":{"row":1742,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["endothelial"],"highest_observed_percent_expressing":87.35832606800349,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":45.952677459526775,"b_cell":78.08196170641585,"dc":75.16339869281046,"endothelial":87.35832606800349,"fibroblast":65.61509433962264,"granulocyte":53.93835616438356,"macrophage_group_a":66.11081226465842,"macrophage_group_b":72.97077922077922,"nk_cell":72.68408551068883,"t_cd4":81.0634063121979,"t_cd8":80.10398613518197,"t_reg":83.17399617590823,"tumor":42.103223806571606},"owner_category":"endothelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-HLA-E","source_id":"cancer-surfaceome-atlas","source_row":{"row":658,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-HLA-E","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":47,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":87.35832606800349,"points":6.49,"state":"derived","tumor_percent":42.103223806571606}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":46.49},"gene_symbol":"HLA-E","identifiers":{"approved_symbol":"HLA-E","ensembl_gene_id":"ENSG00000204592","uniprot_accessions":["P13747"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"HLA-E","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":70.0,"observed_signals":[{"highest_other_cell_type":"endothelial","highest_other_percent":87.35832606800349,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":42.103223806571606},{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.97},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":1.58}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":8.55},"structure_resource_rank":51,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":8.55,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":51,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P13747"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000204592"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":633,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":455,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":60,"sheet":"Table S6"},"values":{"adipocyte":16.189290161892902,"b_cell":1.7803157541148806,"dc":5.88235294117647,"endothelial":29.11944202266783,"fibroblast":39.35094339622642,"granulocyte":4.623287671232877,"macrophage_group_a":7.315761161915008,"macrophage_group_b":22.88961038961039,"nk_cell":2.375296912114014,"t_cd4":1.7059994313335227,"t_cd8":1.733102253032929,"t_reg":3.3652007648183555,"tumor":12.631742095474271}},"transcript_fusion_event_count":{"source_row":{"row":374,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["fibroblast"],"highest_observed_percent_expressing":39.35094339622642,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":16.189290161892902,"b_cell":1.7803157541148806,"dc":5.88235294117647,"endothelial":29.11944202266783,"fibroblast":39.35094339622642,"granulocyte":4.623287671232877,"macrophage_group_a":7.315761161915008,"macrophage_group_b":22.88961038961039,"nk_cell":2.375296912114014,"t_cd4":1.7059994313335227,"t_cd8":1.733102253032929,"t_reg":3.3652007648183555,"tumor":12.631742095474271},"owner_category":"stromal","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000138448","source_id":"cancer-surfaceome-atlas","source_row":{"row":60,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000138448","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":48,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":39.35094339622642,"points":3.55,"state":"derived","tumor_percent":12.631742095474271}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":46.38},"gene_symbol":"ITGAV","identifiers":{"approved_symbol":"ITGAV","ensembl_gene_id":"ENSG00000138448","uniprot_accessions":["P06756"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17},{"basis":"verified experimental target anchor","points":10},{"basis":"verified miniprotein complex","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":95},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"verified experimental target anchor","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":77},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12},{"basis":"verified experimental target anchor","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":72},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"verified experimental target anchor","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"verified experimental target anchor","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":23}],"open_targets_association":{"associated_target_rank":381,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"ITGAV","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"fibroblast","highest_other_percent":39.35094339622642,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":12.631742095474271}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"verified-structure-anchor","source_id":"rcsb:8TCG","url":"https://www.rcsb.org/structure/8TCG"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":true,"interaction_classes":["miniprotein-complex"],"pdb_ids":["8TCG"],"verified_anchor_count":1},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":60.0},{"component":"bound-complex-anchor","maximum":10,"points":10.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.96},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":1.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":77.96},"structure_resource_rank":12,"structure_tier":"structure-b","structure_tier_assignment":{"priority_score":77.96,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-b cap.","resource_rank":12,"tier_id":"structure-b"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P06756"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000138448"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":50,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000157168","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000157168","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":49,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":6.27,"raw_score":0.018195916209377355,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":46.27},"gene_symbol":"NRG1","identifiers":{"approved_symbol":"NRG1","ensembl_gene_id":"ENSG00000157168","uniprot_accessions":["Q02297"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":23,"datasource_scores":[{"id":"europepmc","score":0.14965450246034323}],"score":0.018195916209377355,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"NRG1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":20.0,"observed_signals":[{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.94},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.94},"structure_resource_rank":89,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.94,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":89,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["Q02297"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000157168"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":418,"sheet":"Table S6"},"values":{"adipocyte":20.96305520963055,"b_cell":1.0413167618407793,"dc":4.57516339869281,"endothelial":35.61464690496949,"fibroblast":31.743396226415094,"granulocyte":0.684931506849315,"macrophage_group_a":1.1296395911780528,"macrophage_group_b":1.2987012987012987,"nk_cell":19.71496437054632,"t_cd4":8.586863804378732,"t_cd8":23.951473136915077,"t_reg":3.518164435946463,"tumor":9.99690018598884}},"transcript_fusion_event_count":{"source_row":{"row":1752,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["endothelial"],"highest_observed_percent_expressing":35.61464690496949,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":20.96305520963055,"b_cell":1.0413167618407793,"dc":4.57516339869281,"endothelial":35.61464690496949,"fibroblast":31.743396226415094,"granulocyte":0.684931506849315,"macrophage_group_a":1.1296395911780528,"macrophage_group_b":1.2987012987012987,"nk_cell":19.71496437054632,"t_cd4":8.586863804378732,"t_cd8":23.951473136915077,"t_reg":3.518164435946463,"tumor":9.99690018598884},"owner_category":"endothelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000213949","source_id":"cancer-surfaceome-atlas","source_row":{"row":418,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000213949","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":50,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":35.61464690496949,"points":3.16,"state":"derived","tumor_percent":9.99690018598884}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":45.99},"gene_symbol":"ITGA1","identifiers":{"approved_symbol":"ITGA1","ensembl_gene_id":"ENSG00000213949","uniprot_accessions":["P56199"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":383,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"ITGA1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"endothelial","highest_other_percent":35.61464690496949,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":9.99690018598884}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.9},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.9},"structure_resource_rank":90,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.9,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":90,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":false,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P56199"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000213949"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":262,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":471,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":221,"sheet":"Table S6"},"values":{"adipocyte":6.18513906185139,"b_cell":0.5374538125629829,"dc":2.6143790849673203,"endothelial":15.823888404533564,"fibroblast":24.588679245283018,"granulocyte":3.2534246575342465,"macrophage_group_a":1.4523937600860677,"macrophage_group_b":15.706168831168831,"nk_cell":0.7125890736342043,"t_cd4":0.7108330963889679,"t_cd8":0.2772963604852686,"t_reg":1.4531548757170172,"tumor":6.695598264104154}},"transcript_fusion_event_count":{"source_row":{"row":870,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["fibroblast"],"highest_observed_percent_expressing":24.588679245283018,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":6.18513906185139,"b_cell":0.5374538125629829,"dc":2.6143790849673203,"endothelial":15.823888404533564,"fibroblast":24.588679245283018,"granulocyte":3.2534246575342465,"macrophage_group_a":1.4523937600860677,"macrophage_group_b":15.706168831168831,"nk_cell":0.7125890736342043,"t_cd4":0.7108330963889679,"t_cd8":0.2772963604852686,"t_reg":1.4531548757170172,"tumor":6.695598264104154},"owner_category":"stromal","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000103855","source_id":"cancer-surfaceome-atlas","source_row":{"row":221,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000103855","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":51,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":3.24,"raw_score":0.004866134753348573,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":24.588679245283018,"points":2.59,"state":"derived","tumor_percent":6.695598264104154}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":45.83},"gene_symbol":"CD276","identifiers":{"approved_symbol":"CD276","ensembl_gene_id":"ENSG00000103855","uniprot_accessions":["Q5ZPR3"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":3,"curated_candidate_alias_count":3,"directness_counts":{"curated-candidate-alias":3},"intervention_ids":["I-CTG-vobramitamab-duocarmazine-2-0-mg-arm-a-070889dad2","I-CTG-vobramitamab-duocarmazine-2-7-mg-arm-b-61467fa51b","I-CTG-vobramitamab-duocarmazine-50a4e37d35"],"modality_counts":{"antibody-drug-conjugate":3},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"explicit assigned antibody-format intervention","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":85},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10},{"basis":"explicit assigned ADC intervention","points":20}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":85},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":181,"datasource_scores":[{"id":"europepmc","score":0.04002211084276505}],"score":0.004866134753348573,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CD276","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"fibroblast","highest_other_percent":24.588679245283018,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":6.695598264104154}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":1.5},{"component":"evidence-readiness","maximum":15,"points":6.87},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":1.58}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":9.95},"structure_resource_rank":33,"structure_tier":"structure-c","structure_tier_assignment":{"priority_score":9.95,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-c cap.","resource_rank":33,"tier_id":"structure-c"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":false,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q5ZPR3"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000103855"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":354,"sheet":"Table S6"},"values":{"adipocyte":0.7471980074719801,"b_cell":0.38629492777964397,"dc":3.9215686274509802,"endothelial":3.6181342632955533,"fibroblast":0.4377358490566038,"granulocyte":0,"macrophage_group_a":22.485207100591715,"macrophage_group_b":51.37987012987013,"nk_cell":0,"t_cd4":0.398066533977822,"t_cd8":0.20797227036395147,"t_reg":0.8413001912045889,"tumor":0.6432114073155611}},"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["macrophage_group_b"],"highest_observed_percent_expressing":51.37987012987013,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":0.7471980074719801,"b_cell":0.38629492777964397,"dc":3.9215686274509802,"endothelial":3.6181342632955533,"fibroblast":0.4377358490566038,"granulocyte":0.0,"macrophage_group_a":22.485207100591715,"macrophage_group_b":51.37987012987013,"nk_cell":0.0,"t_cd4":0.398066533977822,"t_cd8":0.20797227036395147,"t_reg":0.8413001912045889,"tumor":0.6432114073155611},"owner_category":"immune","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000260314","source_id":"cancer-surfaceome-atlas","source_row":{"row":354,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000260314","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":52,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":4.89,"raw_score":0.011069524582923039,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":51.37987012987013,"points":0.8,"state":"derived","tumor_percent":0.6432114073155611}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":45.69},"gene_symbol":"MRC1","identifiers":{"approved_symbol":"MRC1","ensembl_gene_id":"ENSG00000260314","uniprot_accessions":["P22897"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":57,"datasource_scores":[{"id":"europepmc","score":0.09104263697785916}],"score":0.011069524582923039,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"MRC1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"macrophage_group_b","highest_other_percent":51.37987012987013,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":0.6432114073155611}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.85},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.85},"structure_resource_rank":91,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.85,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":91,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P22897"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000260314"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":168,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":89,"sheet":"Table S6"},"values":{"adipocyte":2.28310502283105,"b_cell":36.19415518978838,"dc":38.56209150326798,"endothelial":1.9616390584132521,"fibroblast":2.0226415094339623,"granulocyte":27.56849315068493,"macrophage_group_a":53.14685314685315,"macrophage_group_b":51.826298701298704,"nk_cell":64.37054631828978,"t_cd4":65.11231162922945,"t_cd8":76.08318890814559,"t_reg":79.96175908221798,"tumor":1.9606323620582764}},"transcript_fusion_event_count":{"source_row":{"row":1242,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["t_reg"],"highest_observed_percent_expressing":79.96175908221798,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":2.28310502283105,"b_cell":36.19415518978838,"dc":38.56209150326798,"endothelial":1.9616390584132521,"fibroblast":2.0226415094339623,"granulocyte":27.56849315068493,"macrophage_group_a":53.14685314685315,"macrophage_group_b":51.826298701298704,"nk_cell":64.37054631828978,"t_cd4":65.11231162922945,"t_cd8":76.08318890814559,"t_reg":79.96175908221798,"tumor":1.9606323620582764},"owner_category":"immune","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000081237","source_id":"cancer-surfaceome-atlas","source_row":{"row":89,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000081237","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":53,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":4.24,"raw_score":0.008315546730405791,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":79.96175908221798,"points":1.4,"state":"derived","tumor_percent":1.9606323620582764}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":45.64},"gene_symbol":"PTPRC","identifiers":{"approved_symbol":"PTPRC","ensembl_gene_id":"ENSG00000081237","uniprot_accessions":["P08575"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":98,"datasource_scores":[{"id":"europepmc","score":0.06839221473130737}],"score":0.008315546730405791,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"PTPRC","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"t_reg","highest_other_percent":79.96175908221798,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":1.9606323620582764}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.85},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.85},"structure_resource_rank":92,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.85,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":92,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P08575"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000081237"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":176,"sheet":"Table S6"},"values":{"adipocyte":0.20755500207555005,"b_cell":0.4534766543500168,"dc":1.3071895424836601,"endothelial":0.6974716652136007,"fibroblast":0.5886792452830188,"granulocyte":0.684931506849315,"macrophage_group_a":0.32275416890801506,"macrophage_group_b":0.689935064935065,"nk_cell":13.30166270783848,"t_cd4":5.345464884845039,"t_cd8":50.43327556325823,"t_reg":3.5946462715105163,"tumor":0.49597024178549287}},"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["t_cd8"],"highest_observed_percent_expressing":50.43327556325823,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":0.20755500207555005,"b_cell":0.4534766543500168,"dc":1.3071895424836601,"endothelial":0.6974716652136007,"fibroblast":0.5886792452830188,"granulocyte":0.684931506849315,"macrophage_group_a":0.32275416890801506,"macrophage_group_b":0.689935064935065,"nk_cell":13.30166270783848,"t_cd4":5.345464884845039,"t_cd8":50.43327556325823,"t_reg":3.5946462715105163,"tumor":0.49597024178549287},"owner_category":"immune","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000153563","source_id":"cancer-surfaceome-atlas","source_row":{"row":176,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000153563","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":54,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":4.93,"raw_score":0.011251653353734256,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":50.43327556325823,"points":0.7,"state":"derived","tumor_percent":0.49597024178549287}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":45.63},"gene_symbol":"CD8A","identifiers":{"approved_symbol":"CD8A","ensembl_gene_id":"ENSG00000153563","uniprot_accessions":["P01732"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":51,"datasource_scores":[{"id":"europepmc","score":0.09254057696976899}],"score":0.011251653353734256,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CD8A","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":70.0,"observed_signals":[{"highest_other_cell_type":"t_cd8","highest_other_percent":50.43327556325823,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":0.49597024178549287},{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.84},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.84},"structure_resource_rank":93,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.84,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":93,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P01732"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000153563"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":571,"sheet":"Table S6"},"values":{"adipocyte":17.31008717310087,"b_cell":31.743365804501178,"dc":27.450980392156865,"endothelial":29.86050566695728,"fibroblast":38.73207547169811,"granulocyte":17.636986301369863,"macrophage_group_a":30.984400215169444,"macrophage_group_b":43.79058441558442,"nk_cell":26.128266033254157,"t_cd4":29.087290304236564,"t_cd8":22.287694974003465,"t_reg":25.621414913957935,"tumor":31.10663360198388}},"transcript_fusion_event_count":{"source_row":{"row":429,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["macrophage_group_b"],"highest_observed_percent_expressing":43.79058441558442,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":17.31008717310087,"b_cell":31.743365804501178,"dc":27.450980392156865,"endothelial":29.86050566695728,"fibroblast":38.73207547169811,"granulocyte":17.636986301369863,"macrophage_group_a":30.984400215169444,"macrophage_group_b":43.79058441558442,"nk_cell":26.128266033254157,"t_cd4":29.087290304236564,"t_cd8":22.287694974003465,"t_reg":25.621414913957935,"tumor":31.10663360198388},"owner_category":"immune","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-CD47","source_id":"cancer-surfaceome-atlas","source_row":{"row":571,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-CD47","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":55,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":43.79058441558442,"points":5.58,"state":"derived","tumor_percent":31.10663360198388}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":45.58},"gene_symbol":"CD47","identifiers":{"approved_symbol":"CD47","ensembl_gene_id":"ENSG00000196776","uniprot_accessions":["Q08722"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17},{"basis":"verified experimental target anchor","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":85},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"verified experimental target anchor","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":77},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12},{"basis":"verified experimental target anchor","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":72},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"verified experimental target anchor","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"verified experimental target anchor","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":23}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CD47","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"macrophage_group_b","highest_other_percent":43.79058441558442,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":31.10663360198388}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"verified-structure-anchor","source_id":"rcsb:2JJS","url":"https://www.rcsb.org/structure/2JJS"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":true,"interaction_classes":["natural-partner-complex"],"pdb_ids":["2JJS"],"verified_anchor_count":1},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":60.0},{"component":"bound-complex-anchor","maximum":10,"points":10.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.84},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":2.58}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":79.42},"structure_resource_rank":10,"structure_tier":"structure-a","structure_tier_assignment":{"priority_score":79.42,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-a cap.","resource_rank":10,"tier_id":"structure-a"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q08722"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000196776"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":1165,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000181143","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000181143","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":56,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":5.56,"raw_score":0.014276902260890368,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":45.56},"gene_symbol":"MUC16","identifiers":{"approved_symbol":"MUC16","ensembl_gene_id":"ENSG00000181143","uniprot_accessions":["Q8WXI7"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":38,"datasource_scores":[{"id":"europepmc","score":0.11742210064846247}],"score":0.014276902260890368,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"MUC16","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":20.0,"observed_signals":[{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.83},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.83},"structure_resource_rank":94,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.83,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":94,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["Q8WXI7"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000181143"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":1398,"sheet":"Table S22"},"values":{"count":1}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000130234","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000130234","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":57,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":5.51,"raw_score":0.01404403447801867,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":45.51},"gene_symbol":"ACE2","identifiers":{"approved_symbol":"ACE2","ensembl_gene_id":"ENSG00000130234","uniprot_accessions":["Q9BYF1"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":40,"datasource_scores":[{"id":"europepmc","score":0.115506851546208}],"score":0.01404403447801867,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"ACE2","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":20.0,"observed_signals":[{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.83},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.83},"structure_resource_rank":95,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.83,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":95,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q9BYF1"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000130234"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":242,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":492,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":222,"sheet":"Table S6"},"values":{"adipocyte":16.43835616438356,"b_cell":0.6550218340611353,"dc":3.9215686274509802,"endothelial":32.82476024411508,"fibroblast":21.464150943396227,"granulocyte":1.1986301369863013,"macrophage_group_a":3.012372243141474,"macrophage_group_b":3.2873376623376624,"nk_cell":1.66270783847981,"t_cd4":0.796133067955644,"t_cd8":0.5545927209705372,"t_reg":0.7265774378585086,"tumor":10.771853688778673}},"transcript_fusion_event_count":{"source_row":{"row":1275,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["endothelial"],"highest_observed_percent_expressing":32.82476024411508,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":16.43835616438356,"b_cell":0.6550218340611353,"dc":3.9215686274509802,"endothelial":32.82476024411508,"fibroblast":21.464150943396227,"granulocyte":1.1986301369863013,"macrophage_group_a":3.012372243141474,"macrophage_group_b":3.2873376623376624,"nk_cell":1.66270783847981,"t_cd4":0.796133067955644,"t_cd8":0.5545927209705372,"t_reg":0.7265774378585086,"tumor":10.771853688778673},"owner_category":"endothelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000101384","source_id":"cancer-surfaceome-atlas","source_row":{"row":222,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000101384","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":58,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.19,"raw_score":0.0022174791281082107,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":32.82476024411508,"points":3.28,"state":"derived","tumor_percent":10.771853688778673}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":45.47},"gene_symbol":"JAG1","identifiers":{"approved_symbol":"JAG1","ensembl_gene_id":"ENSG00000101384","uniprot_accessions":["P78504"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":445,"datasource_scores":[{"id":"europepmc","score":0.01823792392834863}],"score":0.0022174791281082107,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"JAG1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"endothelial","highest_other_percent":32.82476024411508,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":10.771853688778673}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.82},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.82},"structure_resource_rank":96,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.82,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":96,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P78504"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000101384"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":40,"sheet":"Table S6"},"values":{"adipocyte":23.28767123287671,"b_cell":0.3023177695666779,"dc":0.6535947712418301,"endothelial":2.092414995640802,"fibroblast":44.135849056603774,"granulocyte":0.684931506849315,"macrophage_group_a":1.0758472296933834,"macrophage_group_b":1.0146103896103895,"nk_cell":2.6128266033254155,"t_cd4":0.6255331248222917,"t_cd8":1.1785095320623917,"t_reg":0.5353728489483747,"tumor":1.069435833849969}},"transcript_fusion_event_count":{"source_row":{"row":1338,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["fibroblast"],"highest_observed_percent_expressing":44.135849056603774,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":23.28767123287671,"b_cell":0.3023177695666779,"dc":0.6535947712418301,"endothelial":2.092414995640802,"fibroblast":44.135849056603774,"granulocyte":0.684931506849315,"macrophage_group_a":1.0758472296933834,"macrophage_group_b":1.0146103896103895,"nk_cell":2.6128266033254155,"t_cd4":0.6255331248222917,"t_cd8":1.1785095320623917,"t_reg":0.5353728489483747,"tumor":1.069435833849969},"owner_category":"stromal","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000113721","source_id":"cancer-surfaceome-atlas","source_row":{"row":40,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000113721","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":59,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":4.19,"raw_score":0.00813075680306344,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":44.135849056603774,"points":1.03,"state":"derived","tumor_percent":1.069435833849969}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":45.22},"gene_symbol":"PDGFRB","identifiers":{"approved_symbol":"PDGFRB","ensembl_gene_id":"ENSG00000113721","uniprot_accessions":["P09619"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":103,"datasource_scores":[{"id":"europepmc","score":0.06687238773727831}],"score":0.00813075680306344,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"PDGFRB","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"fibroblast","highest_other_percent":44.135849056603774,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":1.069435833849969}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.78},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":1.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":7.78},"structure_resource_rank":58,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":7.78,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":58,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P09619"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000113721"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":299,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":10,"sheet":"Table S6"},"values":{"adipocyte":21.378165213781653,"b_cell":0.7222035606315083,"dc":4.57516339869281,"endothelial":1.1333914559721012,"fibroblast":49.11698113207547,"granulocyte":0.3424657534246575,"macrophage_group_a":0.8068854222700376,"macrophage_group_b":1.4204545454545454,"nk_cell":0.23752969121140144,"t_cd4":0.398066533977822,"t_cd8":0.17331022530329288,"t_reg":0.07648183556405354,"tumor":0.8137011779293243}},"transcript_fusion_event_count":{"source_row":{"row":512,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["fibroblast"],"highest_observed_percent_expressing":49.11698113207547,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":21.378165213781653,"b_cell":0.7222035606315083,"dc":4.57516339869281,"endothelial":1.1333914559721012,"fibroblast":49.11698113207547,"granulocyte":0.3424657534246575,"macrophage_group_a":0.8068854222700376,"macrophage_group_b":1.4204545454545454,"nk_cell":0.23752969121140144,"t_cd4":0.398066533977822,"t_cd8":0.17331022530329288,"t_reg":0.07648183556405354,"tumor":0.8137011779293243},"owner_category":"stromal","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000134853","source_id":"cancer-surfaceome-atlas","source_row":{"row":10,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000134853","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":60,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":4.19,"raw_score":0.00813075680306344,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":49.11698113207547,"points":0.9,"state":"derived","tumor_percent":0.8137011779293243}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":45.09},"gene_symbol":"PDGFRA","identifiers":{"approved_symbol":"PDGFRA","ensembl_gene_id":"ENSG00000134853","uniprot_accessions":["P16234"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":102,"datasource_scores":[{"id":"europepmc","score":0.06687238773727831}],"score":0.00813075680306344,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"PDGFRA","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"fibroblast","highest_other_percent":49.11698113207547,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":0.8137011779293243}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.76},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.76},"structure_resource_rank":97,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.76,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":97,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P16234"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000134853"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":46,"sheet":"Table S6"},"values":{"adipocyte":3.7775010377750107,"b_cell":0.11756802149815251,"dc":13.071895424836603,"endothelial":0.8282476024411508,"fibroblast":18.4,"granulocyte":13.698630136986301,"macrophage_group_a":0.8068854222700376,"macrophage_group_b":1.7857142857142856,"nk_cell":0.23752969121140144,"t_cd4":2.104065965311345,"t_cd8":0.5545927209705372,"t_reg":5.736137667304015,"tumor":1.1314321140731556}},"transcript_fusion_event_count":{"source_row":{"row":1008,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["fibroblast"],"highest_observed_percent_expressing":18.4,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":3.7775010377750107,"b_cell":0.11756802149815251,"dc":13.071895424836603,"endothelial":0.8282476024411508,"fibroblast":18.4,"granulocyte":13.698630136986301,"macrophage_group_a":0.8068854222700376,"macrophage_group_b":1.7857142857142856,"nk_cell":0.23752969121140144,"t_cd4":2.104065965311345,"t_cd8":0.5545927209705372,"t_reg":5.736137667304015,"tumor":1.1314321140731556},"owner_category":"stromal","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000148848","source_id":"cancer-surfaceome-atlas","source_row":{"row":46,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000148848","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":61,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":4.0,"raw_score":0.0073915970936940375,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":18.4,"points":1.06,"state":"derived","tumor_percent":1.1314321140731556}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":45.06},"gene_symbol":"ADAM12","identifiers":{"approved_symbol":"ADAM12","ensembl_gene_id":"ENSG00000148848","uniprot_accessions":["O43184"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":129,"datasource_scores":[{"id":"europepmc","score":0.06079307976116211}],"score":0.0073915970936940375,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"ADAM12","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":70.0,"observed_signals":[{"highest_other_cell_type":"fibroblast","highest_other_percent":18.4,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":1.1314321140731556},{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.76},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.76},"structure_resource_rank":98,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.76,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":98,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["O43184"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000148848"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":63,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":1364,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000120217","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000120217","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":62,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":5.06,"raw_score":0.011851006329951928,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":45.06},"gene_symbol":"CD274","identifiers":{"approved_symbol":"CD274","ensembl_gene_id":"ENSG00000120217","uniprot_accessions":["Q9NZQ7"]},"intervention_summary":{"action_counts":{"binder":3,"blocker":3,"inhibitor":1},"assigned_intervention_count":4,"curated_candidate_alias_count":2,"directness_counts":{"curated-candidate-alias":2,"registry-explicit":2},"intervention_ids":["I-CTG-anti-pd-l1-monoclonal-antibody-b15c504477","I-CTG-atezolizumab-5dd1e8658b","I-CTG-avelumab-b59aea15d3","I-CTG-durvalumab-a8c0108ba9"],"modality_counts":{"antibody":4},"registry_explicit_count":2},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"explicit assigned antibody-format intervention","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":85},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":48,"datasource_scores":[{"id":"europepmc","score":0.09747002764550669}],"score":0.011851006329951928,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CD274","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":20.0,"observed_signals":[{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":3.0},{"component":"evidence-readiness","maximum":15,"points":6.76},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":5.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":14.76},"structure_resource_rank":18,"structure_tier":"structure-b","structure_tier_assignment":{"priority_score":14.76,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-b cap.","resource_rank":18,"tier_id":"structure-b"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q9NZQ7"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000120217"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":130,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":306,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":113,"sheet":"Table S6"},"values":{"adipocyte":17.47613117476131,"b_cell":0.40309035942223714,"dc":1.3071895424836601,"endothelial":2.048823016564952,"fibroblast":23.69811320754717,"granulocyte":0.17123287671232876,"macrophage_group_a":0.48413125336202256,"macrophage_group_b":1.37987012987013,"nk_cell":0,"t_cd4":0.48336650554449817,"t_cd8":0.4506065857885615,"t_reg":0.5353728489483747,"tumor":4.1692498450093}},"transcript_fusion_event_count":{"source_row":{"row":174,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["fibroblast"],"highest_observed_percent_expressing":23.69811320754717,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":17.47613117476131,"b_cell":0.40309035942223714,"dc":1.3071895424836601,"endothelial":2.048823016564952,"fibroblast":23.69811320754717,"granulocyte":0.17123287671232876,"macrophage_group_a":0.48413125336202256,"macrophage_group_b":1.37987012987013,"nk_cell":0.0,"t_cd4":0.48336650554449817,"t_cd8":0.4506065857885615,"t_reg":0.5353728489483747,"tumor":4.1692498450093},"owner_category":"stromal","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000074181","source_id":"cancer-surfaceome-atlas","source_row":{"row":113,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000074181","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":63,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":23.69811320754717,"points":2.04,"state":"derived","tumor_percent":4.1692498450093}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":44.87},"gene_symbol":"NOTCH3","identifiers":{"approved_symbol":"NOTCH3","ensembl_gene_id":"ENSG00000074181","uniprot_accessions":["Q9UM47"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":299,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"NOTCH3","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"fibroblast","highest_other_percent":23.69811320754717,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":4.1692498450093}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.73},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.73},"structure_resource_rank":99,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.73,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":99,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q9UM47"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000074181"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":{"source_row":{"row":29,"sheet":"Table S17"},"values":{"in_frame":null,"missense":null,"silent":null,"truncating":null}},"mutation_clonality":{"source_row":{"row":29,"sheet":"Table S20"},"values":{"clonal":null,"subclonal":null,"unknown":null}},"mutation_frequency_percent":{"source_row":{"row":27,"sheet":"Table S15"},"values":{"percent":null}},"mutation_timing":{"source_row":{"row":29,"sheet":"Table S19"},"values":{"early":null,"late":null,"unknown":null}},"mutation_zygosity":{"source_row":{"row":29,"sheet":"Table S18"},"values":{"heter":null,"homo":null,"unknown":null}},"potential_target_summary":{"source_row":{"row":1269,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":{"source_row":{"row":27,"sheet":"Table S14"},"values":{"flag":0}},"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":116,"sheet":"Table S6"},"values":{"adipocyte":0.8302200083022002,"b_cell":15.88847833389318,"dc":23.52941176470588,"endothelial":4.228421970357454,"fibroblast":0.6339622641509434,"granulocyte":3.595890410958904,"macrophage_group_a":14.577729962345348,"macrophage_group_b":4.504870129870129,"nk_cell":11.401425178147269,"t_cd4":19.30622689792437,"t_cd8":9.185441941074524,"t_reg":33.766730401529635,"tumor":0.5502169869807811}},"transcript_fusion_event_count":{"source_row":{"row":1718,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["t_reg"],"highest_observed_percent_expressing":33.766730401529635,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":0.8302200083022002,"b_cell":15.88847833389318,"dc":23.52941176470588,"endothelial":4.228421970357454,"fibroblast":0.6339622641509434,"granulocyte":3.595890410958904,"macrophage_group_a":14.577729962345348,"macrophage_group_b":4.504870129870129,"nk_cell":11.401425178147269,"t_cd4":19.30622689792437,"t_cd8":9.185441941074524,"t_reg":33.766730401529635,"tumor":0.5502169869807811},"owner_category":"immune","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000188404","source_id":"cancer-surfaceome-atlas","source_row":{"row":116,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000188404","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":64,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":4.1,"raw_score":0.007761176948378739,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":33.766730401529635,"points":0.74,"state":"derived","tumor_percent":0.5502169869807811}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":44.84},"gene_symbol":"SELL","identifiers":{"approved_symbol":"SELL","ensembl_gene_id":"ENSG00000188404","uniprot_accessions":["P14151"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":107,"datasource_scores":[{"id":"europepmc","score":0.06383273374922022}],"score":0.007761176948378739,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"SELL","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"t_reg","highest_other_percent":33.766730401529635,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":0.5502169869807811}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.73},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.73},"structure_resource_rank":100,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.73,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":100,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P14151"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000188404"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":{"source_row":{"row":27,"sheet":"Table S17"},"values":{"in_frame":null,"missense":null,"silent":null,"truncating":null}},"mutation_clonality":{"source_row":{"row":27,"sheet":"Table S20"},"values":{"clonal":null,"subclonal":null,"unknown":null}},"mutation_frequency_percent":{"source_row":{"row":25,"sheet":"Table S15"},"values":{"percent":null}},"mutation_timing":{"source_row":{"row":27,"sheet":"Table S19"},"values":{"early":null,"late":null,"unknown":null}},"mutation_zygosity":{"source_row":{"row":27,"sheet":"Table S18"},"values":{"heter":null,"homo":null,"unknown":null}},"potential_target_summary":null,"recurrent_mutation_flag":{"source_row":{"row":25,"sheet":"Table S14"},"values":{"flag":0}},"scna_g_score":{"source_row":{"row":624,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":26,"sheet":"Table S6"},"values":{"adipocyte":3.1548360315483603,"b_cell":0.3694994961370507,"dc":7.18954248366013,"endothelial":14.734088927637314,"fibroblast":6.30943396226415,"granulocyte":0.5136986301369862,"macrophage_group_a":0.9682625067240451,"macrophage_group_b":1.5016233766233766,"nk_cell":0.23752969121140144,"t_cd4":0.4264998578333807,"t_cd8":0.41594454072790293,"t_reg":0.3441682600382409,"tumor":16.76224426534408}},"transcript_fusion_event_count":{"source_row":{"row":525,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["tumor"],"highest_observed_percent_expressing":16.76224426534408,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":3.1548360315483603,"b_cell":0.3694994961370507,"dc":7.18954248366013,"endothelial":14.734088927637314,"fibroblast":6.30943396226415,"granulocyte":0.5136986301369862,"macrophage_group_a":0.9682625067240451,"macrophage_group_b":1.5016233766233766,"nk_cell":0.23752969121140144,"t_cd4":0.4264998578333807,"t_cd8":0.41594454072790293,"t_reg":0.3441682600382409,"tumor":16.76224426534408},"owner_category":"malignant-epithelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-EPHA2","source_id":"cancer-surfaceome-atlas","source_row":{"row":26,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-EPHA2","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":65,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":14.734088927637314,"points":4.7,"state":"derived","tumor_percent":16.76224426534408}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":44.7},"gene_symbol":"EPHA2","identifiers":{"approved_symbol":"EPHA2","ensembl_gene_id":"ENSG00000142627","uniprot_accessions":["P29317"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"EPHA2","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":43.95,"observed_signals":[{"highest_other_cell_type":"endothelial","highest_other_percent":14.734088927637314,"points":43.95,"signal":"tumor-microenvironment-sharing","tumor_percent":16.76224426534408}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.71},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":2.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":8.71},"structure_resource_rank":46,"structure_tier":"structure-c","structure_tier_assignment":{"priority_score":8.71,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-c cap.","resource_rank":46,"tier_id":"structure-c"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P29317"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000142627"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":{"source_row":{"row":14,"sheet":"Table S17"},"values":{"in_frame":null,"missense":null,"silent":null,"truncating":null}},"mutation_clonality":{"source_row":{"row":14,"sheet":"Table S20"},"values":{"clonal":null,"subclonal":null,"unknown":null}},"mutation_frequency_percent":{"source_row":{"row":12,"sheet":"Table S15"},"values":{"percent":null}},"mutation_timing":{"source_row":{"row":14,"sheet":"Table S19"},"values":{"early":null,"late":null,"unknown":null}},"mutation_zygosity":{"source_row":{"row":14,"sheet":"Table S18"},"values":{"heter":null,"homo":null,"unknown":null}},"potential_target_summary":null,"recurrent_mutation_flag":{"source_row":{"row":12,"sheet":"Table S14"},"values":{"flag":0}},"scna_g_score":{"source_row":{"row":271,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":37,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000066468","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000066468","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":66,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":4.47,"raw_score":0.009239496367117545,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":44.47},"gene_symbol":"FGFR2","identifiers":{"approved_symbol":"FGFR2","ensembl_gene_id":"ENSG00000066468","uniprot_accessions":["P21802"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":79,"datasource_scores":[{"id":"europepmc","score":0.07599134970145263}],"score":0.009239496367117545,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"FGFR2","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":20.0,"observed_signals":[{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.67},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":1.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":7.67},"structure_resource_rank":62,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":7.67,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":62,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P21802"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000066468"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":495,"sheet":"Table S6"},"values":{"adipocyte":7.181403071814032,"b_cell":7.138058448102116,"dc":11.76470588235294,"endothelial":33.43504795117698,"fibroblast":15.818867924528302,"granulocyte":7.191780821917808,"macrophage_group_a":17.1059709521248,"macrophage_group_b":27.92207792207792,"nk_cell":11.63895486935867,"t_cd4":9.610463463178846,"t_cd8":7.383015597920277,"t_reg":15.334608030592733,"tumor":19.69156850588965}},"transcript_fusion_event_count":{"source_row":{"row":295,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["endothelial"],"highest_observed_percent_expressing":33.43504795117698,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":7.181403071814032,"b_cell":7.138058448102116,"dc":11.76470588235294,"endothelial":33.43504795117698,"fibroblast":15.818867924528302,"granulocyte":7.191780821917808,"macrophage_group_a":17.1059709521248,"macrophage_group_b":27.92207792207792,"nk_cell":11.63895486935867,"t_cd4":9.610463463178846,"t_cd8":7.383015597920277,"t_reg":15.334608030592733,"tumor":19.69156850588965},"owner_category":"endothelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-ADAM10","source_id":"cancer-surfaceome-atlas","source_row":{"row":495,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-ADAM10","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":67,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":33.43504795117698,"points":4.44,"state":"derived","tumor_percent":19.69156850588965}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":44.44},"gene_symbol":"ADAM10","identifiers":{"approved_symbol":"ADAM10","ensembl_gene_id":"ENSG00000137845","uniprot_accessions":["O14672"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"ADAM10","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"endothelial","highest_other_percent":33.43504795117698,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":19.69156850588965}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.67},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":2.58}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":9.25},"structure_resource_rank":40,"structure_tier":"structure-c","structure_tier_assignment":{"priority_score":9.25,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-c cap.","resource_rank":40,"tier_id":"structure-c"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["O14672"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000137845"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":261,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000047936","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000047936","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":68,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":4.4,"raw_score":0.008938083463408023,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":44.4},"gene_symbol":"ROS1","identifiers":{"approved_symbol":"ROS1","ensembl_gene_id":"ENSG00000047936","uniprot_accessions":["P08922"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":80,"datasource_scores":[{"id":"europepmc","score":0.07351234300452525}],"score":0.008938083463408023,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"ROS1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.66},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.66},"structure_resource_rank":101,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.66,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":101,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P08922"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000047936"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":849,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000085563","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000085563","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":69,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":4.38,"raw_score":0.008869916512432843,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":44.38},"gene_symbol":"ABCB1","identifiers":{"approved_symbol":"ABCB1","ensembl_gene_id":"ENSG00000085563","uniprot_accessions":["P08183"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":81,"datasource_scores":[{"id":"europepmc","score":0.07295169571339452}],"score":0.008869916512432843,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"ABCB1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.66},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.66},"structure_resource_rank":102,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.66,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":102,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["P08183"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000085563"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":471,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000101842","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000101842","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":70,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":4.38,"raw_score":0.008869916512432843,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":44.38},"gene_symbol":"VSIG1","identifiers":{"approved_symbol":"VSIG1","ensembl_gene_id":"ENSG00000101842","uniprot_accessions":["Q86XK7"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":86,"datasource_scores":[{"id":"europepmc","score":0.07295169571339452}],"score":0.008869916512432843,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"VSIG1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.66},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.66},"structure_resource_rank":103,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.66,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":103,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":false,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q86XK7"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000101842"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":28,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":727,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":101,"sheet":"Table S6"},"values":{"adipocyte":7.638024076380241,"b_cell":2.1498152502519314,"dc":11.76470588235294,"endothelial":13.905841325196164,"fibroblast":24.437735849056605,"granulocyte":30.47945205479452,"macrophage_group_a":45.615922538999456,"macrophage_group_b":50.93344155844156,"nk_cell":2.375296912114014,"t_cd4":3.6678987773670744,"t_cd8":1.386481802426343,"t_reg":2.2562141491395793,"tumor":19.07935523868568}},"transcript_fusion_event_count":{"source_row":{"row":256,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["macrophage_group_b"],"highest_observed_percent_expressing":50.93344155844156,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":7.638024076380241,"b_cell":2.1498152502519314,"dc":11.76470588235294,"endothelial":13.905841325196164,"fibroblast":24.437735849056605,"granulocyte":30.47945205479452,"macrophage_group_a":45.615922538999456,"macrophage_group_b":50.93344155844156,"nk_cell":2.375296912114014,"t_cd4":3.6678987773670744,"t_cd8":1.386481802426343,"t_reg":2.2562141491395793,"tumor":19.07935523868568},"owner_category":"immune","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-PLAUR","source_id":"cancer-surfaceome-atlas","source_row":{"row":101,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-PLAUR","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":71,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":50.93344155844156,"points":4.37,"state":"derived","tumor_percent":19.07935523868568}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":44.37},"gene_symbol":"PLAUR","identifiers":{"approved_symbol":"PLAUR","ensembl_gene_id":"ENSG00000011422","uniprot_accessions":["Q03405"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"PLAUR","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":70.0,"observed_signals":[{"highest_other_cell_type":"macrophage_group_b","highest_other_percent":50.93344155844156,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":19.07935523868568},{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.66},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":4.7}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":11.36},"structure_resource_rank":24,"structure_tier":"structure-b","structure_tier_assignment":{"priority_score":11.36,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-b cap.","resource_rank":24,"tier_id":"structure-b"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt records an integral or GPI-anchored membrane form."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":true,"explicit_extracellular_matrix":false,"extracellular_topology":false,"gpi_anchored":true,"integral_membrane":false,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q03405"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000011422"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":358,"sheet":"Table S6"},"values":{"adipocyte":7.804068078040681,"b_cell":9.942895532415182,"dc":13.071895424836603,"endothelial":81.77855274629468,"fibroblast":1.9018867924528302,"granulocyte":1.5410958904109588,"macrophage_group_a":21.785906401291015,"macrophage_group_b":31.087662337662337,"nk_cell":4.038004750593824,"t_cd4":4.634631788456071,"t_cd8":6.932409012131716,"t_reg":1.835564053537285,"tumor":2.301611903285803}},"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["endothelial"],"highest_observed_percent_expressing":81.77855274629468,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":7.804068078040681,"b_cell":9.942895532415182,"dc":13.071895424836603,"endothelial":81.77855274629468,"fibroblast":1.9018867924528302,"granulocyte":1.5410958904109588,"macrophage_group_a":21.785906401291015,"macrophage_group_b":31.087662337662337,"nk_cell":4.038004750593824,"t_cd4":4.634631788456071,"t_cd8":6.932409012131716,"t_reg":1.835564053537285,"tumor":2.301611903285803},"owner_category":"endothelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000261371","source_id":"cancer-surfaceome-atlas","source_row":{"row":358,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000261371","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":72,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":81.77855274629468,"points":1.52,"state":"derived","tumor_percent":2.301611903285803}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":44.35},"gene_symbol":"PECAM1","identifiers":{"approved_symbol":"PECAM1","ensembl_gene_id":"ENSG00000261371","uniprot_accessions":["P16284"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":353,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"PECAM1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"endothelial","highest_other_percent":81.77855274629468,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":2.301611903285803}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.65},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.65},"structure_resource_rank":104,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.65,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":104,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":true,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P16284"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000261371"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":{"source_row":{"row":26,"sheet":"Table S17"},"values":{"in_frame":null,"missense":null,"silent":null,"truncating":null}},"mutation_clonality":{"source_row":{"row":26,"sheet":"Table S20"},"values":{"clonal":null,"subclonal":null,"unknown":null}},"mutation_frequency_percent":{"source_row":{"row":24,"sheet":"Table S15"},"values":{"percent":null}},"mutation_timing":{"source_row":{"row":26,"sheet":"Table S19"},"values":{"early":null,"late":null,"unknown":null}},"mutation_zygosity":{"source_row":{"row":26,"sheet":"Table S18"},"values":{"heter":null,"homo":null,"unknown":null}},"potential_target_summary":null,"recurrent_mutation_flag":{"source_row":{"row":24,"sheet":"Table S14"},"values":{"flag":0}},"scna_g_score":{"source_row":{"row":441,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":9,"sheet":"Table S6"},"values":{"adipocyte":0.4151100041511001,"b_cell":0.15115888478333894,"dc":0.6535947712418301,"endothelial":3.6181342632955533,"fibroblast":0.6188679245283019,"granulocyte":65.58219178082192,"macrophage_group_a":5.486820871436256,"macrophage_group_b":0.4464285714285714,"nk_cell":1.4251781472684086,"t_cd4":0.8245663918112027,"t_cd8":0.17331022530329288,"t_reg":0.15296367112810708,"tumor":1.0926844389336638}},"transcript_fusion_event_count":{"source_row":{"row":228,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["granulocyte"],"highest_observed_percent_expressing":65.58219178082192,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":0.4151100041511001,"b_cell":0.15115888478333894,"dc":0.6535947712418301,"endothelial":3.6181342632955533,"fibroblast":0.6188679245283019,"granulocyte":65.58219178082192,"macrophage_group_a":5.486820871436256,"macrophage_group_b":0.4464285714285714,"nk_cell":1.4251781472684086,"t_cd4":0.8245663918112027,"t_cd8":0.17331022530329288,"t_reg":0.15296367112810708,"tumor":1.0926844389336638},"owner_category":"immune","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000157404","source_id":"cancer-surfaceome-atlas","source_row":{"row":9,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000157404","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":73,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":3.29,"raw_score":0.004990765293233916,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":65.58219178082192,"points":1.05,"state":"derived","tumor_percent":1.0926844389336638}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":44.34},"gene_symbol":"KIT","identifiers":{"approved_symbol":"KIT","ensembl_gene_id":"ENSG00000157404","uniprot_accessions":["P10721"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":177,"datasource_scores":[{"id":"europepmc","score":0.04104714971540465}],"score":0.004990765293233916,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"KIT","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"granulocyte","highest_other_percent":65.58219178082192,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":1.0926844389336638}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.65},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.65},"structure_resource_rank":105,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.65,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":105,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P10721"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000157404"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000007062","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000007062","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":74,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":4.33,"raw_score":0.008685126585090493,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":44.33},"gene_symbol":"PROM1","identifiers":{"approved_symbol":"PROM1","ensembl_gene_id":"ENSG00000007062","uniprot_accessions":["O43490"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":1,"curated_candidate_alias_count":0,"directness_counts":{"registry-explicit":1},"intervention_ids":["I-CTG-anti-cd133-car-vector-transduced-t-cells-71f6e37e6a"],"modality_counts":{"car-t-cell-therapy":1},"registry_explicit_count":1},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12},{"basis":"explicit assigned cell-therapy intervention","points":20}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":87},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":89,"datasource_scores":[{"id":"europepmc","score":0.07143186871936548}],"score":0.008685126585090493,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"PROM1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":1.0},{"component":"evidence-readiness","maximum":15,"points":6.65},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":7.65},"structure_resource_rank":63,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":7.65,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":63,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["O43490"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000007062"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":{"source_row":{"row":78,"sheet":"Table S17"},"values":{"in_frame":null,"missense":null,"silent":null,"truncating":null}},"mutation_clonality":{"source_row":{"row":78,"sheet":"Table S20"},"values":{"clonal":null,"subclonal":null,"unknown":null}},"mutation_frequency_percent":{"source_row":{"row":76,"sheet":"Table S15"},"values":{"percent":null}},"mutation_timing":{"source_row":{"row":78,"sheet":"Table S19"},"values":{"early":null,"late":null,"unknown":null}},"mutation_zygosity":{"source_row":{"row":78,"sheet":"Table S18"},"values":{"heter":null,"homo":null,"unknown":null}},"potential_target_summary":{"source_row":{"row":512,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":{"source_row":{"row":76,"sheet":"Table S14"},"values":{"flag":0}},"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":657,"sheet":"Table S6"},"values":{"adipocyte":5.93607305936073,"b_cell":1.4779979845482027,"dc":5.228758169934641,"endothelial":73.67044463818657,"fibroblast":2.1735849056603773,"granulocyte":1.0273972602739725,"macrophage_group_a":1.0758472296933834,"macrophage_group_b":3.2467532467532463,"nk_cell":1.187648456057007,"t_cd4":1.0804663065112312,"t_cd8":1.0051993067590987,"t_reg":1.1089866156787764,"tumor":2.0768753874767514}},"transcript_fusion_event_count":{"source_row":{"row":287,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["endothelial"],"highest_observed_percent_expressing":73.67044463818657,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":5.93607305936073,"b_cell":1.4779979845482027,"dc":5.228758169934641,"endothelial":73.67044463818657,"fibroblast":2.1735849056603773,"granulocyte":1.0273972602739725,"macrophage_group_a":1.0758472296933834,"macrophage_group_b":3.2467532467532463,"nk_cell":1.187648456057007,"t_cd4":1.0804663065112312,"t_cd8":1.0051993067590987,"t_reg":1.1089866156787764,"tumor":2.0768753874767514},"owner_category":"endothelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000130300","source_id":"cancer-surfaceome-atlas","source_row":{"row":657,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000130300","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":75,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":73.67044463818657,"points":1.44,"state":"derived","tumor_percent":2.0768753874767514}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":44.27},"gene_symbol":"PLVAP","identifiers":{"approved_symbol":"PLVAP","ensembl_gene_id":"ENSG00000130300","uniprot_accessions":["Q9BX97"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":329,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"PLVAP","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"endothelial","highest_other_percent":73.67044463818657,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":2.0768753874767514}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.64},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.64},"structure_resource_rank":106,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.64,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":106,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["Q9BX97"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000130300"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":947,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":676,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":null,"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000164850","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000164850","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":76,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":4.24,"raw_score":0.008315546730405791,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":44.24},"gene_symbol":"GPER1","identifiers":{"approved_symbol":"GPER1","ensembl_gene_id":"ENSG00000164850","uniprot_accessions":["Q99527"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":96,"datasource_scores":[{"id":"europepmc","score":0.06839221473130737}],"score":0.008315546730405791,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"GPER1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.64},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.64},"structure_resource_rank":107,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.64,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":107,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":true,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["Q99527"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000164850"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":{"source_row":{"row":21,"sheet":"Table S17"},"values":{"in_frame":null,"missense":null,"silent":null,"truncating":null}},"mutation_clonality":{"source_row":{"row":21,"sheet":"Table S20"},"values":{"clonal":null,"subclonal":null,"unknown":null}},"mutation_frequency_percent":{"source_row":{"row":19,"sheet":"Table S15"},"values":{"percent":null}},"mutation_timing":{"source_row":{"row":21,"sheet":"Table S19"},"values":{"early":null,"late":null,"unknown":null}},"mutation_zygosity":{"source_row":{"row":21,"sheet":"Table S18"},"values":{"heter":null,"homo":null,"unknown":null}},"potential_target_summary":{"source_row":{"row":978,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":{"source_row":{"row":19,"sheet":"Table S14"},"values":{"flag":0}},"scna_g_score":{"source_row":{"row":722,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":126,"sheet":"Table S6"},"values":{"adipocyte":97.30178497301785,"b_cell":99.07625125965738,"dc":99.34640522875817,"endothelial":99.4768962510898,"fibroblast":98.47547169811321,"granulocyte":99.65753424657534,"macrophage_group_a":97.9020979020979,"macrophage_group_b":99.2288961038961,"nk_cell":99.04988123515439,"t_cd4":99.60193346602217,"t_cd8":99.79202772963605,"t_reg":99.5793499043977,"tumor":89.92560446373218}},"transcript_fusion_event_count":{"source_row":{"row":750,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["t_cd8"],"highest_observed_percent_expressing":99.79202772963605,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":97.30178497301785,"b_cell":99.07625125965738,"dc":99.34640522875817,"endothelial":99.4768962510898,"fibroblast":98.47547169811321,"granulocyte":99.65753424657534,"macrophage_group_a":97.9020979020979,"macrophage_group_b":99.2288961038961,"nk_cell":99.04988123515439,"t_cd4":99.60193346602217,"t_cd8":99.79202772963605,"t_reg":99.5793499043977,"tumor":89.92560446373218},"owner_category":"immune","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000166710","source_id":"cancer-surfaceome-atlas","source_row":{"row":126,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000166710","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":77,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA global GESP membership","component":"surface-accessibility","maximum":40,"points":30.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":4.73,"raw_score":0.010348235931171651,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":99.79202772963605,"points":9.48,"state":"derived","tumor_percent":89.92560446373218}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":44.21},"gene_symbol":"B2M","identifiers":{"approved_symbol":"B2M","ensembl_gene_id":"ENSG00000166710","uniprot_accessions":["P61769"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":60},{"components":[{"basis":"retained surface-accessibility decision","points":58}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":58},{"components":[{"basis":"retained surface-accessibility decision","points":52}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":52},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":40}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":40},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":62,"datasource_scores":[{"id":"europepmc","score":0.08511031166562696}],"score":0.010348235931171651,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"B2M","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":70.0,"observed_signals":[{"highest_other_cell_type":"t_cd8","highest_other_percent":99.79202772963605,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":89.92560446373218},{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.63},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.63},"structure_resource_rank":108,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.63,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":108,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":true,"explicit_extracellular_matrix":false,"extracellular_topology":false,"gpi_anchored":false,"integral_membrane":false,"peripheral_membrane":false,"plasma_membrane":false,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P61769"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000166710"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":289,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000133067","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000133067","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":78,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":4.0,"raw_score":0.0073915970936940375,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":44.0},"gene_symbol":"LGR6","identifiers":{"approved_symbol":"LGR6","ensembl_gene_id":"ENSG00000133067","uniprot_accessions":["Q9HBX8"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":137,"datasource_scores":[{"id":"europepmc","score":0.06079307976116211}],"score":0.0073915970936940375,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"LGR6","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.6},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.6},"structure_resource_rank":109,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.6,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":109,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q9HBX8"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000133067"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":791,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":861,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":94,"sheet":"Table S6"},"values":{"adipocyte":11.16645911166459,"b_cell":0.3527040644944575,"dc":4.57516339869281,"endothelial":45.902353966870095,"fibroblast":28.241509433962264,"granulocyte":0.684931506849315,"macrophage_group_a":0.5379236148466917,"macrophage_group_b":1.0551948051948052,"nk_cell":0.23752969121140144,"t_cd4":0.34119988626670456,"t_cd8":0.4506065857885615,"t_reg":0.26768642447418733,"tumor":1.208927464352139}},"transcript_fusion_event_count":{"source_row":{"row":1023,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["endothelial"],"highest_observed_percent_expressing":45.902353966870095,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":11.16645911166459,"b_cell":0.3527040644944575,"dc":4.57516339869281,"endothelial":45.902353966870095,"fibroblast":28.241509433962264,"granulocyte":0.684931506849315,"macrophage_group_a":0.5379236148466917,"macrophage_group_b":1.0551948051948052,"nk_cell":0.23752969121140144,"t_cd4":0.34119988626670456,"t_cd8":0.4506065857885615,"t_reg":0.26768642447418733,"tumor":1.208927464352139},"owner_category":"endothelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000152661","source_id":"cancer-surfaceome-atlas","source_row":{"row":94,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000152661","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":79,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":45.902353966870095,"points":1.1,"state":"derived","tumor_percent":1.208927464352139}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":43.93},"gene_symbol":"GJA1","identifiers":{"approved_symbol":"GJA1","ensembl_gene_id":"ENSG00000152661","uniprot_accessions":["P17302"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":317,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"GJA1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"endothelial","highest_other_percent":45.902353966870095,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":1.208927464352139}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.59},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.59},"structure_resource_rank":110,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.59,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":110,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["P17302"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000152661"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":243,"sheet":"Table S6"},"values":{"adipocyte":2.4491490244914904,"b_cell":0.43668122270742354,"dc":26.797385620915033,"endothelial":0.6538796861377506,"fibroblast":4.271698113207547,"granulocyte":4.280821917808219,"macrophage_group_a":29.047875201721357,"macrophage_group_b":48.57954545454545,"nk_cell":0.4750593824228029,"t_cd4":16.007961330679557,"t_cd8":1.2131715771230502,"t_reg":28.030592734225625,"tumor":0.5734655920644761}},"transcript_fusion_event_count":{"source_row":{"row":1190,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["macrophage_group_b"],"highest_observed_percent_expressing":48.57954545454545,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":2.4491490244914904,"b_cell":0.43668122270742354,"dc":26.797385620915033,"endothelial":0.6538796861377506,"fibroblast":4.271698113207547,"granulocyte":4.280821917808219,"macrophage_group_a":29.047875201721357,"macrophage_group_b":48.57954545454545,"nk_cell":0.4750593824228029,"t_cd4":16.007961330679557,"t_cd8":1.2131715771230502,"t_reg":28.030592734225625,"tumor":0.5734655920644761},"owner_category":"immune","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000010610","source_id":"cancer-surfaceome-atlas","source_row":{"row":243,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000010610","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":80,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":3.12,"raw_score":0.004496554898663872,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":48.57954545454545,"points":0.76,"state":"derived","tumor_percent":0.5734655920644761}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":43.88},"gene_symbol":"CD4","identifiers":{"approved_symbol":"CD4","ensembl_gene_id":"ENSG00000010610","uniprot_accessions":["P01730"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":195,"datasource_scores":[{"id":"europepmc","score":0.03698245685470695}],"score":0.004496554898663872,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CD4","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"macrophage_group_b","highest_other_percent":48.57954545454545,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":0.5734655920644761}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.58},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.58},"structure_resource_rank":111,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.58,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":111,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":true,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P01730"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000010610"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":{"source_row":{"row":63,"sheet":"Table S17"},"values":{"in_frame":null,"missense":null,"silent":null,"truncating":null}},"mutation_clonality":{"source_row":{"row":63,"sheet":"Table S20"},"values":{"clonal":null,"subclonal":null,"unknown":null}},"mutation_frequency_percent":{"source_row":{"row":61,"sheet":"Table S15"},"values":{"percent":null}},"mutation_timing":{"source_row":{"row":63,"sheet":"Table S19"},"values":{"early":null,"late":null,"unknown":null}},"mutation_zygosity":{"source_row":{"row":63,"sheet":"Table S18"},"values":{"heter":null,"homo":null,"unknown":null}},"potential_target_summary":{"source_row":{"row":1286,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":{"source_row":{"row":61,"sheet":"Table S14"},"values":{"flag":0}},"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":1723,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000196549","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000196549","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":81,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":3.79,"raw_score":0.006653874639315074,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":43.79},"gene_symbol":"MME","identifiers":{"approved_symbol":"MME","ensembl_gene_id":"ENSG00000196549","uniprot_accessions":["P08473"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":145,"datasource_scores":[{"id":"europepmc","score":0.05472559266166613}],"score":0.006653874639315074,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"MME","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.57},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.57},"structure_resource_rank":112,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.57,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":112,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["P08473"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000196549"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":1248,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":679,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":164,"sheet":"Table S6"},"values":{"adipocyte":2.1585720215857203,"b_cell":12.042324487739336,"dc":9.15032679738562,"endothelial":28.77070619006103,"fibroblast":2.9132075471698116,"granulocyte":11.815068493150685,"macrophage_group_a":3.7116729424421733,"macrophage_group_b":6.087662337662338,"nk_cell":6.413301662707839,"t_cd4":20.045493318168894,"t_cd8":2.4956672443674175,"t_reg":48.33652007648184,"tumor":2.0768753874767514}},"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["t_reg"],"highest_observed_percent_expressing":48.33652007648184,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":2.1585720215857203,"b_cell":12.042324487739336,"dc":9.15032679738562,"endothelial":28.77070619006103,"fibroblast":2.9132075471698116,"granulocyte":11.815068493150685,"macrophage_group_a":3.7116729424421733,"macrophage_group_b":6.087662337662338,"nk_cell":6.413301662707839,"t_cd4":20.045493318168894,"t_cd8":2.4956672443674175,"t_reg":48.33652007648184,"tumor":2.0768753874767514},"owner_category":"immune","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000186827","source_id":"cancer-surfaceome-atlas","source_row":{"row":164,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000186827","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":82,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.19,"raw_score":0.0022174791281082107,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":48.33652007648184,"points":1.44,"state":"derived","tumor_percent":2.0768753874767514}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":43.63},"gene_symbol":"TNFRSF4","identifiers":{"approved_symbol":"TNFRSF4","ensembl_gene_id":"ENSG00000186827","uniprot_accessions":["P43489"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":457,"datasource_scores":[{"id":"europepmc","score":0.01823792392834863}],"score":0.0022174791281082107,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"TNFRSF4","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"t_reg","highest_other_percent":48.33652007648184,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":2.0768753874767514}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.54},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.54},"structure_resource_rank":113,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.54,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":113,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":false,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P43489"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000186827"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":838,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":82,"sheet":"Table S6"},"values":{"adipocyte":17.849730178497303,"b_cell":0.9237487403426269,"dc":1.3071895424836601,"endothelial":29.11944202266783,"fibroblast":48.679245283018865,"granulocyte":1.36986301369863,"macrophage_group_a":6.616460462614309,"macrophage_group_b":40.50324675324675,"nk_cell":0.4750593824228029,"t_cd4":1.1088996303667897,"t_cd8":0.48526863084922006,"t_reg":0.9177820267686425,"tumor":12.693738375697459}},"transcript_fusion_event_count":{"source_row":{"row":537,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["fibroblast"],"highest_observed_percent_expressing":48.679245283018865,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":17.849730178497303,"b_cell":0.9237487403426269,"dc":1.3071895424836601,"endothelial":29.11944202266783,"fibroblast":48.679245283018865,"granulocyte":1.36986301369863,"macrophage_group_a":6.616460462614309,"macrophage_group_b":40.50324675324675,"nk_cell":0.4750593824228029,"t_cd4":1.1088996303667897,"t_cd8":0.48526863084922006,"t_reg":0.9177820267686425,"tumor":12.693738375697459},"owner_category":"stromal","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-MMP14","source_id":"cancer-surfaceome-atlas","source_row":{"row":82,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-MMP14","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":83,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":48.679245283018865,"points":3.56,"state":"derived","tumor_percent":12.693738375697459}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":43.56},"gene_symbol":"MMP14","identifiers":{"approved_symbol":"MMP14","ensembl_gene_id":"ENSG00000157227","uniprot_accessions":["P50281"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"MMP14","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"fibroblast","highest_other_percent":48.679245283018865,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":12.693738375697459}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.53},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":2.58}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":9.11},"structure_resource_rank":42,"structure_tier":"structure-c","structure_tier_assignment":{"priority_score":9.11,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-c cap.","resource_rank":42,"tier_id":"structure-c"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P50281"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000157227"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":18,"sheet":"Table S6"},"values":{"adipocyte":0.33208800332088,"b_cell":19.8018139066174,"dc":0,"endothelial":0.3051438535309503,"fibroblast":0.6339622641509434,"granulocyte":0.17123287671232876,"macrophage_group_a":0.43033889187735336,"macrophage_group_b":0.7711038961038961,"nk_cell":0,"t_cd4":0.995166334944555,"t_cd8":0.4506065857885615,"t_reg":0.6118546845124283,"tumor":0.33323000619962806}},"transcript_fusion_event_count":{"source_row":{"row":1666,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["b_cell"],"highest_observed_percent_expressing":19.8018139066174,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":0.33208800332088,"b_cell":19.8018139066174,"dc":0.0,"endothelial":0.3051438535309503,"fibroblast":0.6339622641509434,"granulocyte":0.17123287671232876,"macrophage_group_a":0.43033889187735336,"macrophage_group_b":0.7711038961038961,"nk_cell":0.0,"t_cd4":0.995166334944555,"t_cd8":0.4506065857885615,"t_reg":0.6118546845124283,"tumor":0.33323000619962806},"owner_category":"immune","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000177455","source_id":"cancer-surfaceome-atlas","source_row":{"row":18,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000177455","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":84,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":19.8018139066174,"points":0.58,"state":"derived","tumor_percent":0.33323000619962806}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":43.41},"gene_symbol":"CD19","identifiers":{"approved_symbol":"CD19","ensembl_gene_id":"ENSG00000177455","uniprot_accessions":["P15391"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":368,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CD19","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"b_cell","highest_other_percent":19.8018139066174,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":0.33323000619962806}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.51},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.51},"structure_resource_rank":114,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.51,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":114,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P15391"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000177455"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":{"source_row":{"row":69,"sheet":"Table S17"},"values":{"in_frame":null,"missense":null,"silent":null,"truncating":null}},"mutation_clonality":{"source_row":{"row":69,"sheet":"Table S20"},"values":{"clonal":null,"subclonal":null,"unknown":null}},"mutation_frequency_percent":{"source_row":{"row":67,"sheet":"Table S15"},"values":{"percent":null}},"mutation_timing":{"source_row":{"row":69,"sheet":"Table S19"},"values":{"early":null,"late":null,"unknown":null}},"mutation_zygosity":{"source_row":{"row":69,"sheet":"Table S18"},"values":{"heter":null,"homo":null,"unknown":null}},"potential_target_summary":null,"recurrent_mutation_flag":{"source_row":{"row":67,"sheet":"Table S14"},"values":{"flag":0}},"scna_g_score":{"source_row":{"row":461,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":35,"sheet":"Table S6"},"values":{"adipocyte":1.9925280199252802,"b_cell":0.15115888478333894,"dc":0,"endothelial":40.58413251961639,"fibroblast":0.25660377358490566,"granulocyte":0,"macrophage_group_a":0,"macrophage_group_b":0.16233766233766234,"nk_cell":0.4750593824228029,"t_cd4":0.199033266988911,"t_cd8":0.17331022530329288,"t_reg":0.26768642447418733,"tumor":0.33323000619962806}},"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["endothelial"],"highest_observed_percent_expressing":40.58413251961639,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":1.9925280199252802,"b_cell":0.15115888478333894,"dc":0.0,"endothelial":40.58413251961639,"fibroblast":0.25660377358490566,"granulocyte":0.0,"macrophage_group_a":0.0,"macrophage_group_b":0.16233766233766234,"nk_cell":0.4750593824228029,"t_cd4":0.199033266988911,"t_cd8":0.17331022530329288,"t_reg":0.26768642447418733,"tumor":0.33323000619962806},"owner_category":"endothelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000128052","source_id":"cancer-surfaceome-atlas","source_row":{"row":35,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000128052","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":85,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":40.58413251961639,"points":0.58,"state":"derived","tumor_percent":0.33323000619962806}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":43.41},"gene_symbol":"KDR","identifiers":{"approved_symbol":"KDR","ensembl_gene_id":"ENSG00000128052","uniprot_accessions":["P35968"]},"intervention_summary":{"action_counts":{"antagonist":1,"binder":1,"blocker":1,"inhibitor":2},"assigned_intervention_count":3,"curated_candidate_alias_count":1,"directness_counts":{"curated-candidate-alias":1,"registry-explicit":2},"intervention_ids":["I-CTG-ramucirumab-3e3bf3aa35","I-CTG-ramucirumab-injection-cyramza-f05ac3bf5c","I-CTG-regorafenib-9aec6927fe"],"modality_counts":{"antibody":2,"small-molecule":1},"registry_explicit_count":2},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"explicit assigned antibody-format intervention","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":85},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30},{"basis":"explicit assigned small-molecule intervention","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":63}],"open_targets_association":{"associated_target_rank":230,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"KDR","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":70.0,"observed_signals":[{"highest_other_cell_type":"endothelial","highest_other_percent":40.58413251961639,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":0.33323000619962806},{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":2.5},{"component":"evidence-readiness","maximum":15,"points":6.51},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":3.81}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":12.82},"structure_resource_rank":21,"structure_tier":"structure-b","structure_tier_assignment":{"priority_score":12.82,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-b cap.","resource_rank":21,"tier_id":"structure-b"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":true,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P35968"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000128052"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":258,"sheet":"Table S6"},"values":{"adipocyte":5.147364051473641,"b_cell":0.16795431642593214,"dc":0,"endothelial":0.7846556233653008,"fibroblast":8.166037735849056,"granulocyte":0.17123287671232876,"macrophage_group_a":0.16137708445400753,"macrophage_group_b":0.4464285714285714,"nk_cell":0,"t_cd4":0.199033266988911,"t_cd8":0.20797227036395147,"t_reg":0.15296367112810708,"tumor":0.27898326100433973}},"transcript_fusion_event_count":{"source_row":{"row":1106,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["fibroblast"],"highest_observed_percent_expressing":8.166037735849056,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":5.147364051473641,"b_cell":0.16795431642593214,"dc":0.0,"endothelial":0.7846556233653008,"fibroblast":8.166037735849056,"granulocyte":0.17123287671232876,"macrophage_group_a":0.16137708445400753,"macrophage_group_b":0.4464285714285714,"nk_cell":0.0,"t_cd4":0.199033266988911,"t_cd8":0.20797227036395147,"t_reg":0.15296367112810708,"tumor":0.27898326100433973},"owner_category":"stromal","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000173546","source_id":"cancer-surfaceome-atlas","source_row":{"row":258,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000173546","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":86,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":8.166037735849056,"points":0.53,"state":"derived","tumor_percent":0.27898326100433973}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":43.36},"gene_symbol":"CSPG4","identifiers":{"approved_symbol":"CSPG4","ensembl_gene_id":"ENSG00000173546","uniprot_accessions":["Q6UVK1"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":244,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CSPG4","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"fibroblast","highest_other_percent":8.166037735849056,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":0.27898326100433973}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.5},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.5},"structure_resource_rank":115,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.5,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":115,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":true,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q6UVK1"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000173546"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":218,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":208,"sheet":"Table S6"},"values":{"adipocyte":17.849730178497303,"b_cell":0.26872690628149143,"dc":13.071895424836603,"endothelial":49.869224062772446,"fibroblast":25.14716981132075,"granulocyte":1.5410958904109588,"macrophage_group_a":7.100591715976331,"macrophage_group_b":42.12662337662338,"nk_cell":0.23752969121140144,"t_cd4":0.398066533977822,"t_cd8":0.38128249566724437,"t_reg":0.6118546845124283,"tumor":2.464352138871668}},"transcript_fusion_event_count":{"source_row":{"row":465,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["endothelial"],"highest_observed_percent_expressing":49.869224062772446,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":17.849730178497303,"b_cell":0.26872690628149143,"dc":13.071895424836603,"endothelial":49.869224062772446,"fibroblast":25.14716981132075,"granulocyte":1.5410958904109588,"macrophage_group_a":7.100591715976331,"macrophage_group_b":42.12662337662338,"nk_cell":0.23752969121140144,"t_cd4":0.398066533977822,"t_cd8":0.38128249566724437,"t_reg":0.6118546845124283,"tumor":2.464352138871668},"owner_category":"endothelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000099250","source_id":"cancer-surfaceome-atlas","source_row":{"row":208,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000099250","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":87,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":1.79,"raw_score":0.0014783194187388072,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":49.869224062772446,"points":1.57,"state":"derived","tumor_percent":2.464352138871668}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":43.36},"gene_symbol":"NRP1","identifiers":{"approved_symbol":"NRP1","ensembl_gene_id":"ENSG00000099250","uniprot_accessions":["O14786"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":542,"datasource_scores":[{"id":"europepmc","score":0.012158615952232422}],"score":0.0014783194187388072,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":13503,"filename":"MONDO_0005007-associated-targets-page-2.json","sha256":"26a9df77e260244ca3b7d5d09ea58127fca45365ce5ac3dd036ffb2a38df2b0d"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"NRP1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":70.0,"observed_signals":[{"highest_other_cell_type":"endothelial","highest_other_percent":49.869224062772446,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":2.464352138871668},{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.5},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.5},"structure_resource_rank":116,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.5,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":116,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["O14786"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000099250"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":313,"sheet":"Table S6"},"values":{"adipocyte":0.62266500622665,"b_cell":1.1420893516963386,"dc":3.2679738562091507,"endothelial":0.5231037489102005,"fibroblast":0.5735849056603773,"granulocyte":0.5136986301369862,"macrophage_group_a":0.26896180742334586,"macrophage_group_b":1.2175324675324677,"nk_cell":51.543942992874115,"t_cd4":25.163491612169466,"t_cd8":28.838821490467936,"t_reg":39.38814531548757,"tumor":0.5579665220086795}},"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["nk_cell"],"highest_observed_percent_expressing":51.543942992874115,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":0.62266500622665,"b_cell":1.1420893516963386,"dc":3.2679738562091507,"endothelial":0.5231037489102005,"fibroblast":0.5735849056603773,"granulocyte":0.5136986301369862,"macrophage_group_a":0.26896180742334586,"macrophage_group_b":1.2175324675324677,"nk_cell":51.543942992874115,"t_cd4":25.163491612169466,"t_cd8":28.838821490467936,"t_reg":39.38814531548757,"tumor":0.5579665220086795},"owner_category":"immune","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000198821","source_id":"cancer-surfaceome-atlas","source_row":{"row":313,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000198821","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":88,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.53,"raw_score":0.0029566388374776143,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":51.543942992874115,"points":0.75,"state":"derived","tumor_percent":0.5579665220086795}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":43.28},"gene_symbol":"CD247","identifiers":{"approved_symbol":"CD247","ensembl_gene_id":"ENSG00000198821","uniprot_accessions":["P20963"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":419,"datasource_scores":[{"id":"europepmc","score":0.024317231904464845}],"score":0.0029566388374776143,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CD247","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"nk_cell","highest_other_percent":51.543942992874115,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":0.5579665220086795}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.49},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.49},"structure_resource_rank":117,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.49,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":117,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P20963"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000198821"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":436,"sheet":"Table S6"},"values":{"adipocyte":12.826899128268993,"b_cell":3.3422908968760496,"dc":27.450980392156865,"endothelial":6.713164777680906,"fibroblast":28.830188679245282,"granulocyte":11.13013698630137,"macrophage_group_a":8.230231307154384,"macrophage_group_b":10.917207792207792,"nk_cell":0.9501187648456058,"t_cd4":5.061131646289451,"t_cd8":2.4263431542461005,"t_reg":7.304015296367113,"tumor":10.485120892746435}},"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["fibroblast"],"highest_observed_percent_expressing":28.830188679245282,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":12.826899128268993,"b_cell":3.3422908968760496,"dc":27.450980392156865,"endothelial":6.713164777680906,"fibroblast":28.830188679245282,"granulocyte":11.13013698630137,"macrophage_group_a":8.230231307154384,"macrophage_group_b":10.917207792207792,"nk_cell":0.9501187648456058,"t_cd4":5.061131646289451,"t_cd8":2.4263431542461005,"t_reg":7.304015296367113,"tumor":10.485120892746435},"owner_category":"stromal","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-ANTXR2","source_id":"cancer-surfaceome-atlas","source_row":{"row":436,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-ANTXR2","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":89,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":28.830188679245282,"points":3.24,"state":"derived","tumor_percent":10.485120892746435}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":43.24},"gene_symbol":"ANTXR2","identifiers":{"approved_symbol":"ANTXR2","ensembl_gene_id":"ENSG00000163297","uniprot_accessions":["P58335"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"ANTXR2","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":70.0,"observed_signals":[{"highest_other_cell_type":"fibroblast","highest_other_percent":28.830188679245282,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":10.485120892746435},{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.49},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.49},"structure_resource_rank":118,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.49,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":118,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":true,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P58335"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000163297"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":{"source_row":{"row":59,"sheet":"Table S17"},"values":{"in_frame":null,"missense":null,"silent":null,"truncating":null}},"mutation_clonality":{"source_row":{"row":59,"sheet":"Table S20"},"values":{"clonal":null,"subclonal":null,"unknown":null}},"mutation_frequency_percent":{"source_row":{"row":57,"sheet":"Table S15"},"values":{"percent":null}},"mutation_timing":{"source_row":{"row":59,"sheet":"Table S19"},"values":{"early":null,"late":null,"unknown":null}},"mutation_zygosity":{"source_row":{"row":59,"sheet":"Table S18"},"values":{"heter":null,"homo":null,"unknown":null}},"potential_target_summary":null,"recurrent_mutation_flag":{"source_row":{"row":57,"sheet":"Table S14"},"values":{"flag":0}},"scna_g_score":{"source_row":{"row":195,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":11,"sheet":"Table S6"},"values":{"adipocyte":21.793275217932752,"b_cell":0.8733624454148471,"dc":0,"endothelial":24.803836094158672,"fibroblast":47.199999999999996,"granulocyte":1.8835616438356164,"macrophage_group_a":1.8827326519634213,"macrophage_group_b":5.2353896103896105,"nk_cell":1.66270783847981,"t_cd4":1.8765993744668752,"t_cd8":0.9358752166377816,"t_reg":4.168260038240918,"tumor":1.0074395536267824}},"transcript_fusion_event_count":{"source_row":{"row":204,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["fibroblast"],"highest_observed_percent_expressing":47.199999999999996,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":21.793275217932752,"b_cell":0.8733624454148471,"dc":0.0,"endothelial":24.803836094158672,"fibroblast":47.199999999999996,"granulocyte":1.8835616438356164,"macrophage_group_a":1.8827326519634213,"macrophage_group_b":5.2353896103896105,"nk_cell":1.66270783847981,"t_cd4":1.8765993744668752,"t_cd8":0.9358752166377816,"t_reg":4.168260038240918,"tumor":1.0074395536267824},"owner_category":"stromal","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000077782","source_id":"cancer-surfaceome-atlas","source_row":{"row":11,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000077782","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":90,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.19,"raw_score":0.0022174791281082107,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":47.199999999999996,"points":1.0,"state":"derived","tumor_percent":1.0074395536267824}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":43.19},"gene_symbol":"FGFR1","identifiers":{"approved_symbol":"FGFR1","ensembl_gene_id":"ENSG00000077782","uniprot_accessions":["P11362"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":449,"datasource_scores":[{"id":"europepmc","score":0.01823792392834863}],"score":0.0022174791281082107,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"FGFR1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"fibroblast","highest_other_percent":47.199999999999996,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":1.0074395536267824}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.48},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.48},"structure_resource_rank":119,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.48,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":119,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P11362"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000077782"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":125,"sheet":"Table S6"},"values":{"adipocyte":10.12868410128684,"b_cell":0.7389989922741014,"dc":0,"endothelial":63.12118570183086,"fibroblast":18.626415094339624,"granulocyte":0.5136986301369862,"macrophage_group_a":0.48413125336202256,"macrophage_group_b":0.7711038961038961,"nk_cell":0.23752969121140144,"t_cd4":0.5402331532556156,"t_cd8":0.48526863084922006,"t_reg":1.0325047801147227,"tumor":0.8601983880967142}},"transcript_fusion_event_count":{"source_row":{"row":1108,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["endothelial"],"highest_observed_percent_expressing":63.12118570183086,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":10.12868410128684,"b_cell":0.7389989922741014,"dc":0.0,"endothelial":63.12118570183086,"fibroblast":18.626415094339624,"granulocyte":0.5136986301369862,"macrophage_group_a":0.48413125336202256,"macrophage_group_b":0.7711038961038961,"nk_cell":0.23752969121140144,"t_cd4":0.5402331532556156,"t_cd8":0.48526863084922006,"t_reg":1.0325047801147227,"tumor":0.8601983880967142},"owner_category":"endothelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000174059","source_id":"cancer-surfaceome-atlas","source_row":{"row":125,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000174059","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":91,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.19,"raw_score":0.0022174791281082107,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":63.12118570183086,"points":0.93,"state":"derived","tumor_percent":0.8601983880967142}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":43.12},"gene_symbol":"CD34","identifiers":{"approved_symbol":"CD34","ensembl_gene_id":"ENSG00000174059","uniprot_accessions":["P28906"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":476,"datasource_scores":[{"id":"europepmc","score":0.01823792392834863}],"score":0.0022174791281082107,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CD34","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"endothelial","highest_other_percent":63.12118570183086,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":0.8601983880967142}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.47},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.47},"structure_resource_rank":120,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.47,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":120,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":false,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P28906"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000174059"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":485,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000126010","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000126010","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":92,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":3.1,"raw_score":0.0044349582562164215,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":43.1},"gene_symbol":"GRPR","identifiers":{"approved_symbol":"GRPR","ensembl_gene_id":"ENSG00000126010","uniprot_accessions":["P30550"]},"intervention_summary":{"action_counts":{"antagonist":1,"radionuclide-delivery":1},"assigned_intervention_count":2,"curated_candidate_alias_count":0,"directness_counts":{"registry-explicit":2},"intervention_ids":["I-CTG-212pb-dotam-grpr1-28e4663353","I-CTG-68ga-neobomb1-9353e21018"],"modality_counts":{"molecular-imaging-agent":1,"radioligand-therapy":1},"registry_explicit_count":2},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"explicit assigned radioligand or radioimmunotherapy intervention","points":20}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":210,"datasource_scores":[{"id":"europepmc","score":0.03647584785669726}],"score":0.0044349582562164215,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"GRPR","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":2.0},{"component":"evidence-readiness","maximum":15,"points":6.46},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":8.46},"structure_resource_rank":52,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":8.46,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":52,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["P30550"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000126010"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":753,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":757,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":1011,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000149294","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000149294","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":93,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":3.1,"raw_score":0.004434958256216422,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":43.1},"gene_symbol":"NCAM1","identifiers":{"approved_symbol":"NCAM1","ensembl_gene_id":"ENSG00000149294","uniprot_accessions":["P13591"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":197,"datasource_scores":[{"id":"europepmc","score":0.03647584785669727}],"score":0.004434958256216422,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"NCAM1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":20.0,"observed_signals":[{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.46},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":3.7}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":10.16},"structure_resource_rank":30,"structure_tier":"structure-b","structure_tier_assignment":{"priority_score":10.16,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-b cap.","resource_rank":30,"tier_id":"structure-b"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":true,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P13591"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000149294"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":1139,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000185483","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000185483","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":94,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":3.1,"raw_score":0.0044349582562164215,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":43.1},"gene_symbol":"ROR1","identifiers":{"approved_symbol":"ROR1","ensembl_gene_id":"ENSG00000185483","uniprot_accessions":["Q01973"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":208,"datasource_scores":[{"id":"europepmc","score":0.03647584785669726}],"score":0.0044349582562164215,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"ROR1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.46},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.46},"structure_resource_rank":121,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.46,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":121,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q01973"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000185483"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":665,"sheet":"Table S6"},"values":{"adipocyte":8.924865089248652,"b_cell":0.3359086328518643,"dc":0.6535947712418301,"endothelial":13.818657367044466,"fibroblast":30.098113207547172,"granulocyte":0.5136986301369862,"macrophage_group_a":0.914470145239376,"macrophage_group_b":1.7857142857142856,"nk_cell":0,"t_cd4":0.8814330395223202,"t_cd8":0.34662045060658575,"t_reg":0.26768642447418733,"tumor":9.338189708617483}},"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["fibroblast"],"highest_observed_percent_expressing":30.098113207547172,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":8.924865089248652,"b_cell":0.3359086328518643,"dc":0.6535947712418301,"endothelial":13.818657367044466,"fibroblast":30.098113207547172,"granulocyte":0.5136986301369862,"macrophage_group_a":0.914470145239376,"macrophage_group_b":1.7857142857142856,"nk_cell":0.0,"t_cd4":0.8814330395223202,"t_cd8":0.34662045060658575,"t_reg":0.26768642447418733,"tumor":9.338189708617483},"owner_category":"stromal","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-TPBG","source_id":"cancer-surfaceome-atlas","source_row":{"row":665,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-TPBG","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":95,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":30.098113207547172,"points":3.06,"state":"derived","tumor_percent":9.338189708617483}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":43.06},"gene_symbol":"TPBG","identifiers":{"approved_symbol":"TPBG","ensembl_gene_id":"ENSG00000146242","uniprot_accessions":["Q13641"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"TPBG","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"fibroblast","highest_other_percent":30.098113207547172,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":9.338189708617483}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.46},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":2.81}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":9.27},"structure_resource_rank":38,"structure_tier":"structure-c","structure_tier_assignment":{"priority_score":9.27,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-c cap.","resource_rank":38,"tier_id":"structure-c"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q13641"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000146242"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":1284,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":394,"sheet":"Table S6"},"values":{"adipocyte":2.4491490244914904,"b_cell":0.38629492777964397,"dc":0,"endothelial":33.43504795117698,"fibroblast":4.030188679245283,"granulocyte":0.3424657534246575,"macrophage_group_a":0.591715976331361,"macrophage_group_b":0.9334415584415584,"nk_cell":0.23752969121140144,"t_cd4":0.34119988626670456,"t_cd8":0.38128249566724437,"t_reg":0.3441682600382409,"tumor":9.175449473031618}},"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["endothelial"],"highest_observed_percent_expressing":33.43504795117698,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":2.4491490244914904,"b_cell":0.38629492777964397,"dc":0.0,"endothelial":33.43504795117698,"fibroblast":4.030188679245283,"granulocyte":0.3424657534246575,"macrophage_group_a":0.591715976331361,"macrophage_group_b":0.9334415584415584,"nk_cell":0.23752969121140144,"t_cd4":0.34119988626670456,"t_cd8":0.38128249566724437,"t_reg":0.3441682600382409,"tumor":9.175449473031618},"owner_category":"endothelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-EPHB4","source_id":"cancer-surfaceome-atlas","source_row":{"row":394,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-EPHB4","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":96,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":33.43504795117698,"points":3.03,"state":"derived","tumor_percent":9.175449473031618}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":43.03},"gene_symbol":"EPHB4","identifiers":{"approved_symbol":"EPHB4","ensembl_gene_id":"ENSG00000196411","uniprot_accessions":["P54760"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"EPHB4","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"endothelial","highest_other_percent":33.43504795117698,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":9.175449473031618}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.45},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":1.58}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":8.03},"structure_resource_rank":55,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":8.03,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":55,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P54760"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000196411"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":708,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":340,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":699,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000145113","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000145113","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":97,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":3.03,"raw_score":0.0042501683288740716,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":43.03},"gene_symbol":"MUC4","identifiers":{"approved_symbol":"MUC4","ensembl_gene_id":"ENSG00000145113","uniprot_accessions":["Q99102"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":60},{"components":[{"basis":"retained surface-accessibility decision","points":58}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":58},{"components":[{"basis":"retained surface-accessibility decision","points":52}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":52},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":40}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":40},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":216,"datasource_scores":[{"id":"europepmc","score":0.03495602086266821}],"score":0.0042501683288740716,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"MUC4","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":20.0,"observed_signals":[{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.45},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.45},"structure_resource_rank":122,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.45,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":122,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt records an integral or GPI-anchored membrane form."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":false,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q99102"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000145113"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":710,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":null,"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000188389","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000188389","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":98,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":3.02,"raw_score":0.004229636114724921,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":43.02},"gene_symbol":"PDCD1","identifiers":{"approved_symbol":"PDCD1","ensembl_gene_id":"ENSG00000188389","uniprot_accessions":["Q15116"]},"intervention_summary":{"action_counts":{"binder":3,"blocker":2,"inhibitor":4},"assigned_intervention_count":19,"curated_candidate_alias_count":3,"directness_counts":{"curated-candidate-alias":3,"registry-explicit":16},"intervention_ids":["I-CTG-anti-pd-1-antibody-0f75f0b392","I-CTG-anti-pd-1-monoclonal-antibody-83ef48eab2","I-CTG-balstilimab-5a47b9bd23","I-CTG-cemiplimab-fianlimab-fixed-dose-combinatio-2883943204","I-CTG-favezelimab-pembrolizumab-4da1038787","I-CTG-fruquintinib-combined-with-anti-pd-1-antib-d7689fe1ff","I-CTG-js207-13bb7c5a22","I-CTG-keytruda-8266394dac","I-CTG-long-course-radiotherapy-capecitabine-pd-1-717aefe155","I-CTG-nivolumab-af64a27aa2","I-CTG-pembrolizumab-d8acadde7d","I-CTG-regorafenib-plus-anti-pd-1-antibodies-89d65224dd","I-CTG-sasanlimab-dd86800660","I-CTG-sintilimab-77dca9d617","I-CTG-sintilimab-ibi308-bevacizumab-oxaliplatin--9f8d711e91","I-CTG-sintilimab-mfolfox6-or-folfiri-bevacizumab-6e665e903a","I-CTG-soc-anti-pd-1-platinum-based-chemo-fa3d4d0cf3","I-CTG-tislelizumab-45f8cec74e","I-CTG-zimberelimab-7422e0c132"],"modality_counts":{"antibody":13,"bispecific-antibody":2,"conventional-cytotoxic-regimen":2,"other-or-unclear":2},"registry_explicit_count":16},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"explicit assigned antibody-format intervention","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":85},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":219,"datasource_scores":[{"id":"europepmc","score":0.034787151196664985}],"score":0.004229636114724921,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"PDCD1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":10.0},{"component":"evidence-readiness","maximum":15,"points":6.45},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":16.45},"structure_resource_rank":15,"structure_tier":"structure-b","structure_tier_assignment":{"priority_score":16.45,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-b cap.","resource_rank":15,"tier_id":"structure-b"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q15116"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000188389"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":421,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":981,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":null,"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000118777","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000118777","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":99,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.83},"gene_symbol":"ABCG2","identifiers":{"approved_symbol":"ABCG2","ensembl_gene_id":"ENSG00000118777","uniprot_accessions":["Q9UNQ0"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":239,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"ABCG2","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.42},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.42},"structure_resource_rank":123,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.42,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":123,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["Q9UNQ0"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000118777"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":724,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":513,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":999,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000146205","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000146205","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":100,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.83},"gene_symbol":"ANO7","identifiers":{"approved_symbol":"ANO7","ensembl_gene_id":"ENSG00000146205","uniprot_accessions":["Q6IWH7"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":343,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"ANO7","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.42},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.42},"structure_resource_rank":124,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.42,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":124,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["Q6IWH7"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000146205"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":91,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":380,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":334,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000062038","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000062038","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":101,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.83},"gene_symbol":"CDH3","identifiers":{"approved_symbol":"CDH3","ensembl_gene_id":"ENSG00000062038","uniprot_accessions":["P22223"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":324,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CDH3","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.42},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.42},"structure_resource_rank":125,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.42,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":125,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P22223"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000062038"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":837,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000066405","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000066405","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":102,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.83},"gene_symbol":"CLDN18","identifiers":{"approved_symbol":"CLDN18","ensembl_gene_id":"ENSG00000066405","uniprot_accessions":["P56856"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":2,"curated_candidate_alias_count":0,"directness_counts":{"registry-explicit":2},"intervention_ids":["I-CTG-claudin18-2-targeted-car-dcs-af64bdaa0d","I-CTG-claudin18-2-targeted-car-t-cells-84d6f72ad0"],"modality_counts":{"car-t-cell-therapy":1,"cellular-therapy":1},"registry_explicit_count":2},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12},{"basis":"explicit assigned cell-therapy intervention","points":20}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":87},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":285,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CLDN18","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":2.0},{"component":"evidence-readiness","maximum":15,"points":6.42},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":1.58}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":10.0},"structure_resource_rank":32,"structure_tier":"structure-c","structure_tier_assignment":{"priority_score":10.0,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-c cap.","resource_rank":32,"tier_id":"structure-c"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["P56856"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000066405"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":803,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000197635","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000197635","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":103,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.83},"gene_symbol":"DPP4","identifiers":{"approved_symbol":"DPP4","ensembl_gene_id":"ENSG00000197635","uniprot_accessions":["P27487"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":302,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"DPP4","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":20.0,"observed_signals":[{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.42},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.42},"structure_resource_rank":126,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.42,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":126,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":true,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["P27487"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000197635"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000171124","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000171124","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":104,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.83},"gene_symbol":"FUT3","identifiers":{"approved_symbol":"FUT3","ensembl_gene_id":"ENSG00000171124","uniprot_accessions":["P21217"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":60},{"components":[{"basis":"retained surface-accessibility decision","points":58}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":58},{"components":[{"basis":"retained surface-accessibility decision","points":52}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":52},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":40}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":40},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":226,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"FUT3","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.42},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.42},"structure_resource_rank":127,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.42,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":127,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt records an integral or GPI-anchored membrane form."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":false,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":false,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["P21217"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000171124"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000132975","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000132975","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":105,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.83},"gene_symbol":"GPR12","identifiers":{"approved_symbol":"GPR12","ensembl_gene_id":"ENSG00000132975","uniprot_accessions":["P47775"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":268,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"GPR12","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.42},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.42},"structure_resource_rank":128,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.42,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":128,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["P47775"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000132975"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":248,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000183454","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000183454","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":106,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.83},"gene_symbol":"GRIN2A","identifiers":{"approved_symbol":"GRIN2A","ensembl_gene_id":"ENSG00000183454","uniprot_accessions":["Q12879"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":234,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"GRIN2A","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.42},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.42},"structure_resource_rank":129,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.42,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":129,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q12879"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000183454"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":21,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":154,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000140443","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000140443","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":107,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.83},"gene_symbol":"IGF1R","identifiers":{"approved_symbol":"IGF1R","ensembl_gene_id":"ENSG00000140443","uniprot_accessions":["P08069"]},"intervention_summary":{"action_counts":{"binder":1},"assigned_intervention_count":3,"curated_candidate_alias_count":2,"directness_counts":{"curated-candidate-alias":2,"registry-explicit":1},"intervention_ids":["I-CTG-amg-479-f079f70775","I-CTG-cp-751-871-7112346d32","I-CTG-ganitumab-5365bed8a8"],"modality_counts":{"antibody":3},"registry_explicit_count":1},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"explicit assigned antibody-format intervention","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":85},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":286,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"IGF1R","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":2.0},{"component":"evidence-readiness","maximum":15,"points":6.42},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":2.32}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":10.74},"structure_resource_rank":27,"structure_tier":"structure-b","structure_tier_assignment":{"priority_score":10.74,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-b cap.","resource_rank":27,"tier_id":"structure-b"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P08069"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000140443"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":969,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000137809","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000137809","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":108,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.83},"gene_symbol":"ITGA11","identifiers":{"approved_symbol":"ITGA11","ensembl_gene_id":"ENSG00000137809","uniprot_accessions":["Q9UKX5"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":327,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"ITGA11","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.42},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.42},"structure_resource_rank":130,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.42,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":130,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":false,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q9UKX5"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000137809"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":380,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000144668","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000144668","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":109,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.83},"gene_symbol":"ITGA9","identifiers":{"approved_symbol":"ITGA9","ensembl_gene_id":"ENSG00000144668","uniprot_accessions":["Q13797"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":321,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"ITGA9","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.42},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.42},"structure_resource_rank":131,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.42,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":131,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":false,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q13797"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000144668"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":{"source_row":{"row":56,"sheet":"Table S17"},"values":{"in_frame":null,"missense":null,"silent":null,"truncating":null}},"mutation_clonality":{"source_row":{"row":56,"sheet":"Table S20"},"values":{"clonal":null,"subclonal":null,"unknown":null}},"mutation_frequency_percent":{"source_row":{"row":54,"sheet":"Table S15"},"values":{"percent":null}},"mutation_timing":{"source_row":{"row":56,"sheet":"Table S19"},"values":{"early":null,"late":null,"unknown":null}},"mutation_zygosity":{"source_row":{"row":56,"sheet":"Table S18"},"values":{"heter":null,"homo":null,"unknown":null}},"potential_target_summary":{"source_row":{"row":1424,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":{"source_row":{"row":54,"sheet":"Table S14"},"values":{"flag":0}},"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000259207","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000259207","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":110,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.83},"gene_symbol":"ITGB3","identifiers":{"approved_symbol":"ITGB3","ensembl_gene_id":"ENSG00000259207","uniprot_accessions":["P05106"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":240,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"ITGB3","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.42},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.42},"structure_resource_rank":132,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.42,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":132,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P05106"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000259207"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":{"source_row":{"row":82,"sheet":"Table S17"},"values":{"in_frame":null,"missense":null,"silent":null,"truncating":null}},"mutation_clonality":{"source_row":{"row":82,"sheet":"Table S20"},"values":{"clonal":null,"subclonal":null,"unknown":null}},"mutation_frequency_percent":{"source_row":{"row":80,"sheet":"Table S15"},"values":{"percent":null}},"mutation_timing":{"source_row":{"row":82,"sheet":"Table S19"},"values":{"early":null,"late":null,"unknown":null}},"mutation_zygosity":{"source_row":{"row":82,"sheet":"Table S18"},"values":{"heter":null,"homo":null,"unknown":null}},"potential_target_summary":{"source_row":{"row":641,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":{"source_row":{"row":80,"sheet":"Table S14"},"values":{"flag":0}},"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":192,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000139292","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000139292","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":111,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.83},"gene_symbol":"LGR5","identifiers":{"approved_symbol":"LGR5","ensembl_gene_id":"ENSG00000139292","uniprot_accessions":["O75473"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17},{"basis":"verified experimental target anchor","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":85},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"verified experimental target anchor","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":77},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12},{"basis":"verified experimental target anchor","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":72},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"verified experimental target anchor","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30},{"basis":"verified experimental target anchor","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":53}],"open_targets_association":{"associated_target_rank":326,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"LGR5","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"verified-structure-anchor","source_id":"rcsb:4BSU","url":"https://www.rcsb.org/structure/4BSU"}],"structure_anchor_summary":{"all_anchors_validated":true,"interaction_classes":["natural-partner-complex"],"pdb_ids":["4BSU"],"verified_anchor_count":1},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":60.0},{"component":"bound-complex-anchor","maximum":10,"points":10.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.42},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":76.42},"structure_resource_rank":13,"structure_tier":"structure-b","structure_tier_assignment":{"priority_score":76.42,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-b cap.","resource_rank":13,"tier_id":"structure-b"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["O75473"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000139292"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":1009,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000148948","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000148948","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":112,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.83},"gene_symbol":"LRRC4C","identifiers":{"approved_symbol":"LRRC4C","ensembl_gene_id":"ENSG00000148948","uniprot_accessions":["Q9HCJ2"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":60},{"components":[{"basis":"retained surface-accessibility decision","points":58}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":58},{"components":[{"basis":"retained surface-accessibility decision","points":52}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":52},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":40}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":40},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":318,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"LRRC4C","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.42},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.42},"structure_resource_rank":133,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.42,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":133,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt records an integral or GPI-anchored membrane form."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":false,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q9HCJ2"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000148948"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000169876","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000169876","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":113,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.83},"gene_symbol":"MUC17","identifiers":{"approved_symbol":"MUC17","ensembl_gene_id":"ENSG00000169876","uniprot_accessions":["Q685J3"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":309,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"MUC17","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":20.0,"observed_signals":[{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.42},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":1.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":7.42},"structure_resource_rank":70,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":7.42,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":70,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q685J3"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000169876"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":202,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000067141","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000067141","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":114,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.83},"gene_symbol":"NEO1","identifiers":{"approved_symbol":"NEO1","ensembl_gene_id":"ENSG00000067141","uniprot_accessions":["Q92859"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":269,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"NEO1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.42},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.42},"structure_resource_rank":134,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.42,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":134,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q92859"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000067141"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":835,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000064300","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000064300","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":115,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.83},"gene_symbol":"NGFR","identifiers":{"approved_symbol":"NGFR","ensembl_gene_id":"ENSG00000064300","uniprot_accessions":["P08138"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":403,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"NGFR","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.42},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.42},"structure_resource_rank":135,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.42,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":135,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P08138"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000064300"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000090402","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000090402","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":116,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.83},"gene_symbol":"SI","identifiers":{"approved_symbol":"SI","ensembl_gene_id":"ENSG00000090402","uniprot_accessions":["P14410"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":60},{"components":[{"basis":"retained surface-accessibility decision","points":58}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":58},{"components":[{"basis":"retained surface-accessibility decision","points":52}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":52},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":40}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":40},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":385,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"SI","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.42},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.42},"structure_resource_rank":136,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.42,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":136,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt records an integral or GPI-anchored membrane form."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":false,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["P14410"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000090402"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":316,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000169507","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000169507","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":117,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.83},"gene_symbol":"SLC38A11","identifiers":{"approved_symbol":"SLC38A11","ensembl_gene_id":"ENSG00000169507","uniprot_accessions":["Q08AI6"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":60},{"components":[{"basis":"retained surface-accessibility decision","points":58}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":58},{"components":[{"basis":"retained surface-accessibility decision","points":52}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":52},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":40}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":40},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":377,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"SLC38A11","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.42},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.42},"structure_resource_rank":137,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.42,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":137,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt records an integral or GPI-anchored membrane form."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":false,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":false,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["Q08AI6"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000169507"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":193,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":199,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":null,"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000088836","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000088836","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":118,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.83},"gene_symbol":"SLC4A11","identifiers":{"approved_symbol":"SLC4A11","ensembl_gene_id":"ENSG00000088836","uniprot_accessions":["Q8NBS3"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":263,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"SLC4A11","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.42},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.42},"structure_resource_rank":138,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.42,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":138,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["Q8NBS3"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000088836"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000089060","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000089060","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":119,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.83},"gene_symbol":"SLC8B1","identifiers":{"approved_symbol":"SLC8B1","ensembl_gene_id":"ENSG00000089060","uniprot_accessions":["Q6J4K2"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":60},{"components":[{"basis":"retained surface-accessibility decision","points":58}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":58},{"components":[{"basis":"retained surface-accessibility decision","points":52}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":52},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":40}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":40},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":316,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"SLC8B1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.42},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.42},"structure_resource_rank":139,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.42,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":139,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt records an integral or GPI-anchored membrane form."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":false,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":false,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q6J4K2"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000089060"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":237,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":489,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":1273,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000101187","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000101187","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":120,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.83},"gene_symbol":"SLCO4A1","identifiers":{"approved_symbol":"SLCO4A1","ensembl_gene_id":"ENSG00000101187","uniprot_accessions":["Q96BD0"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":373,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"SLCO4A1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.42},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.42},"structure_resource_rank":140,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.42,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":140,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["Q96BD0"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000101187"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":496,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000127954","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000127954","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":121,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.83},"gene_symbol":"STEAP4","identifiers":{"approved_symbol":"STEAP4","ensembl_gene_id":"ENSG00000127954","uniprot_accessions":["Q687X5"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":60},{"components":[{"basis":"retained surface-accessibility decision","points":58}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":58},{"components":[{"basis":"retained surface-accessibility decision","points":52}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":52},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":40}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":40},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":235,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"STEAP4","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.42},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.42},"structure_resource_rank":141,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.42,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":141,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt records an integral or GPI-anchored membrane form."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":false,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["Q687X5"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000127954"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000185873","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000185873","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":122,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.83},"gene_symbol":"TMPRSS11B","identifiers":{"approved_symbol":"TMPRSS11B","ensembl_gene_id":"ENSG00000185873","uniprot_accessions":["Q86T26"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":232,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"TMPRSS11B","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.42},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.42},"structure_resource_rank":142,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.42,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":142,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["Q86T26"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000185873"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":968,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":660,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000120949","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000120949","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":123,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.83},"gene_symbol":"TNFRSF8","identifiers":{"approved_symbol":"TNFRSF8","ensembl_gene_id":"ENSG00000120949","uniprot_accessions":["P28908"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":231,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"TNFRSF8","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.42},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.42},"structure_resource_rank":143,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.42,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":143,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P28908"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000120949"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":1572,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000165125","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000165125","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":124,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.83},"gene_symbol":"TRPV6","identifiers":{"approved_symbol":"TRPV6","ensembl_gene_id":"ENSG00000165125","uniprot_accessions":["Q9H1D0"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":344,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"TRPV6","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.42},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.42},"structure_resource_rank":144,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.42,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":144,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["Q9H1D0"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000165125"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":109,"sheet":"Table S6"},"values":{"adipocyte":0.16604400166044,"b_cell":0.15115888478333894,"dc":3.2679738562091507,"endothelial":0.2179598953792502,"fibroblast":0.25660377358490566,"granulocyte":0,"macrophage_group_a":0.6455083378160301,"macrophage_group_b":0.689935064935065,"nk_cell":0,"t_cd4":11.913562695479103,"t_cd8":8.284228769497402,"t_reg":17.934990439770555,"tumor":0.27898326100433973}},"transcript_fusion_event_count":{"source_row":{"row":1322,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["t_reg"],"highest_observed_percent_expressing":17.934990439770555,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":0.16604400166044,"b_cell":0.15115888478333894,"dc":3.2679738562091507,"endothelial":0.2179598953792502,"fibroblast":0.25660377358490566,"granulocyte":0.0,"macrophage_group_a":0.6455083378160301,"macrophage_group_b":0.689935064935065,"nk_cell":0.0,"t_cd4":11.913562695479103,"t_cd8":8.284228769497402,"t_reg":17.934990439770555,"tumor":0.27898326100433973},"owner_category":"immune","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000110448","source_id":"cancer-surfaceome-atlas","source_row":{"row":109,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000110448","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":125,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.19,"raw_score":0.0022174791281082107,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":17.934990439770555,"points":0.53,"state":"derived","tumor_percent":0.27898326100433973}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.72},"gene_symbol":"CD5","identifiers":{"approved_symbol":"CD5","ensembl_gene_id":"ENSG00000110448","uniprot_accessions":["P06127"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":450,"datasource_scores":[{"id":"europepmc","score":0.01823792392834863}],"score":0.0022174791281082107,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CD5","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"t_reg","highest_other_percent":17.934990439770555,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":0.27898326100433973}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.41},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.41},"structure_resource_rank":145,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.41,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":145,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P06127"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000110448"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":250,"sheet":"Table S6"},"values":{"adipocyte":0.8302200083022002,"b_cell":0.21834061135371177,"dc":1.3071895424836601,"endothelial":0.3923278116826504,"fibroblast":0.4377358490566038,"granulocyte":0,"macrophage_group_a":25.174825174825177,"macrophage_group_b":52.394480519480524,"nk_cell":0,"t_cd4":0.25589991470002843,"t_cd8":0.3119584055459272,"t_reg":0.30592734225621415,"tumor":0.45722256664600125}},"transcript_fusion_event_count":{"source_row":{"row":1667,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["macrophage_group_b"],"highest_observed_percent_expressing":52.394480519480524,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":0.8302200083022002,"b_cell":0.21834061135371177,"dc":1.3071895424836601,"endothelial":0.3923278116826504,"fibroblast":0.4377358490566038,"granulocyte":0.0,"macrophage_group_a":25.174825174825177,"macrophage_group_b":52.394480519480524,"nk_cell":0.0,"t_cd4":0.25589991470002843,"t_cd8":0.3119584055459272,"t_reg":0.30592734225621415,"tumor":0.45722256664600125},"owner_category":"immune","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000177575","source_id":"cancer-surfaceome-atlas","source_row":{"row":250,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000177575","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":126,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.0,"raw_score":0.0018478992734235094,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":52.394480519480524,"points":0.68,"state":"derived","tumor_percent":0.45722256664600125}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.68},"gene_symbol":"CD163","identifiers":{"approved_symbol":"CD163","ensembl_gene_id":"ENSG00000177575","uniprot_accessions":["Q86VB7"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":504,"datasource_scores":[{"id":"europepmc","score":0.015198269940290528}],"score":0.0018478992734235094,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":13503,"filename":"MONDO_0005007-associated-targets-page-2.json","sha256":"26a9df77e260244ca3b7d5d09ea58127fca45365ce5ac3dd036ffb2a38df2b0d"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CD163","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":70.0,"observed_signals":[{"highest_other_cell_type":"macrophage_group_b","highest_other_percent":52.394480519480524,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":0.45722256664600125},{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.4},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.4},"structure_resource_rank":146,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.4,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":146,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q86VB7"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000177575"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":{"source_row":{"row":46,"sheet":"Table S17"},"values":{"in_frame":null,"missense":null,"silent":null,"truncating":null}},"mutation_clonality":{"source_row":{"row":46,"sheet":"Table S20"},"values":{"clonal":null,"subclonal":null,"unknown":null}},"mutation_frequency_percent":{"source_row":{"row":44,"sheet":"Table S15"},"values":{"percent":null}},"mutation_timing":{"source_row":{"row":46,"sheet":"Table S19"},"values":{"early":null,"late":null,"unknown":null}},"mutation_zygosity":{"source_row":{"row":46,"sheet":"Table S18"},"values":{"heter":null,"homo":null,"unknown":null}},"potential_target_summary":null,"recurrent_mutation_flag":{"source_row":{"row":44,"sheet":"Table S14"},"values":{"flag":0}},"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":14,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000165731","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000165731","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":127,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.44,"raw_score":0.002751316695986113,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.44},"gene_symbol":"RET","identifiers":{"approved_symbol":"RET","ensembl_gene_id":"ENSG00000165731","uniprot_accessions":["P07949"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":427,"datasource_scores":[{"id":"europepmc","score":0.02262853524443256}],"score":0.002751316695986113,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"RET","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.37},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":1.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":7.37},"structure_resource_rank":71,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":7.37,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":71,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P07949"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000165731"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":{"source_row":{"row":68,"sheet":"Table S17"},"values":{"in_frame":null,"missense":null,"silent":null,"truncating":null}},"mutation_clonality":{"source_row":{"row":68,"sheet":"Table S20"},"values":{"clonal":null,"subclonal":null,"unknown":null}},"mutation_frequency_percent":{"source_row":{"row":66,"sheet":"Table S15"},"values":{"percent":null}},"mutation_timing":{"source_row":{"row":68,"sheet":"Table S19"},"values":{"early":null,"late":null,"unknown":null}},"mutation_zygosity":{"source_row":{"row":68,"sheet":"Table S18"},"values":{"heter":null,"homo":null,"unknown":null}},"potential_target_summary":{"source_row":{"row":910,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":{"source_row":{"row":66,"sheet":"Table S14"},"values":{"flag":0}},"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000163283","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000163283","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":128,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.19,"raw_score":0.0022174791281082107,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.19},"gene_symbol":"ALPP","identifiers":{"approved_symbol":"ALPP","ensembl_gene_id":"ENSG00000163283","uniprot_accessions":["P05187"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":464,"datasource_scores":[{"id":"europepmc","score":0.01823792392834863}],"score":0.0022174791281082107,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"ALPP","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.33},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.33},"structure_resource_rank":147,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.33,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":147,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt records an integral or GPI-anchored membrane form."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":false,"gpi_anchored":true,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P05187"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000163283"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":885,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000107779","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000107779","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":129,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.19,"raw_score":0.0022174791281082107,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.19},"gene_symbol":"BMPR1A","identifiers":{"approved_symbol":"BMPR1A","ensembl_gene_id":"ENSG00000107779","uniprot_accessions":["P36894"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":481,"datasource_scores":[{"id":"europepmc","score":0.01823792392834863}],"score":0.0022174791281082107,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"BMPR1A","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.33},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.33},"structure_resource_rank":148,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.33,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":148,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":true,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P36894"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000107779"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":1446,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000138798","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000138798","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":130,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.19,"raw_score":0.0022174791281082107,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.19},"gene_symbol":"EGF","identifiers":{"approved_symbol":"EGF","ensembl_gene_id":"ENSG00000138798","uniprot_accessions":["P01133"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":491,"datasource_scores":[{"id":"europepmc","score":0.01823792392834863}],"score":0.0022174791281082107,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"EGF","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.33},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.33},"structure_resource_rank":149,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.33,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":149,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":false,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P01133"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000138798"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":1033,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000154928","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000154928","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":131,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.19,"raw_score":0.0022174791281082107,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.19},"gene_symbol":"EPHB1","identifiers":{"approved_symbol":"EPHB1","ensembl_gene_id":"ENSG00000154928","uniprot_accessions":["P54762"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":492,"datasource_scores":[{"id":"europepmc","score":0.01823792392834863}],"score":0.0022174791281082107,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"EPHB1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.33},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.33},"structure_resource_rank":150,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.33,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":150,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P54762"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000154928"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":1354,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000117560","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000117560","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":132,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.19,"raw_score":0.0022174791281082107,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.19},"gene_symbol":"FASLG","identifiers":{"approved_symbol":"FASLG","ensembl_gene_id":"ENSG00000117560","uniprot_accessions":["P48023"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":435,"datasource_scores":[{"id":"europepmc","score":0.01823792392834863}],"score":0.0022174791281082107,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"FASLG","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":20.0,"observed_signals":[{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.33},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.33},"structure_resource_rank":151,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.33,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":151,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":true,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["P48023"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000117560"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":839,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000070019","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000070019","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":133,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.19,"raw_score":0.0022174791281082107,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.19},"gene_symbol":"GUCY2C","identifiers":{"approved_symbol":"GUCY2C","ensembl_gene_id":"ENSG00000070019","uniprot_accessions":["P25092"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":4,"curated_candidate_alias_count":2,"directness_counts":{"curated-candidate-alias":2,"registry-explicit":2},"intervention_ids":["I-CTG-chimeric-antigen-receptor-t-cell-preparati-2461b7b2f2","I-CTG-eb-duo-car-nk-cea-gcc-9ddb5588c2","I-CTG-eb-duo-car-nk-cea-gcc-iv-ea153d70da","I-CTG-im96-car-t-cells-111524d9e1"],"modality_counts":{"car-nk-cell-therapy":2,"car-t-cell-therapy":2},"registry_explicit_count":2},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"verified antibody or nanobody complex","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":90},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17},{"basis":"verified experimental target anchor","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":85},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"verified experimental target anchor","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":77},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10},{"basis":"verified antibody complex","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12},{"basis":"explicit assigned cell-therapy intervention","points":20},{"basis":"verified experimental target anchor","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":92},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"verified experimental target anchor","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30},{"basis":"verified experimental target anchor","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":53}],"open_targets_association":{"associated_target_rank":454,"datasource_scores":[{"id":"europepmc","score":0.01823792392834863}],"score":0.0022174791281082107,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"GUCY2C","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"verified-structure-anchor","source_id":"rcsb:8GHP","url":"https://www.rcsb.org/structure/8GHP"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":true,"interaction_classes":["research-antibody-complex"],"pdb_ids":["8GHP"],"verified_anchor_count":1},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":60.0},{"component":"bound-complex-anchor","maximum":10,"points":10.0},{"component":"assigned-interventions","maximum":10,"points":3.0},{"component":"evidence-readiness","maximum":15,"points":6.33},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":2.81}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":82.14},"structure_resource_rank":8,"structure_tier":"structure-a","structure_tier_assignment":{"priority_score":82.14,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-a cap.","resource_rank":8,"tier_id":"structure-a"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":true,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P25092"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000070019"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":1412,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000133116","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000133116","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":134,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.19,"raw_score":0.0022174791281082107,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.19},"gene_symbol":"KL","identifiers":{"approved_symbol":"KL","ensembl_gene_id":"ENSG00000133116","uniprot_accessions":["Q9UEF7"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":479,"datasource_scores":[{"id":"europepmc","score":0.01823792392834863}],"score":0.0022174791281082107,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"KL","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":20.0,"observed_signals":[{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.33},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.33},"structure_resource_rank":152,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.33,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":152,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q9UEF7"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000133116"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000176299","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000176299","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":135,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.19,"raw_score":0.0022174791281082107,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.19},"gene_symbol":"OR4M1","identifiers":{"approved_symbol":"OR4M1","ensembl_gene_id":"ENSG00000176299","uniprot_accessions":["Q8NGD0"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":471,"datasource_scores":[{"id":"europepmc","score":0.01823792392834863}],"score":0.0022174791281082107,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"OR4M1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.33},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.33},"structure_resource_rank":153,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.33,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":153,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["Q8NGD0"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000176299"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":1321,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000110436","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000110436","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":136,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.19,"raw_score":0.0022174791281082107,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.19},"gene_symbol":"SLC1A2","identifiers":{"approved_symbol":"SLC1A2","ensembl_gene_id":"ENSG00000110436","uniprot_accessions":["P43004"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":474,"datasource_scores":[{"id":"europepmc","score":0.01823792392834863}],"score":0.0022174791281082107,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"SLC1A2","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.33},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.33},"structure_resource_rank":154,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.33,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":154,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["P43004"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000110436"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":8,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":590,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000004809","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000004809","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":137,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.19,"raw_score":0.0022174791281082107,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.19},"gene_symbol":"SLC22A16","identifiers":{"approved_symbol":"SLC22A16","ensembl_gene_id":"ENSG00000004809","uniprot_accessions":["Q86VW1"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":60},{"components":[{"basis":"retained surface-accessibility decision","points":58}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":58},{"components":[{"basis":"retained surface-accessibility decision","points":52}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":52},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":40}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":40},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":497,"datasource_scores":[{"id":"europepmc","score":0.01823792392834863}],"score":0.0022174791281082107,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"SLC22A16","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.33},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.33},"structure_resource_rank":155,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.33,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":155,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt records an integral or GPI-anchored membrane form."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":false,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["Q86VW1"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000004809"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":908,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":1553,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000163235","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000163235","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":138,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.19,"raw_score":0.0022174791281082107,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.19},"gene_symbol":"TGFA","identifiers":{"approved_symbol":"TGFA","ensembl_gene_id":"ENSG00000163235","uniprot_accessions":["P01135"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":500,"datasource_scores":[{"id":"europepmc","score":0.01823792392834863}],"score":0.0022174791281082107,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"TGFA","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":20.0,"observed_signals":[{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.33},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.33},"structure_resource_rank":156,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.33,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":156,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P01135"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000163235"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":1355,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000117586","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000117586","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":139,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.19,"raw_score":0.0022174791281082107,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":42.19},"gene_symbol":"TNFSF4","identifiers":{"approved_symbol":"TNFSF4","ensembl_gene_id":"ENSG00000117586","uniprot_accessions":["P23510"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":478,"datasource_scores":[{"id":"europepmc","score":0.01823792392834863}],"score":0.0022174791281082107,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"TNFSF4","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.33},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.33},"structure_resource_rank":157,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.33,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":157,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":false,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["P23510"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000117586"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":416,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000178568","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000178568","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":140,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":1.79,"raw_score":0.0014783194187388072,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":41.79},"gene_symbol":"ERBB4","identifiers":{"approved_symbol":"ERBB4","ensembl_gene_id":"ENSG00000178568","uniprot_accessions":["Q15303"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":522,"datasource_scores":[{"id":"europepmc","score":0.012158615952232422}],"score":0.0014783194187388072,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":13503,"filename":"MONDO_0005007-associated-targets-page-2.json","sha256":"26a9df77e260244ca3b7d5d09ea58127fca45365ce5ac3dd036ffb2a38df2b0d"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"ERBB4","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.27},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.27},"structure_resource_rank":158,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.27,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":158,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q15303"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000178568"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":{"source_row":{"row":15,"sheet":"Table S17"},"values":{"in_frame":null,"missense":null,"silent":null,"truncating":null}},"mutation_clonality":{"source_row":{"row":15,"sheet":"Table S20"},"values":{"clonal":null,"subclonal":null,"unknown":null}},"mutation_frequency_percent":{"source_row":{"row":13,"sheet":"Table S15"},"values":{"percent":null}},"mutation_timing":{"source_row":{"row":15,"sheet":"Table S19"},"values":{"early":null,"late":null,"unknown":null}},"mutation_zygosity":{"source_row":{"row":15,"sheet":"Table S18"},"values":{"heter":null,"homo":null,"unknown":null}},"potential_target_summary":null,"recurrent_mutation_flag":{"source_row":{"row":13,"sheet":"Table S14"},"values":{"flag":0}},"scna_g_score":{"source_row":{"row":26,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":7,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000068078","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000068078","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":141,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":1.79,"raw_score":0.0014783194187388072,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":41.79},"gene_symbol":"FGFR3","identifiers":{"approved_symbol":"FGFR3","ensembl_gene_id":"ENSG00000068078","uniprot_accessions":["P22607"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":3,"curated_candidate_alias_count":2,"directness_counts":{"curated-candidate-alias":2,"registry-explicit":1},"intervention_ids":["I-CTG-111in-fpi-1967-89b7f5ed6d","I-CTG-225ac-fpi-1966-e299fbd736","I-CTG-vofatamab-eb0c930491"],"modality_counts":{"antibody":1,"molecular-imaging-agent":1,"radioligand-therapy":1},"registry_explicit_count":1},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"explicit assigned antibody-format intervention","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":85},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"explicit assigned radioligand or radioimmunotherapy intervention","points":20}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":552,"datasource_scores":[{"id":"europepmc","score":0.012158615952232422}],"score":0.0014783194187388072,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":13503,"filename":"MONDO_0005007-associated-targets-page-2.json","sha256":"26a9df77e260244ca3b7d5d09ea58127fca45365ce5ac3dd036ffb2a38df2b0d"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"FGFR3","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":20.0,"observed_signals":[{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":2.0},{"component":"evidence-readiness","maximum":15,"points":6.27},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":1.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":9.27},"structure_resource_rank":39,"structure_tier":"structure-c","structure_tier_assignment":{"priority_score":9.27,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-c cap.","resource_rank":39,"tier_id":"structure-c"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P22607"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000068078"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":733,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":704,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000147257","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000147257","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":142,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":1.79,"raw_score":0.0014783194187388072,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":41.79},"gene_symbol":"GPC3","identifiers":{"approved_symbol":"GPC3","ensembl_gene_id":"ENSG00000147257","uniprot_accessions":["P51654"]},"intervention_summary":{"action_counts":{"molecular-imaging":2},"assigned_intervention_count":2,"curated_candidate_alias_count":0,"directness_counts":{"registry-explicit":2},"intervention_ids":["I-CTG-18f-f-resca-g5-733d72e44e","I-CTG-68ga-ga-nota-g5-6d44b3e9a5"],"modality_counts":{"molecular-imaging-agent":2},"registry_explicit_count":2},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":558,"datasource_scores":[{"id":"europepmc","score":0.012158615952232422}],"score":0.0014783194187388072,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":13503,"filename":"MONDO_0005007-associated-targets-page-2.json","sha256":"26a9df77e260244ca3b7d5d09ea58127fca45365ce5ac3dd036ffb2a38df2b0d"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"GPC3","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":2.0},{"component":"evidence-readiness","maximum":15,"points":6.27},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":8.27},"structure_resource_rank":53,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":8.27,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":53,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt records an integral or GPI-anchored membrane form."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":false,"gpi_anchored":true,"integral_membrane":false,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P51654"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000147257"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":278,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":828,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":null,"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000104972","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000104972","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":143,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":1.79,"raw_score":0.0014783194187388072,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":41.79},"gene_symbol":"LILRB1","identifiers":{"approved_symbol":"LILRB1","ensembl_gene_id":"ENSG00000104972","uniprot_accessions":["Q8NHL6"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":510,"datasource_scores":[{"id":"europepmc","score":0.012158615952232422}],"score":0.0014783194187388072,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":13503,"filename":"MONDO_0005007-associated-targets-page-2.json","sha256":"26a9df77e260244ca3b7d5d09ea58127fca45365ce5ac3dd036ffb2a38df2b0d"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"LILRB1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":20.0,"observed_signals":[{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.27},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.27},"structure_resource_rank":159,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.27,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":159,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q8NHL6"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000104972"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000130368","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000130368","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":144,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":1.79,"raw_score":0.0014783194187388072,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":41.79},"gene_symbol":"MAS1","identifiers":{"approved_symbol":"MAS1","ensembl_gene_id":"ENSG00000130368","uniprot_accessions":["P04201"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":556,"datasource_scores":[{"id":"europepmc","score":0.012158615952232422}],"score":0.0014783194187388072,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":13503,"filename":"MONDO_0005007-associated-targets-page-2.json","sha256":"26a9df77e260244ca3b7d5d09ea58127fca45365ce5ac3dd036ffb2a38df2b0d"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"MAS1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.27},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.27},"structure_resource_rank":160,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.27,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":160,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["P04201"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000130368"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000163914","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000163914","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":145,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":1.79,"raw_score":0.0014783194187388072,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":41.79},"gene_symbol":"RHO","identifiers":{"approved_symbol":"RHO","ensembl_gene_id":"ENSG00000163914","uniprot_accessions":["P08100"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":550,"datasource_scores":[{"id":"europepmc","score":0.012158615952232422}],"score":0.0014783194187388072,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":13503,"filename":"MONDO_0005007-associated-targets-page-2.json","sha256":"26a9df77e260244ca3b7d5d09ea58127fca45365ce5ac3dd036ffb2a38df2b0d"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"RHO","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.27},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.27},"structure_resource_rank":161,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.27,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":161,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":false,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["P08100"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000163914"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":159,"sheet":"Table S6"},"values":{"adipocyte":14.61187214611872,"b_cell":1.41081625797783,"dc":3.2679738562091507,"endothelial":77.72449869224063,"fibroblast":34.47547169811321,"granulocyte":2.910958904109589,"macrophage_group_a":12.42603550295858,"macrophage_group_b":33.80681818181818,"nk_cell":2.6128266033254155,"t_cd4":2.1609326130224624,"t_cd8":2.4263431542461005,"t_reg":1.5296367112810707,"tumor":3.037817730936144}},"transcript_fusion_event_count":{"source_row":{"row":637,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["endothelial"],"highest_observed_percent_expressing":77.72449869224063,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":14.61187214611872,"b_cell":1.41081625797783,"dc":3.2679738562091507,"endothelial":77.72449869224063,"fibroblast":34.47547169811321,"granulocyte":2.910958904109589,"macrophage_group_a":12.42603550295858,"macrophage_group_b":33.80681818181818,"nk_cell":2.6128266033254155,"t_cd4":2.1609326130224624,"t_cd8":2.4263431542461005,"t_reg":1.5296367112810707,"tumor":3.037817730936144},"owner_category":"endothelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-ENG","source_id":"cancer-surfaceome-atlas","source_row":{"row":159,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-ENG","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":146,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":77.72449869224063,"points":1.74,"state":"derived","tumor_percent":3.037817730936144}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":41.74},"gene_symbol":"ENG","identifiers":{"approved_symbol":"ENG","ensembl_gene_id":"ENSG00000106991","uniprot_accessions":["P17813"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"ENG","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"endothelial","highest_other_percent":77.72449869224063,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":3.037817730936144}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.26},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":2.32}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":8.58},"structure_resource_rank":48,"structure_tier":"structure-c","structure_tier_assignment":{"priority_score":8.58,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-c cap.","resource_rank":48,"tier_id":"structure-c"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P17813"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000106991"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":500,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":985,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":195,"sheet":"Table S6"},"values":{"adipocyte":1.41137401411374,"b_cell":0.7725898555592879,"dc":1.3071895424836601,"endothelial":21.708805579773323,"fibroblast":0.7094339622641509,"granulocyte":0,"macrophage_group_a":0.05379236148466917,"macrophage_group_b":0.12175324675324675,"nk_cell":1.187648456057007,"t_cd4":0.5117998294000569,"t_cd8":0.10398613518197573,"t_reg":0,"tumor":2.712337259764414}},"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["endothelial"],"highest_observed_percent_expressing":21.708805579773323,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":1.41137401411374,"b_cell":0.7725898555592879,"dc":1.3071895424836601,"endothelial":21.708805579773323,"fibroblast":0.7094339622641509,"granulocyte":0.0,"macrophage_group_a":0.05379236148466917,"macrophage_group_b":0.12175324675324675,"nk_cell":1.187648456057007,"t_cd4":0.5117998294000569,"t_cd8":0.10398613518197573,"t_reg":0.0,"tumor":2.712337259764414},"owner_category":"endothelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-DLL4","source_id":"cancer-surfaceome-atlas","source_row":{"row":195,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-DLL4","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":147,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":21.708805579773323,"points":1.65,"state":"derived","tumor_percent":2.712337259764414}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":41.65},"gene_symbol":"DLL4","identifiers":{"approved_symbol":"DLL4","ensembl_gene_id":"ENSG00000128917","uniprot_accessions":["Q9NR61"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"DLL4","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"endothelial","highest_other_percent":21.708805579773323,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":2.712337259764414}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.25},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":1.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":7.25},"structure_resource_rank":73,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":7.25,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":73,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q9NR61"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000128917"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":364,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":286,"sheet":"Table S6"},"values":{"adipocyte":5.0228310502283104,"b_cell":0.23513604299630503,"dc":3.9215686274509802,"endothelial":7.933740191804708,"fibroblast":23.894339622641507,"granulocyte":0.17123287671232876,"macrophage_group_a":0.48413125336202256,"macrophage_group_b":0.6087662337662338,"nk_cell":0.23752969121140144,"t_cd4":0.2274665908444697,"t_cd8":0.4506065857885615,"t_reg":0.42065009560229444,"tumor":2.518598884066956}},"transcript_fusion_event_count":{"source_row":{"row":182,"sheet":"Table S22"},"values":{"count":1}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["fibroblast"],"highest_observed_percent_expressing":23.894339622641507,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":5.0228310502283104,"b_cell":0.23513604299630503,"dc":3.9215686274509802,"endothelial":7.933740191804708,"fibroblast":23.894339622641507,"granulocyte":0.17123287671232876,"macrophage_group_a":0.48413125336202256,"macrophage_group_b":0.6087662337662338,"nk_cell":0.23752969121140144,"t_cd4":0.2274665908444697,"t_cd8":0.4506065857885615,"t_reg":0.42065009560229444,"tumor":2.518598884066956},"owner_category":"stromal","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-PTK7","source_id":"cancer-surfaceome-atlas","source_row":{"row":286,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-PTK7","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":148,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":23.894339622641507,"points":1.59,"state":"derived","tumor_percent":2.518598884066956}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":41.59},"gene_symbol":"PTK7","identifiers":{"approved_symbol":"PTK7","ensembl_gene_id":"ENSG00000112655","uniprot_accessions":["Q13308"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"PTK7","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"fibroblast","highest_other_percent":23.894339622641507,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":2.518598884066956}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.24},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":1.58}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":7.82},"structure_resource_rank":57,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":7.82,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":57,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q13308"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000112655"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":697,"sheet":"Table S6"},"values":{"adipocyte":15.276048152760483,"b_cell":0.41988579106483037,"dc":1.9607843137254901,"endothelial":2.4411508282476024,"fibroblast":42.74716981132076,"granulocyte":0.17123287671232876,"macrophage_group_a":0.8606777837547067,"macrophage_group_b":6.209415584415585,"nk_cell":0.23752969121140144,"t_cd4":0.597099800966733,"t_cd8":0.41594454072790293,"t_reg":0.7265774378585086,"tumor":2.0613763174209545}},"transcript_fusion_event_count":{"source_row":{"row":758,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["fibroblast"],"highest_observed_percent_expressing":42.74716981132076,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":15.276048152760483,"b_cell":0.41988579106483037,"dc":1.9607843137254901,"endothelial":2.4411508282476024,"fibroblast":42.74716981132076,"granulocyte":0.17123287671232876,"macrophage_group_a":0.8606777837547067,"macrophage_group_b":6.209415584415585,"nk_cell":0.23752969121140144,"t_cd4":0.597099800966733,"t_cd8":0.41594454072790293,"t_reg":0.7265774378585086,"tumor":2.0613763174209545},"owner_category":"stromal","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-ANTXR1","source_id":"cancer-surfaceome-atlas","source_row":{"row":697,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-ANTXR1","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":149,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":42.74716981132076,"points":1.44,"state":"derived","tumor_percent":2.0613763174209545}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":41.44},"gene_symbol":"ANTXR1","identifiers":{"approved_symbol":"ANTXR1","ensembl_gene_id":"ENSG00000169604","uniprot_accessions":["Q9H6X2"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"ANTXR1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"fibroblast","highest_other_percent":42.74716981132076,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":2.0613763174209545}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.22},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":2.58}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":8.8},"structure_resource_rank":45,"structure_tier":"structure-c","structure_tier_assignment":{"priority_score":8.8,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-c cap.","resource_rank":45,"tier_id":"structure-c"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q9H6X2"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000169604"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":58,"sheet":"Table S6"},"values":{"adipocyte":6.226650062266501,"b_cell":0.11756802149815251,"dc":0,"endothelial":18.352223190932868,"fibroblast":26.113207547169807,"granulocyte":0.17123287671232876,"macrophage_group_a":0.16137708445400753,"macrophage_group_b":0.4058441558441558,"nk_cell":0,"t_cd4":0.2274665908444697,"t_cd8":0.10398613518197573,"t_reg":0.15296367112810708,"tumor":1.7048977061376318}},"transcript_fusion_event_count":{"source_row":{"row":1235,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["fibroblast"],"highest_observed_percent_expressing":26.113207547169807,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":6.226650062266501,"b_cell":0.11756802149815251,"dc":0.0,"endothelial":18.352223190932868,"fibroblast":26.113207547169807,"granulocyte":0.17123287671232876,"macrophage_group_a":0.16137708445400753,"macrophage_group_b":0.4058441558441558,"nk_cell":0.0,"t_cd4":0.2274665908444697,"t_cd8":0.10398613518197573,"t_reg":0.15296367112810708,"tumor":1.7048977061376318},"owner_category":"stromal","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-FAP","source_id":"cancer-surfaceome-atlas","source_row":{"row":58,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-FAP","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":150,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":26.113207547169807,"points":1.31,"state":"derived","tumor_percent":1.7048977061376318}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":41.31},"gene_symbol":"FAP","identifiers":{"approved_symbol":"FAP","ensembl_gene_id":"ENSG00000078098","uniprot_accessions":["Q12884"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"verified antibody or nanobody complex","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":90},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17},{"basis":"verified experimental target anchor","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":85},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"verified experimental target anchor","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":77},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10},{"basis":"verified antibody complex","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12},{"basis":"verified experimental target anchor","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":72},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15},{"basis":"verified experimental target anchor","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30},{"basis":"verified small-molecule complex","points":30},{"basis":"verified experimental target anchor","points":5}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":83}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"FAP","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":70.0,"observed_signals":[{"highest_other_cell_type":"fibroblast","highest_other_percent":26.113207547169807,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":1.7048977061376318},{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"verified-structure-anchor","source_id":"rcsb:6Y0F","url":"https://www.rcsb.org/structure/6Y0F"},{"evidence_role":"verified-structure-anchor","source_id":"rcsb:9DVR","url":"https://www.rcsb.org/structure/9DVR"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":true,"interaction_classes":["nanobody-complex","small-molecule-complex"],"pdb_ids":["6Y0F","9DVR"],"verified_anchor_count":2},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":60.0},{"component":"bound-complex-anchor","maximum":10,"points":10.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.2},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":4.17}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":80.37},"structure_resource_rank":9,"structure_tier":"structure-a","structure_tier_assignment":{"priority_score":80.37,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-a cap.","resource_rank":9,"tier_id":"structure-a"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":true,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["Q12884"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000078098"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":375,"sheet":"Table S6"},"values":{"adipocyte":3.9435450394354503,"b_cell":3.3087000335908634,"dc":16.99346405228758,"endothelial":24.324324324324326,"fibroblast":9.524528301886793,"granulocyte":0.3424657534246575,"macrophage_group_a":0.591715976331361,"macrophage_group_b":0.4464285714285714,"nk_cell":0.23752969121140144,"t_cd4":2.1609326130224624,"t_cd8":0.5545927209705372,"t_reg":6.5009560229445515,"tumor":1.3406695598264105}},"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["endothelial"],"highest_observed_percent_expressing":24.324324324324326,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":3.9435450394354503,"b_cell":3.3087000335908634,"dc":16.99346405228758,"endothelial":24.324324324324326,"fibroblast":9.524528301886793,"granulocyte":0.3424657534246575,"macrophage_group_a":0.591715976331361,"macrophage_group_b":0.4464285714285714,"nk_cell":0.23752969121140144,"t_cd4":2.1609326130224624,"t_cd8":0.5545927209705372,"t_reg":6.5009560229445515,"tumor":1.3406695598264105},"owner_category":"endothelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-CD200","source_id":"cancer-surfaceome-atlas","source_row":{"row":375,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-CD200","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":151,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":24.324324324324326,"points":1.16,"state":"derived","tumor_percent":1.3406695598264105}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":41.16},"gene_symbol":"CD200","identifiers":{"approved_symbol":"CD200","ensembl_gene_id":"ENSG00000091972","uniprot_accessions":["P41217"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CD200","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"endothelial","highest_other_percent":24.324324324324326,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":1.3406695598264105}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.17},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":1.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":7.17},"structure_resource_rank":75,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":7.17,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":75,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P41217"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000091972"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":162,"sheet":"Table S6"},"values":{"adipocyte":19.88376919883769,"b_cell":0.3527040644944575,"dc":1.9607843137254901,"endothelial":1.046207497820401,"fibroblast":39.47169811320755,"granulocyte":0,"macrophage_group_a":8.122646584185047,"macrophage_group_b":23.41720779220779,"nk_cell":0.7125890736342043,"t_cd4":0.3696332101222633,"t_cd8":0.20797227036395147,"t_reg":0.42065009560229444,"tumor":1.0926844389336638}},"transcript_fusion_event_count":{"source_row":{"row":1083,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["fibroblast"],"highest_observed_percent_expressing":39.47169811320755,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":19.88376919883769,"b_cell":0.3527040644944575,"dc":1.9607843137254901,"endothelial":1.046207497820401,"fibroblast":39.47169811320755,"granulocyte":0.0,"macrophage_group_a":8.122646584185047,"macrophage_group_b":23.41720779220779,"nk_cell":0.7125890736342043,"t_cd4":0.3696332101222633,"t_cd8":0.20797227036395147,"t_reg":0.42065009560229444,"tumor":1.0926844389336638},"owner_category":"stromal","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-AXL","source_id":"cancer-surfaceome-atlas","source_row":{"row":162,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-AXL","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":152,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":39.47169811320755,"points":1.05,"state":"derived","tumor_percent":1.0926844389336638}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":41.05},"gene_symbol":"AXL","identifiers":{"approved_symbol":"AXL","ensembl_gene_id":"ENSG00000167601","uniprot_accessions":["P30530"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"AXL","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"fibroblast","highest_other_percent":39.47169811320755,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":1.0926844389336638}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.16},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":1.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":7.16},"structure_resource_rank":76,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":7.16,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":76,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P30530"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000167601"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":1107,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":296,"sheet":"Table S6"},"values":{"adipocyte":14.362806143628063,"b_cell":0.6046355391333558,"dc":0,"endothelial":1.918047079337402,"fibroblast":40.25660377358491,"granulocyte":0.17123287671232876,"macrophage_group_a":0.48413125336202256,"macrophage_group_b":0.689935064935065,"nk_cell":0,"t_cd4":0.7676997441000852,"t_cd8":0.901213171577123,"t_reg":0.22944550669216063,"tumor":0.8989460632362059}},"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["fibroblast"],"highest_observed_percent_expressing":40.25660377358491,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":14.362806143628063,"b_cell":0.6046355391333558,"dc":0.0,"endothelial":1.918047079337402,"fibroblast":40.25660377358491,"granulocyte":0.17123287671232876,"macrophage_group_a":0.48413125336202256,"macrophage_group_b":0.689935064935065,"nk_cell":0.0,"t_cd4":0.7676997441000852,"t_cd8":0.901213171577123,"t_reg":0.22944550669216063,"tumor":0.8989460632362059},"owner_category":"stromal","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-CD248","source_id":"cancer-surfaceome-atlas","source_row":{"row":296,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-CD248","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":153,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":40.25660377358491,"points":0.95,"state":"derived","tumor_percent":0.8989460632362059}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":40.95},"gene_symbol":"CD248","identifiers":{"approved_symbol":"CD248","ensembl_gene_id":"ENSG00000174807","uniprot_accessions":["Q9HCU0"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CD248","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"fibroblast","highest_other_percent":40.25660377358491,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":0.8989460632362059}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.14},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":1.58}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":7.72},"structure_resource_rank":59,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":7.72,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":59,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":false,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q9HCU0"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000174807"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":{"source_row":{"row":65,"sheet":"Table S17"},"values":{"in_frame":null,"missense":null,"silent":null,"truncating":null}},"mutation_clonality":{"source_row":{"row":65,"sheet":"Table S20"},"values":{"clonal":null,"subclonal":null,"unknown":null}},"mutation_frequency_percent":{"source_row":{"row":63,"sheet":"Table S15"},"values":{"percent":null}},"mutation_timing":{"source_row":{"row":65,"sheet":"Table S19"},"values":{"early":null,"late":null,"unknown":null}},"mutation_zygosity":{"source_row":{"row":65,"sheet":"Table S18"},"values":{"heter":null,"homo":null,"unknown":null}},"potential_target_summary":null,"recurrent_mutation_flag":{"source_row":{"row":63,"sheet":"Table S14"},"values":{"flag":0}},"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":52,"sheet":"Table S6"},"values":{"adipocyte":5.0228310502283104,"b_cell":0.47027208599261006,"dc":0,"endothelial":56.10287707061901,"fibroblast":1.7358490566037734,"granulocyte":0.3424657534246575,"macrophage_group_a":3.604088219472835,"macrophage_group_b":4.1396103896103895,"nk_cell":0,"t_cd4":0.5117998294000569,"t_cd8":0.5892547660311959,"t_reg":0.8795411089866157,"tumor":0.5502169869807811}},"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["endothelial"],"highest_observed_percent_expressing":56.10287707061901,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":5.0228310502283104,"b_cell":0.47027208599261006,"dc":0.0,"endothelial":56.10287707061901,"fibroblast":1.7358490566037734,"granulocyte":0.3424657534246575,"macrophage_group_a":3.604088219472835,"macrophage_group_b":4.1396103896103895,"nk_cell":0.0,"t_cd4":0.5117998294000569,"t_cd8":0.5892547660311959,"t_reg":0.8795411089866157,"tumor":0.5502169869807811},"owner_category":"endothelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-FLT1","source_id":"cancer-surfaceome-atlas","source_row":{"row":52,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-FLT1","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":154,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":56.10287707061901,"points":0.74,"state":"derived","tumor_percent":0.5502169869807811}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":40.74},"gene_symbol":"FLT1","identifiers":{"approved_symbol":"FLT1","ensembl_gene_id":"ENSG00000102755","uniprot_accessions":["P17948"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"FLT1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":70.0,"observed_signals":[{"highest_other_cell_type":"endothelial","highest_other_percent":56.10287707061901,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":0.5502169869807811},{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.11},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":2.58}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":8.69},"structure_resource_rank":47,"structure_tier":"structure-c","structure_tier_assignment":{"priority_score":8.69,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-c cap.","resource_rank":47,"tier_id":"structure-c"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P17948"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000102755"},{"aliases":[],"cancer_surfaceome_context":null,"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":null,"claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":null,"source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000091831","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":155,"evidence_score":{"component_count":4,"components":[{"basis":"reviewed integral or GPI-anchored plasma-membrane form","component":"surface-accessibility","maximum":40,"points":34.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":6.51,"raw_score":0.01960629509597914,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":40.51},"gene_symbol":"ESR1","identifiers":{"approved_symbol":"ESR1","ensembl_gene_id":"ENSG00000091831","uniprot_accessions":["P03372"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":60},{"components":[{"basis":"retained surface-accessibility decision","points":58}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":58},{"components":[{"basis":"retained surface-accessibility decision","points":52}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":52},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":40}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":40},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":19,"datasource_scores":[{"id":"europepmc","score":0.16125433333042535}],"score":0.01960629509597914,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"ESR1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.08},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.08},"structure_resource_rank":162,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.08,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":162,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"reviewed-anchored-plasma-membrane","reasons":["Reviewed UniProt records an integral or GPI-anchored plasma-membrane form."],"reviewed_uniprot":{"cytoplasmic_face":true,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":false,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":true,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":false,"uniprot_accessions":["P03372"]},"tcsa_global_membership":false},"target_id":"T-ENSG00000091831"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":{"source_row":{"row":6,"sheet":"Table S17"},"values":{"in_frame":0.075,"missense":0.775,"silent":0.05,"truncating":0.1}},"mutation_clonality":{"source_row":{"row":6,"sheet":"Table S20"},"values":{"clonal":0.55,"subclonal":0.175,"unknown":0.275}},"mutation_frequency_percent":{"source_row":{"row":4,"sheet":"Table S15"},"values":{"percent":3.870967742}},"mutation_timing":{"source_row":{"row":6,"sheet":"Table S19"},"values":{"early":0.475,"late":0.25,"unknown":0.275}},"mutation_zygosity":{"source_row":{"row":6,"sheet":"Table S18"},"values":{"heter":0.675,"homo":0.05,"unknown":0.275}},"potential_target_summary":{"source_row":{"row":999,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":{"source_row":{"row":4,"sheet":"Table S14"},"values":{"flag":1}},"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":17,"sheet":"Table S6"},"values":{"adipocyte":22.291407222914074,"b_cell":12.546187437017132,"dc":20.915032679738562,"endothelial":56.75675675675676,"fibroblast":39.21509433962264,"granulocyte":15.753424657534246,"macrophage_group_a":27.918235610543302,"macrophage_group_b":37.01298701298701,"nk_cell":16.152019002375297,"t_cd4":11.373329542223486,"t_cd8":12.062391681109187,"t_reg":19.54110898661568,"tumor":33.113763174209545}},"transcript_fusion_event_count":{"source_row":{"row":235,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["endothelial"],"highest_observed_percent_expressing":56.75675675675676,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":22.291407222914074,"b_cell":12.546187437017132,"dc":20.915032679738562,"endothelial":56.75675675675676,"fibroblast":39.21509433962264,"granulocyte":15.753424657534246,"macrophage_group_a":27.918235610543302,"macrophage_group_b":37.01298701298701,"nk_cell":16.152019002375297,"t_cd4":11.373329542223486,"t_cd8":12.062391681109187,"t_reg":19.54110898661568,"tumor":33.113763174209545},"owner_category":"endothelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000168036","source_id":"cancer-surfaceome-atlas","source_row":{"row":17,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000168036","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":156,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA global GESP membership","component":"surface-accessibility","maximum":40,"points":30.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":4.63,"raw_score":0.009908230581955361,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":56.75675675675676,"points":5.75,"state":"derived","tumor_percent":33.113763174209545}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":40.38},"gene_symbol":"CTNNB1","identifiers":{"approved_symbol":"CTNNB1","ensembl_gene_id":"ENSG00000168036","uniprot_accessions":["P35222"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":60},{"components":[{"basis":"retained surface-accessibility decision","points":58}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":58},{"components":[{"basis":"retained surface-accessibility decision","points":52}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":52},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":40}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":40},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":73,"datasource_scores":[{"id":"europepmc","score":0.08149143472317777}],"score":0.009908230581955361,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CTNNB1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"endothelial","highest_other_percent":56.75675675675676,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":33.113763174209545}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.06},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.06},"structure_resource_rank":163,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.06,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":163,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":false,"gpi_anchored":false,"integral_membrane":false,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["P35222"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000168036"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":841,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":335,"sheet":"Table S6"},"values":{"adipocyte":0.08302200083022,"b_cell":0,"dc":0,"endothelial":0.043591979075850044,"fibroblast":0,"granulocyte":0,"macrophage_group_a":0,"macrophage_group_b":0,"nk_cell":0,"t_cd4":0,"t_cd8":0,"t_reg":0,"tumor":0.038747675139491636}},"transcript_fusion_event_count":{"source_row":{"row":538,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","malignant-epithelial","stromal"],"highest_observed_cell_types":["adipocyte"],"highest_observed_percent_expressing":0.08302200083022,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":0.08302200083022,"b_cell":0.0,"dc":0.0,"endothelial":0.043591979075850044,"fibroblast":0.0,"granulocyte":0.0,"macrophage_group_a":0.0,"macrophage_group_b":0.0,"nk_cell":0.0,"t_cd4":0.0,"t_cd8":0.0,"t_reg":0.0,"tumor":0.038747675139491636},"owner_category":"stromal","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-SLC34A2","source_id":"cancer-surfaceome-atlas","source_row":{"row":335,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-SLC34A2","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":157,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":0.08302200083022,"points":0.2,"state":"derived","tumor_percent":0.038747675139491636}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":40.2},"gene_symbol":"SLC34A2","identifiers":{"approved_symbol":"SLC34A2","ensembl_gene_id":"ENSG00000157765","uniprot_accessions":["O95436"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"SLC34A2","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":4.15,"observed_signals":[{"highest_other_cell_type":"adipocyte","highest_other_percent":0.08302200083022,"points":4.15,"signal":"tumor-microenvironment-sharing","tumor_percent":0.038747675139491636}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.03},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.03},"structure_resource_rank":164,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.03,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":164,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["O95436"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000157765"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":784,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":378,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":1507,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-ADAM17","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-ADAM17","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":158,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":1,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":40.0},"gene_symbol":"ADAM17","identifiers":{"approved_symbol":"ADAM17","ensembl_gene_id":"ENSG00000151694","uniprot_accessions":["P78536"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"ADAM17","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.0},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":3.32}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":9.32},"structure_resource_rank":36,"structure_tier":"structure-c","structure_tier_assignment":{"priority_score":9.32,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-c cap.","resource_rank":36,"tier_id":"structure-c"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P78536"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000151694"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":309,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":167,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":null,"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-CA9","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-CA9","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":159,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":1,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":40.0},"gene_symbol":"CA9","identifiers":{"approved_symbol":"CA9","ensembl_gene_id":"ENSG00000107159","uniprot_accessions":["Q16790"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CA9","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.0},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":2.58}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":8.58},"structure_resource_rank":49,"structure_tier":"structure-c","structure_tier_assignment":{"priority_score":8.58,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-c cap.","resource_rank":49,"tier_id":"structure-c"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q16790"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000107159"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":959,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-CLDN2","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-CLDN2","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":160,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":1,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":40.0},"gene_symbol":"CLDN2","identifiers":{"approved_symbol":"CLDN2","ensembl_gene_id":"ENSG00000165376","uniprot_accessions":["P57739"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CLDN2","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.0},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.0},"structure_resource_rank":165,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.0,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":165,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["P57739"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000165376"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":199,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":90,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":1253,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-DLL3","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-DLL3","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":161,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":1,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":40.0},"gene_symbol":"DLL3","identifiers":{"approved_symbol":"DLL3","ensembl_gene_id":"ENSG00000090932","uniprot_accessions":["Q9NYJ7"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"DLL3","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.0},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.0},"structure_resource_rank":166,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.0,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":166,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":false,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q9NYJ7"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000090932"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":1312,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":653,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":802,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-ENPP1","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-ENPP1","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":162,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":1,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":40.0},"gene_symbol":"ENPP1","identifiers":{"approved_symbol":"ENPP1","ensembl_gene_id":"ENSG00000197594","uniprot_accessions":["P22413"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"ENPP1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":20.0,"observed_signals":[{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.0},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.0},"structure_resource_rank":167,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.0,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":167,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":true,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["P22413"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000197594"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":334,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":481,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-FOLR1","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-FOLR1","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":163,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":1,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":40.0},"gene_symbol":"FOLR1","identifiers":{"approved_symbol":"FOLR1","ensembl_gene_id":"ENSG00000110195","uniprot_accessions":["P15328"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"FOLR1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":20.0,"observed_signals":[{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.0},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.0},"structure_resource_rank":168,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.0,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":168,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt records an integral or GPI-anchored membrane form."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":false,"gpi_anchored":true,"integral_membrane":false,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P15328"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000110195"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":1335,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-L1CAM","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-L1CAM","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":164,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":1,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":40.0},"gene_symbol":"L1CAM","identifiers":{"approved_symbol":"L1CAM","ensembl_gene_id":"ENSG00000198910","uniprot_accessions":["P32004"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"L1CAM","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.0},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":2.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":8.0},"structure_resource_rank":56,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":8.0,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":56,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P32004"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000198910"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":1074,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":1632,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-LRRC15","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-LRRC15","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":165,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":1,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":40.0},"gene_symbol":"LRRC15","identifiers":{"approved_symbol":"LRRC15","ensembl_gene_id":"ENSG00000172061","uniprot_accessions":["Q8TF66"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"LRRC15","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.0},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":1.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":7.0},"structure_resource_rank":86,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":7.0,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":86,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q8TF66"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000172061"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":698,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":1064,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-MST1R","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-MST1R","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":166,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":1,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":40.0},"gene_symbol":"MST1R","identifiers":{"approved_symbol":"MST1R","ensembl_gene_id":"ENSG00000164078","uniprot_accessions":["Q04912"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"MST1R","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.0},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":2.58}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":8.58},"structure_resource_rank":50,"structure_tier":"structure-c","structure_tier_assignment":{"priority_score":8.58,"reason":"Selected by surface-reconciliation-and-prioritization/v0.2 within the declared structure-c cap.","resource_rank":50,"tier_id":"structure-c"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":false,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q04912"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000164078"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":1314,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":74,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":1158,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-PDCD1LG2","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-PDCD1LG2","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":167,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":1,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":40.0},"gene_symbol":"PDCD1LG2","identifiers":{"approved_symbol":"PDCD1LG2","ensembl_gene_id":"ENSG00000197646","uniprot_accessions":["Q9BQ51"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"PDCD1LG2","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":20.0,"observed_signals":[{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.0},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.0},"structure_resource_rank":169,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.0,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":169,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q9BQ51"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000197646"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":125,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":305,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":265,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-PVR","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-PVR","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":168,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":1,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":40.0},"gene_symbol":"PVR","identifiers":{"approved_symbol":"PVR","ensembl_gene_id":"ENSG00000073008","uniprot_accessions":["P15151"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"PVR","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":20.0,"observed_signals":[{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"},{"evidence_role":"retrieval-routing","source_id":"pubmed-compact-index","url":"https://pubmed.ncbi.nlm.nih.gov/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.0},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":1.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":7.0},"structure_resource_rank":87,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":7.0,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":87,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["P15151"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000073008"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-SSTR2","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-SSTR2","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":169,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":1,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":40.0},"gene_symbol":"SSTR2","identifiers":{"approved_symbol":"SSTR2","ensembl_gene_id":"ENSG00000180616","uniprot_accessions":["P30874"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"SSTR2","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.0},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.0},"structure_resource_rank":170,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.0,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":170,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":true,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["P30874"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000180616"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":560,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":903,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":951,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-VTCN1","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-VTCN1","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":170,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA membership plus reviewed extracellular or anchored membrane topology","component":"surface-accessibility","maximum":40,"points":40.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":1,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":40.0},"gene_symbol":"VTCN1","identifiers":{"approved_symbol":"VTCN1","ensembl_gene_id":"ENSG00000134258","uniprot_accessions":["Q7Z7D3"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"VTCN1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":6.0},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":6.0},"structure_resource_rank":171,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":6.0,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":171,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership.","Reviewed UniProt topology includes an extracellular domain."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":true,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":true,"uniprot_accessions":["Q7Z7D3"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000134258"},{"aliases":[],"cancer_surfaceome_context":null,"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":null,"claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":null,"source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000244355","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":171,"evidence_score":{"component_count":4,"components":[{"basis":"reviewed integral or GPI-anchored plasma-membrane form","component":"surface-accessibility","maximum":40,"points":34.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":4.9,"raw_score":0.011087395640541052,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":38.9},"gene_symbol":"LY6G6D","identifiers":{"approved_symbol":"LY6G6D","ensembl_gene_id":"ENSG00000244355","uniprot_accessions":["O95868"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":53,"datasource_scores":[{"id":"europepmc","score":0.09118961964174316}],"score":0.011087395640541052,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"LY6G6D","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":5.83},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":5.83},"structure_resource_rank":172,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":5.83,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":172,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"reviewed-anchored-plasma-membrane","reasons":["Reviewed UniProt records an integral or GPI-anchored plasma-membrane form."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":false,"gpi_anchored":true,"integral_membrane":false,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":true,"tcsa_membership":false,"uniprot_accessions":["O95868"]},"tcsa_global_membership":false},"target_id":"T-ENSG00000244355"},{"aliases":[],"cancer_surfaceome_context":null,"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":null,"claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":null,"source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000083807","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":172,"evidence_score":{"component_count":4,"components":[{"basis":"reviewed integral or GPI-anchored plasma-membrane form","component":"surface-accessibility","maximum":40,"points":34.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":4.9,"raw_score":0.011087395640541052,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":38.9},"gene_symbol":"SLC27A5","identifiers":{"approved_symbol":"SLC27A5","ensembl_gene_id":"ENSG00000083807","uniprot_accessions":["Q9Y2P5"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":60},{"components":[{"basis":"retained surface-accessibility decision","points":58}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":58},{"components":[{"basis":"retained surface-accessibility decision","points":52}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":52},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":40}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":40},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":56,"datasource_scores":[{"id":"europepmc","score":0.09118961964174316}],"score":0.011087395640541052,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"SLC27A5","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":5.83},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":5.83},"structure_resource_rank":173,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":5.83,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":173,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"reviewed-anchored-plasma-membrane","reasons":["Reviewed UniProt records an integral or GPI-anchored plasma-membrane form."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":false,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":false,"uniprot_accessions":["Q9Y2P5"]},"tcsa_global_membership":false},"target_id":"T-ENSG00000083807"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":{"source_row":{"row":103,"sheet":"Table S17"},"values":{"in_frame":null,"missense":null,"silent":null,"truncating":null}},"mutation_clonality":{"source_row":{"row":103,"sheet":"Table S20"},"values":{"clonal":null,"subclonal":null,"unknown":null}},"mutation_frequency_percent":{"source_row":{"row":101,"sheet":"Table S15"},"values":{"percent":null}},"mutation_timing":{"source_row":{"row":103,"sheet":"Table S19"},"values":{"early":null,"late":null,"unknown":null}},"mutation_zygosity":{"source_row":{"row":103,"sheet":"Table S18"},"values":{"heter":null,"homo":null,"unknown":null}},"potential_target_summary":null,"recurrent_mutation_flag":{"source_row":{"row":101,"sheet":"Table S14"},"values":{"flag":0}},"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":839,"sheet":"Table S6"},"values":{"adipocyte":29.514321295143215,"b_cell":4.501175680214981,"dc":9.803921568627452,"endothelial":46.9485614646905,"fibroblast":54.32452830188679,"granulocyte":2.2260273972602738,"macrophage_group_a":5.970952124798279,"macrophage_group_b":14.44805194805195,"nk_cell":5.225653206650831,"t_cd4":7.392664202445267,"t_cd8":7.8336221837088384,"t_reg":18.81453154875717,"tumor":32.80378177309362}},"transcript_fusion_event_count":{"source_row":{"row":262,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["fibroblast"],"highest_observed_percent_expressing":54.32452830188679,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":29.514321295143215,"b_cell":4.501175680214981,"dc":9.803921568627452,"endothelial":46.9485614646905,"fibroblast":54.32452830188679,"granulocyte":2.2260273972602738,"macrophage_group_a":5.970952124798279,"macrophage_group_b":14.44805194805195,"nk_cell":5.225653206650831,"t_cd4":7.392664202445267,"t_cd8":7.8336221837088384,"t_reg":18.81453154875717,"tumor":32.80378177309362},"owner_category":"stromal","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000050405","source_id":"cancer-surfaceome-atlas","source_row":{"row":839,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000050405","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":173,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA global GESP membership","component":"surface-accessibility","maximum":40,"points":30.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":54.32452830188679,"points":5.73,"state":"derived","tumor_percent":32.80378177309362}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":38.56},"gene_symbol":"LIMA1","identifiers":{"approved_symbol":"LIMA1","ensembl_gene_id":"ENSG00000050405","uniprot_accessions":["Q9UHB6"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":60},{"components":[{"basis":"retained surface-accessibility decision","points":58}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":58},{"components":[{"basis":"retained surface-accessibility decision","points":52}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":52},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":40}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":40},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":379,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"LIMA1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"fibroblast","highest_other_percent":54.32452830188679,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":32.80378177309362}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":5.78},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":5.78},"structure_resource_rank":174,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":5.78,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":174,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":false,"gpi_anchored":false,"integral_membrane":false,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["Q9UHB6"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000050405"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":732,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":110,"sheet":"Table S6"},"values":{"adipocyte":8.468244084682441,"b_cell":18.17265703728586,"dc":22.875816993464053,"endothelial":17.829119442022666,"fibroblast":14.641509433962263,"granulocyte":5.993150684931506,"macrophage_group_a":8.49919311457773,"macrophage_group_b":9.577922077922079,"nk_cell":10.21377672209026,"t_cd4":12.027295990901337,"t_cd8":11.369150779896014,"t_reg":13.307839388145315,"tumor":16.692498450092994}},"transcript_fusion_event_count":{"source_row":{"row":703,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["dc"],"highest_observed_percent_expressing":22.875816993464053,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":8.468244084682441,"b_cell":18.17265703728586,"dc":22.875816993464053,"endothelial":17.829119442022666,"fibroblast":14.641509433962263,"granulocyte":5.993150684931506,"macrophage_group_a":8.49919311457773,"macrophage_group_b":9.577922077922079,"nk_cell":10.21377672209026,"t_cd4":12.027295990901337,"t_cd8":11.369150779896014,"t_reg":13.307839388145315,"tumor":16.692498450092994},"owner_category":"immune","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000147162","source_id":"cancer-surfaceome-atlas","source_row":{"row":110,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000147162","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":174,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA global GESP membership","component":"surface-accessibility","maximum":40,"points":30.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":4.24,"raw_score":0.008315546730405791,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":22.875816993464053,"points":4.09,"state":"derived","tumor_percent":16.692498450092994}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":38.33},"gene_symbol":"OGT","identifiers":{"approved_symbol":"OGT","ensembl_gene_id":"ENSG00000147162","uniprot_accessions":["O15294"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":60},{"components":[{"basis":"retained surface-accessibility decision","points":58}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":58},{"components":[{"basis":"retained surface-accessibility decision","points":52}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":52},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":40}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":40},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":95,"datasource_scores":[{"id":"europepmc","score":0.06839221473130737}],"score":0.008315546730405791,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"OGT","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"dc","highest_other_percent":22.875816993464053,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":16.692498450092994}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":5.75},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":5.75},"structure_resource_rank":175,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":5.75,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":175,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":false,"gpi_anchored":false,"integral_membrane":false,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["O15294"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000147162"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":{"source_row":{"row":113,"sheet":"Table S17"},"values":{"in_frame":null,"missense":null,"silent":null,"truncating":null}},"mutation_clonality":{"source_row":{"row":113,"sheet":"Table S20"},"values":{"clonal":null,"subclonal":null,"unknown":null}},"mutation_frequency_percent":{"source_row":{"row":111,"sheet":"Table S15"},"values":{"percent":null}},"mutation_timing":{"source_row":{"row":113,"sheet":"Table S19"},"values":{"early":null,"late":null,"unknown":null}},"mutation_zygosity":{"source_row":{"row":113,"sheet":"Table S18"},"values":{"heter":null,"homo":null,"unknown":null}},"potential_target_summary":{"source_row":{"row":1325,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":{"source_row":{"row":111,"sheet":"Table S14"},"values":{"flag":0}},"scna_g_score":{"source_row":{"row":484,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":331,"sheet":"Table S6"},"values":{"adipocyte":11.955168119551681,"b_cell":2.099428955324152,"dc":8.49673202614379,"endothelial":43.19965126416739,"fibroblast":23.471698113207548,"granulocyte":5.993150684931506,"macrophage_group_a":14.90048413125336,"macrophage_group_b":24.878246753246753,"nk_cell":1.9002375296912115,"t_cd4":1.3932328689223772,"t_cd8":1.1091854419410745,"t_reg":1.9120458891013385,"tumor":30.068195908245503}},"transcript_fusion_event_count":{"source_row":{"row":52,"sheet":"Table S22"},"values":{"count":1}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["endothelial"],"highest_observed_percent_expressing":43.19965126416739,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":11.955168119551681,"b_cell":2.099428955324152,"dc":8.49673202614379,"endothelial":43.19965126416739,"fibroblast":23.471698113207548,"granulocyte":5.993150684931506,"macrophage_group_a":14.90048413125336,"macrophage_group_b":24.878246753246753,"nk_cell":1.9002375296912115,"t_cd4":1.3932328689223772,"t_cd8":1.1091854419410745,"t_reg":1.9120458891013385,"tumor":30.068195908245503},"owner_category":"endothelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000198561","source_id":"cancer-surfaceome-atlas","source_row":{"row":331,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000198561","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":175,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA global GESP membership","component":"surface-accessibility","maximum":40,"points":30.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":43.19965126416739,"points":5.48,"state":"derived","tumor_percent":30.068195908245503}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":38.31},"gene_symbol":"CTNND1","identifiers":{"approved_symbol":"CTNND1","ensembl_gene_id":"ENSG00000198561","uniprot_accessions":["O60716"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":60},{"components":[{"basis":"retained surface-accessibility decision","points":58}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":58},{"components":[{"basis":"retained surface-accessibility decision","points":52}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":52},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":40}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":40},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":296,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"CTNND1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"endothelial","highest_other_percent":43.19965126416739,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":30.068195908245503}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":5.75},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":5.75},"structure_resource_rank":176,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":5.75,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":176,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":false,"gpi_anchored":false,"integral_membrane":false,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["O60716"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000198561"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":144,"sheet":"Table S6"},"values":{"adipocyte":2.86425902864259,"b_cell":0.8229761504870675,"dc":5.88235294117647,"endothelial":0.3923278116826504,"fibroblast":6.4301886792452825,"granulocyte":1.7123287671232876,"macrophage_group_a":5.594405594405594,"macrophage_group_b":8.238636363636363,"nk_cell":0.4750593824228029,"t_cd4":0.3696332101222633,"t_cd8":0.34662045060658575,"t_reg":0.8030592734225621,"tumor":8.803471791692498}},"transcript_fusion_event_count":{"source_row":{"row":796,"sheet":"Table S22"},"values":{"count":1}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["tumor"],"highest_observed_percent_expressing":8.803471791692498,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":2.86425902864259,"b_cell":0.8229761504870675,"dc":5.88235294117647,"endothelial":0.3923278116826504,"fibroblast":6.4301886792452825,"granulocyte":1.7123287671232876,"macrophage_group_a":5.594405594405594,"macrophage_group_b":8.238636363636363,"nk_cell":0.4750593824228029,"t_cd4":0.3696332101222633,"t_cd8":0.34662045060658575,"t_reg":0.8030592734225621,"tumor":8.803471791692498},"owner_category":"malignant-epithelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000197122","source_id":"cancer-surfaceome-atlas","source_row":{"row":144,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000197122","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":176,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA global GESP membership","component":"surface-accessibility","maximum":40,"points":30.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":5.01,"raw_score":0.011621233208418956,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":8.238636363636363,"points":3.29,"state":"derived","tumor_percent":8.803471791692498}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":38.3},"gene_symbol":"SRC","identifiers":{"approved_symbol":"SRC","ensembl_gene_id":"ENSG00000197122","uniprot_accessions":["P12931"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":60},{"components":[{"basis":"retained surface-accessibility decision","points":58}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":58},{"components":[{"basis":"retained surface-accessibility decision","points":52}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":52},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":40}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":40},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":49,"datasource_scores":[{"id":"europepmc","score":0.09558023095782708}],"score":0.011621233208418956,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"SRC","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":46.79,"observed_signals":[{"highest_other_cell_type":"macrophage_group_b","highest_other_percent":8.238636363636363,"points":46.79,"signal":"tumor-microenvironment-sharing","tumor_percent":8.803471791692498}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":5.74},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":5.74},"structure_resource_rank":177,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":5.74,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":177,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":false,"gpi_anchored":false,"integral_membrane":false,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["P12931"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000197122"},{"aliases":[],"cancer_surfaceome_context":null,"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":null,"claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":null,"source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-NECTIN4","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":177,"evidence_score":{"component_count":4,"components":[{"basis":"reviewed extracellular plasma-membrane topology","component":"surface-accessibility","maximum":40,"points":38.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":1,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":38.0},"gene_symbol":"NECTIN4","identifiers":{"approved_symbol":"NECTIN4","uniprot_accessions":["Q96NY8"]},"intervention_summary":{"action_counts":{"molecular-imaging":2},"assigned_intervention_count":2,"curated_candidate_alias_count":0,"directness_counts":{"registry-explicit":2},"intervention_ids":["I-CTG-18f-f-resca-rnd20-5136376ed7","I-CTG-68ga-ga-nota-rnd20-882a3bd082"],"modality_counts":{"molecular-imaging-agent":2},"registry_explicit_count":2},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":58},{"basis":"reviewed extracellular domain or GPI anchor","points":17}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":75},{"components":[{"basis":"retained surface-accessibility decision","points":52},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10},{"basis":"anchored surface form","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":65},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13},{"basis":"reviewed extracellular domain or GPI anchor","points":12}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":67},{"components":[{"basis":"retained surface-accessibility decision","points":40},{"basis":"reviewed extracellular domain or GPI anchor","points":15}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"NECTIN4","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":20.0,"observed_signals":[{"points":20.0,"signal":"secreted-or-shed-form"}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics"]},"source_refs":[{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":2.0},{"component":"evidence-readiness","maximum":15,"points":5.7},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":7.7},"structure_resource_rank":60,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":7.7,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":60,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"reviewed-extracellular-plasma-membrane","reasons":["Reviewed UniProt topology places an extracellular domain on a plasma-membrane protein."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":true,"gpi_anchored":false,"integral_membrane":true,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":true,"signal_peptide":true,"tcsa_membership":false,"uniprot_accessions":["Q96NY8"]},"tcsa_global_membership":false},"target_id":"T-NECTIN4"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":89,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000061337","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000061337","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":178,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA global GESP membership","component":"surface-accessibility","maximum":40,"points":30.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":5.65,"raw_score":0.014783194187388075,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":35.65},"gene_symbol":"LZTS1","identifiers":{"approved_symbol":"LZTS1","ensembl_gene_id":"ENSG00000061337","uniprot_accessions":["Q9Y250"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":60},{"components":[{"basis":"retained surface-accessibility decision","points":58}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":58},{"components":[{"basis":"retained surface-accessibility decision","points":52}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":52},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":40}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":40},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":35,"datasource_scores":[{"id":"europepmc","score":0.12158615952232422}],"score":0.014783194187388075,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"LZTS1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":5.35},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":5.35},"structure_resource_rank":178,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":5.35,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":178,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":false,"gpi_anchored":false,"integral_membrane":false,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["Q9Y250"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000061337"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":1264,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":545,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":220,"sheet":"Table S6"},"values":{"adipocyte":4.02656704026567,"b_cell":3.4766543500167955,"dc":22.22222222222222,"endothelial":10.331299040976461,"fibroblast":14.249056603773585,"granulocyte":2.3972602739726026,"macrophage_group_a":15.814954276492738,"macrophage_group_b":36.810064935064936,"nk_cell":29.928741092636578,"t_cd4":26.215524594825133,"t_cd8":34.280762564991335,"t_reg":29.904397705544934,"tumor":4.238995660260384}},"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["macrophage_group_b"],"highest_observed_percent_expressing":36.810064935064936,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":4.02656704026567,"b_cell":3.4766543500167955,"dc":22.22222222222222,"endothelial":10.331299040976461,"fibroblast":14.249056603773585,"granulocyte":2.3972602739726026,"macrophage_group_a":15.814954276492738,"macrophage_group_b":36.810064935064936,"nk_cell":29.928741092636578,"t_cd4":26.215524594825133,"t_cd8":34.280762564991335,"t_reg":29.904397705544934,"tumor":4.238995660260384},"owner_category":"immune","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000188042","source_id":"cancer-surfaceome-atlas","source_row":{"row":220,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000188042","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":179,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA global GESP membership","component":"surface-accessibility","maximum":40,"points":30.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":3.35,"raw_score":0.0051741179655858255,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":36.810064935064936,"points":2.06,"state":"derived","tumor_percent":4.238995660260384}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":35.41},"gene_symbol":"ARL4C","identifiers":{"approved_symbol":"ARL4C","ensembl_gene_id":"ENSG00000188042","uniprot_accessions":["P56559"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":60},{"components":[{"basis":"retained surface-accessibility decision","points":58}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":58},{"components":[{"basis":"retained surface-accessibility decision","points":52}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":52},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":40}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":40},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":169,"datasource_scores":[{"id":"europepmc","score":0.04255515583281348}],"score":0.0051741179655858255,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"ARL4C","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"macrophage_group_b","highest_other_percent":36.810064935064936,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":4.238995660260384}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":5.31},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":5.31},"structure_resource_rank":179,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":5.31,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":179,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":false,"gpi_anchored":false,"integral_membrane":false,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["P56559"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000188042"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":509,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":304,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":{"source_row":{"row":647,"sheet":"Table S6"},"values":{"adipocyte":12.619344126193441,"b_cell":1.0581121934833726,"dc":21.568627450980394,"endothelial":51.5693112467306,"fibroblast":31.07924528301887,"granulocyte":3.2534246575342465,"macrophage_group_a":10.650887573964498,"macrophage_group_b":25.243506493506494,"nk_cell":1.187648456057007,"t_cd4":1.194199601933466,"t_cd8":0.6239168110918544,"t_reg":1.1089866156787764,"tumor":24.465282083075017}},"transcript_fusion_event_count":{"source_row":{"row":215,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["endothelial"],"highest_observed_percent_expressing":51.5693112467306,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":12.619344126193441,"b_cell":1.0581121934833726,"dc":21.568627450980394,"endothelial":51.5693112467306,"fibroblast":31.07924528301887,"granulocyte":3.2534246575342465,"macrophage_group_a":10.650887573964498,"macrophage_group_b":25.243506493506494,"nk_cell":1.187648456057007,"t_cd4":1.194199601933466,"t_cd8":0.6239168110918544,"t_reg":1.1089866156787764,"tumor":24.465282083075017},"owner_category":"endothelial","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-SEED-MONDO_0005007-PVRL2","source_id":"cancer-surfaceome-atlas","source_row":{"row":647,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-SEED-MONDO_0005007-PVRL2","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"seed-symbol","evidence_rank":180,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA global GESP membership","component":"surface-accessibility","maximum":40,"points":30.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":null,"points":0.0,"raw_score":null,"state":"not-measured"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":51.5693112467306,"points":4.95,"state":"derived","tumor_percent":24.465282083075017}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":34.95},"gene_symbol":"PVRL2","identifiers":{"approved_symbol":"PVRL2","ensembl_gene_id":"ENSG00000130202"},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":60},{"components":[{"basis":"retained surface-accessibility decision","points":58}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":58},{"components":[{"basis":"retained surface-accessibility decision","points":52}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":52},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":40}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":40},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"association_score":null,"datasource_scores":[],"favorable_evidence":false,"source_id":"query-expansion-seed"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"PVRL2","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"endothelial","highest_other_percent":51.5693112467306,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":24.465282083075017}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":5.24},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":5.24},"structure_resource_rank":180,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":5.24,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":180,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":false,"gpi_anchored":false,"integral_membrane":false,"peripheral_membrane":false,"plasma_membrane":false,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":[]},"tcsa_global_membership":true},"target_id":"T-ENSG00000130202"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":{"source_row":{"row":215,"sheet":"Table S6"},"values":{"adipocyte":0.24906600249066002,"b_cell":7.759489418878066,"dc":9.15032679738562,"endothelial":1.4385353095030515,"fibroblast":0.3018867924528302,"granulocyte":4.280821917808219,"macrophage_group_a":5.325443786982249,"macrophage_group_b":6.412337662337662,"nk_cell":4.275534441805226,"t_cd4":3.0992323002559,"t_cd8":4.055459272097054,"t_reg":2.829827915869981,"tumor":0.379727216367018}},"transcript_fusion_event_count":null},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"complete-recorded-cell-types","detected_categories":["endothelial","immune","malignant-epithelial","stromal"],"highest_observed_cell_types":["dc"],"highest_observed_percent_expressing":9.15032679738562,"invalid_cell_types":[],"missing_cell_types":[],"observed_percent_expressing":{"adipocyte":0.24906600249066002,"b_cell":7.759489418878066,"dc":9.15032679738562,"endothelial":1.4385353095030515,"fibroblast":0.3018867924528302,"granulocyte":4.280821917808219,"macrophage_group_a":5.325443786982249,"macrophage_group_b":6.412337662337662,"nk_cell":4.275534441805226,"t_cd4":3.0992323002559,"t_cd8":4.055459272097054,"t_reg":2.829827915869981,"tumor":0.379727216367018},"owner_category":"immune","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000105851","source_id":"cancer-surfaceome-atlas","source_row":{"row":215,"sheet":"Table S6"},"state":"provisional-transcript-context","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000105851","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":181,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA global GESP membership","component":"surface-accessibility","maximum":40,"points":30.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":9.15032679738562,"points":0.62,"state":"derived","tumor_percent":0.379727216367018}],"maximum":100,"measured_component_count":3,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":33.45},"gene_symbol":"PIK3CG","identifiers":{"approved_symbol":"PIK3CG","ensembl_gene_id":"ENSG00000105851","uniprot_accessions":["P48736"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":60},{"components":[{"basis":"retained surface-accessibility decision","points":58}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":58},{"components":[{"basis":"retained surface-accessibility decision","points":52}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":52},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":40}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":40},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":366,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"PIK3CG","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":50.0,"observed_signals":[{"highest_other_cell_type":"dc","highest_other_percent":9.15032679738562,"points":50.0,"signal":"tumor-microenvironment-sharing","tumor_percent":0.379727216367018}],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":5.02},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":5.02},"structure_resource_rank":181,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":5.02,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":181,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":false,"gpi_anchored":false,"integral_membrane":false,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["P48736"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000105851"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":274,"sheet":"Table S22"},"values":{"count":1}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000101752","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000101752","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":182,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA global GESP membership","component":"surface-accessibility","maximum":40,"points":30.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":3.29,"raw_score":0.004989328038243475,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":33.29},"gene_symbol":"MIB1","identifiers":{"approved_symbol":"MIB1","ensembl_gene_id":"ENSG00000101752","uniprot_accessions":["Q86YT6"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":60},{"components":[{"basis":"retained surface-accessibility decision","points":58}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":58},{"components":[{"basis":"retained surface-accessibility decision","points":52}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":52},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":40}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":40},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":179,"datasource_scores":[{"id":"europepmc","score":0.04103532883878443}],"score":0.004989328038243475,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"MIB1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":4.99},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":4.99},"structure_resource_rank":182,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":4.99,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":182,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":false,"gpi_anchored":false,"integral_membrane":false,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["Q86YT6"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000101752"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":{"source_row":{"row":145,"sheet":"Table S17"},"values":{"in_frame":null,"missense":null,"silent":null,"truncating":null}},"mutation_clonality":{"source_row":{"row":145,"sheet":"Table S20"},"values":{"clonal":null,"subclonal":null,"unknown":null}},"mutation_frequency_percent":{"source_row":{"row":143,"sheet":"Table S15"},"values":{"percent":null}},"mutation_timing":{"source_row":{"row":145,"sheet":"Table S19"},"values":{"early":null,"late":null,"unknown":null}},"mutation_zygosity":{"source_row":{"row":145,"sheet":"Table S18"},"values":{"heter":null,"homo":null,"unknown":null}},"potential_target_summary":{"source_row":{"row":1015,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":{"source_row":{"row":143,"sheet":"Table S14"},"values":{"flag":0}},"scna_g_score":{"source_row":{"row":548,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":1604,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000169047","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000169047","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":183,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA global GESP membership","component":"surface-accessibility","maximum":40,"points":30.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":32.83},"gene_symbol":"IRS1","identifiers":{"approved_symbol":"IRS1","ensembl_gene_id":"ENSG00000169047","uniprot_accessions":["P35568"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":60},{"components":[{"basis":"retained surface-accessibility decision","points":58}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":58},{"components":[{"basis":"retained surface-accessibility decision","points":52}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":52},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":40}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":40},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":335,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"IRS1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":4.92},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":4.92},"structure_resource_rank":183,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":4.92,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":183,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":false,"gpi_anchored":false,"integral_membrane":false,"peripheral_membrane":false,"plasma_membrane":false,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["P35568"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000169047"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":{"source_row":{"row":614,"sheet":"Table S40"},"values":{"amplification":0,"cagesp":0,"deletion":0,"fusion":0,"mutation":0}},"recurrent_mutation_flag":null,"scna_g_score":{"source_row":{"row":197,"sheet":"Table S12"},"values":{"amp":null,"del":null}},"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":966,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000137275","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000137275","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":184,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA global GESP membership","component":"surface-accessibility","maximum":40,"points":30.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.83,"raw_score":0.0036957985468470188,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":32.83},"gene_symbol":"RIPK1","identifiers":{"approved_symbol":"RIPK1","ensembl_gene_id":"ENSG00000137275","uniprot_accessions":["Q13546"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":60},{"components":[{"basis":"retained surface-accessibility decision","points":58}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":58},{"components":[{"basis":"retained surface-accessibility decision","points":52}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":52},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":40}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":40},{"components":[{"basis":"retained surface-accessibility decision","points":18},{"basis":"TCSA druggable membrane-protein class","points":30}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":48}],"open_targets_association":{"associated_target_rank":256,"datasource_scores":[{"id":"europepmc","score":0.030396539880581056}],"score":0.0036957985468470188,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"RIPK1","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":4.92},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":4.92},"structure_resource_rank":184,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":4.92,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":184,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":false,"gpi_anchored":false,"integral_membrane":false,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["Q13546"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000137275"},{"aliases":[],"cancer_surfaceome_context":{"cancer_code":"COAD","cancer_specific_gesp":null,"mutation_categories":null,"mutation_clonality":null,"mutation_frequency_percent":null,"mutation_timing":null,"mutation_zygosity":null,"potential_target_summary":null,"recurrent_mutation_flag":null,"scna_g_score":null,"single_cell_percent_expressing":null,"transcript_fusion_event_count":{"source_row":{"row":623,"sheet":"Table S22"},"values":{"count":0}}},"cell_owner":{"assignment_basis":"category of the highest observed percent-expressing cell type; exact cross-category ties are mixed; no abundance threshold or exclusive ownership is inferred","cancer_code":"COAD","claim_ceiling":"relative transcript detection in the recorded public COAD cell groups; not verified cell ownership, protein surface density, individual-tumor expression, or therapeutic selectivity","comparison_coverage":"partial-or-unavailable","detected_categories":[],"highest_observed_cell_types":[],"highest_observed_percent_expressing":null,"invalid_cell_types":[],"missing_cell_types":["adipocyte","b_cell","dc","endothelial","fibroblast","granulocyte","macrophage_group_a","macrophage_group_b","nk_cell","t_cd4","t_cd8","t_reg","tumor"],"observed_percent_expressing":{},"owner_category":"unresolved","policy_id":"tcsa-highest-observed-transcript-prevalence/v0.1","ranking_use":"context-only; evidence and structure ranks are unchanged; molecular jobs require owner-specific review","source_entity_id":"E-OT-MONDO_0005007-ENSG00000095585","source_id":"cancer-surfaceome-atlas","source_row":null,"state":"unresolved","unmapped_cell_types":[]},"claim_ceiling":"derived public-cohort prioritization","discovery_entity_id":"E-OT-MONDO_0005007-ENSG00000095585","disease_context":{"disease_id":"MONDO_0005007","disease_name":"colon mucinous adenocarcinoma"},"entity_class":"protein-coding-gene","evidence_rank":185,"evidence_score":{"component_count":4,"components":[{"basis":"TCSA global GESP membership","component":"surface-accessibility","maximum":40,"points":30.0,"state":"derived"},{"component":"open-targets-disease-association","maximum":25,"normalization_maximum":0.2889653808156401,"points":2.53,"raw_score":0.0029566388374776143,"state":"derived"},{"cagesp_tier":null,"component":"tcsa-cancer-specific-gesp","maximum":20,"points":0.0,"state":"not-measured"},{"component":"tcsa-single-cell-context","maximum":15,"maximum_microenvironment_percent":null,"points":0.0,"state":"not-measured","tumor_percent":null}],"maximum":100,"measured_component_count":2,"missing_data_rule":"A missing component adds zero points and remains not-measured; it is not negative evidence.","policy_id":"surface-reconciliation-and-prioritization/v0.2","score":32.53},"gene_symbol":"BLNK","identifiers":{"approved_symbol":"BLNK","ensembl_gene_id":"ENSG00000095585","uniprot_accessions":["Q8WV28"]},"intervention_summary":{"action_counts":{},"assigned_intervention_count":0,"curated_candidate_alias_count":0,"directness_counts":{},"intervention_ids":[],"modality_counts":{},"registry_explicit_count":0},"modality_fit":[{"components":[{"basis":"retained surface-accessibility decision","points":60}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-format-binder","score":60},{"components":[{"basis":"retained surface-accessibility decision","points":58}],"evidence_class":"planning-fit","maximum":100,"modality":"miniprotein-binder","score":58},{"components":[{"basis":"retained surface-accessibility decision","points":52}],"evidence_class":"planning-fit","maximum":100,"modality":"peptide-or-modified-peptide","score":52},{"components":[{"basis":"retained surface-accessibility decision","points":45},{"basis":"surface-membrane evidence","points":10}],"evidence_class":"planning-fit","maximum":100,"modality":"antibody-drug-conjugate","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":42},{"basis":"surface-membrane evidence","points":13}],"evidence_class":"planning-fit","maximum":100,"modality":"engineered-cell-therapy","score":55},{"components":[{"basis":"retained surface-accessibility decision","points":40}],"evidence_class":"planning-fit","maximum":100,"modality":"radioligand-or-radioimmunotherapy","score":40},{"components":[{"basis":"retained surface-accessibility decision","points":18}],"evidence_class":"planning-fit","maximum":100,"modality":"small-molecule","score":18}],"open_targets_association":{"associated_target_rank":420,"datasource_scores":[{"id":"europepmc","score":0.024317231904464845}],"score":0.0029566388374776143,"source_date":"2026-09-04","source_id":"open-targets","source_name":"Open Targets Platform","source_snapshot":{"bytes":116484,"filename":"MONDO_0005007-associated-targets.json","sha256":"6385e9eb0fc1df40850114d2c3a352662982b4c1071c97562000e8d25fe22e9a"},"source_url":"https://api.platform.opentargets.org/api/v4/graphql"},"patient_specific_measurements":{"required_fields":["surface abundance","cell-state prevalence","normal tissue exposure","nodal/metastatic retention","post-treatment retention"],"state":"not-measured"},"preferred_name":"BLNK","prioritization_status":"provisional-public-cohort","risk":{"assessment_state":"partial-public-cohort","maximum":100,"observed_signal_score":0.0,"observed_signals":[],"score_meaning":"Higher values indicate more measured warning signals; this is not a safety score.","unresolved_dimensions":["matched-normal-organ surface abundance","patient-specific tumor surface abundance","primary-node-metastasis longitudinal retention","post-fluoropyrimidine/oxaliplatin retention","internalization and recycling kinetics","quantitative soluble-antigen and shedding burden"]},"source_refs":[{"evidence_role":"disease-association","source_id":"open-targets","url":"https://api.platform.opentargets.org/api/v4/graphql"},{"evidence_role":"surfaceome-and-cancer-context","source_id":"cancer-surfaceome-atlas","url":"https://www.nature.com/articles/s43018-021-00282-w"},{"evidence_role":"reviewed-topology-and-localization","source_id":"uniprot","url":"https://www.uniprot.org/"}],"structure_anchor_summary":{"all_anchors_validated":false,"interaction_classes":[],"pdb_ids":[],"verified_anchor_count":0},"structure_resource_priority":{"components":[{"component":"verified-experimental-anchor","maximum":60,"points":0.0},{"component":"bound-complex-anchor","maximum":10,"points":0.0},{"component":"assigned-interventions","maximum":10,"points":0.0},{"component":"evidence-readiness","maximum":15,"points":4.88},{"component":"pubmed-review-density","interpretation":"retrieval-routing input; not favorable biological evidence","maximum":5,"points":0.0}],"maximum":100,"policy_id":"surface-reconciliation-and-prioritization/v0.2","score":4.88},"structure_resource_rank":185,"structure_tier":"retained-unmodeled","structure_tier_assignment":{"priority_score":4.88,"reason":"Retained in the surface universe outside the current structure-resource waves.","resource_rank":185,"tier_id":"retained-unmodeled"},"surface_evidence":{"decision":"retained","reason_code":"positive-surfaceome-evidence","reasons":["TCSA reports global GESP membership."],"reviewed_uniprot":{"cytoplasmic_face":false,"direct_cell_surface_text":false,"explicit_extracellular_matrix":false,"extracellular_topology":false,"gpi_anchored":false,"integral_membrane":false,"peripheral_membrane":false,"plasma_membrane":true,"reviewed_surface_conflict":false,"secreted_or_shed":false,"signal_peptide":false,"tcsa_membership":true,"uniprot_accessions":["Q8WV28"]},"tcsa_global_membership":true},"target_id":"T-ENSG00000095585"}],"schema_version":"codex-surface-target-collection/v0.1"}